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Executive summary 
Introduction 
Extracellular vesicles (EVs) are submicron vesicles released by most cells. They contain protein, 
enzymes and microRNA of the donor cells and are believed to play a role in paracrine 
communication. Circulating EVs might reflect heightened inflammatory status in obese individuals 
and play a role in chronic low grade inflammation associated with obesity. 
Aims 
To compare circulating plasma EVs between healthy volunteers across a range of BMI and morbidly 
obese individuals attending a multidisciplinary weight loss clinic, and to assess the effects of lifestyle 
changes and bariatric surgery on the circulating EV profile. Finally, to characterise EVs derived from 
subcutaneous and visceral fat depots.  
Methods 
Plasma EVs were isolated by differential centrifugation. EV cellular origin (platelets CD41, 
monocytes/macrophages CD11b, erythrocytes CD235a, endothelial cells CD144) and adipocytokine 
expression (IL6, TNFα, interferon γ, adiponectin, FABP4, PPARγ) were evaluated by TRF 
immunoassay. 
Results 
Circulating EV profile and concentration in metabolically healthy volunteers was unaffected by BMI 
(all p=ns). The EV profile in healthy men was more pro-inflammatory compared to women, with 
higher EV-expressed CD41, CD144, IL-6, interferon γ and FABP4 (all p<0.05). This was accompanied 
by lower plasma adiponectin concentration in males (128 µg/mL vs. 272.3µg/mL, p<0.005). Plasma 
FABP4 correlated strongly with BMI (r=0.91, p<0.005) and was lower in healthy lean versus obese 
individuals (13.5(6.4) vs 23.8(6.4) ng/mL, respectively (p<0.05)).  
Dietary and lifestyle management affected the EV profile, with lower signals observed from platelet-
derived EVs (p<0.05) as well as FABP4-, TNFα- and Interferon ϒ-expressing EVs at 6 months’ follow-
up (p<0.05, p=0.05, p=0.06, respectively). Bariatric surgery led to transient increase in EV and plasma 
FABP4 at 1 month (p<0.05) which is likely secondary to increased lipolysis during that period. The 
exosomal marker CD9 correlated with FABP4, interferon γ, adiponectin and TNFα (r=0.49, r=0.41, 
r=0.59, r=0.53, all p<0.05), suggesting that exosomes are  the main carriers of these adipokines. 
Adipocyte-derived EVs from both visceral and subcutaneous fat depots were found to express 
numerous adipokines involved in various biological processes and molecular pathways. 
Conclusion 
EVs can be regarded as diverse biological vectors playing an important role in regulation of adipose 
tissue homeostasis and inflammatory processes. Their concentration, cellular origin and content do 
not directly correlate with BMI but are affected by gender and the presence of obesity-driven 
comorbidities. 
x 
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1.Extracellular vesicles 
1.1 History 
Extracellular vesicles (EVs) are a heterogeneous group of submicron vesicles released by most cells 
during the normal cell cycle as well as during cell stress.  Although EVs were first reported over 70 
years ago, they have only gained more attention over the last 3 decades as we learnt more about 
their mechanisms of secretion and multiple biological roles.  
The first report of EVs dates back to 1946 when Chargraff and West  [Chargraff E, 1946] reported 
platelet-derived particles in normal plasma, later described by Wolf as ‘platelet dust’  [Wolf P, 1967].  
However, the significance of these findings was not clear at the time.  In 1987, an exosomal 
secretion pathway from multivesicular bodies was first described from reticulocytes [Johnstone RM, 
1987].   A decade later, evidence emerged that these vesicles are also released from antigen 
presenting cells (B lymphocytes) which triggers antigen-specific MHC class II- restricted T cell 
responses [Raposo G, 1996]. This implicated exosomes in playing a role in immune responses. EVs 
have since been isolated from most biological fluids including blood, urine, cerebrospinal fluid, bile, 
saliva, synovial fluid, semen and amniotic fluid [Yanez-Mo, M 2015]. They have been found to 
contain membrane and cytoplasmic components of their parental cells, including proteins, enzymes 
and cytokines. .[Yanez-Mo, M, 2015] When functional RNA was detected within EVs (evRNA) just 
over a decade ago [Ratajczak J, 2006 ], the interest in EVs rose exponentially, and they have since 
been recognised as biological vectors that can influence gene expression in recipient cells [Valadi H, 
2007]. 
The International Society of Extracellular Vesicles (ISEV) was founded in 2011 and is now established 
as a scientific reference body which evaluates and promotes EV research. Currently, the role of EVs 
as biological messengers involved in numerous physiological and pathological processes is widely 
acknowledged and the main focus of current research in this area is on improvement and 
standardisation of EV isolation and separation methodology, and this will point the way to potential 
clinical applications. 
1.2 EVs nomenclature 
EVs are a heterogeneous group but can be divided broadly into 3 major subgroups based on their 
size and mode of secretion: exosomes (<150nm in diameter) originating from multivesicular bodies, 
microvesicles (150nm-1µm in diameter) released by outwards budding  of the plasma membrane, 
(Fig.1.1) and oncosomes and apoptotic bodies originating from cells undergoing apoptosis (1-5µm in 
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diameter). The latter are not evaluated by the research in this thesis hence will not be described in 
detail. The division of EV subtypes based on size is arbitrary as they do overlap. Moreover, the 
commonly reported exosomal markers such as CD9 and CD63 are also present in larger EVs [Thery C, 
2017].  Additionally, it must be noted that in reality biological fluids are a mixture of various EVs 
secreted by cells and at the time of undertaking the research in this thesis no reliable method of 
isolation of only one EV subtype exists. 
The mechanisms controlling the sorting of EV protein and RNA content are not yet fully understood. 
They exert their effects on target cells via receptor-ligand interaction but EVs can also be 
internalised via phagocytosis and micropinocytosis. The circulating EV concentration is believed to 
depend on the balance between generation and clearance; the latter is believed to mainly occur via 
uptake into target cells. Therefore, EV biodistribution and half-life varies depending on the cell of 
origin and the proximity of the target tissue [Yanez-Mo M, 2015]. 
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Fig.1.1: Summary of EV nomenclature. 
 Exosomes  Microvesicles  Apoptotic bodies 
 Size    30-150nm  150-1000nm 1-5µm
range 
Origin    Intracellular processing        Plasma membrane  Plasma membrane 
 and recycling 
Markers Tetraspanins  PS Binding: Annexin V,  PS binding: Annexin V 
 CD9, CD63, CD81  lactadherin  Nuclear material:  
 Other: TSG101, Alix, GM1      Cell surface proteins   Propidium iodide 
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1.3 EV biogenesis 
EVs differ not only in size but also in the mode of generation. There are 2 major pathways involved in 
EV formation: the classical pathway for exosome generation and the direct pathway where 
microvesicle budding occurs.  
1.3.1 Exosome secretion -the classical pathway 
This pathway forms part of the endocytic pathway which regulates the expression of cell surface 
receptors which are internalised and degraded or recycled depending on the biological 
circumstances [Vanlandingham PA, 2009]. Briefly, in this process an intracellular vesicle is formed 
firstly by invagination of the plasma membrane and endocytosis of the membrane proteins and 
surrounding material. Next, intraluminal vesicles (ILVs) are generated by an inward budding of the 
intracellular vesicle membrane. This process is regulated by the Endosomal Sorting Complex 
Required for Transport (ESCRT) [Colombo M, 2014]. There are 4 different ESCRT complexes which 
regulate different functions: ESCRT complexes 0, I and II are involved in recognition and 
ubiquitination of the endocytosed proteins, whilst ESCRT III complex (Alix, TSG101 (tumour 
susceptibility gene 101)) regulates the inward budding and scission of the ILVs, which leads to 
formation of multivesicular bodies (MVBs) [Colombo M, 2014, Gruenberg J, 2004]. The Alix protein 
plays an important role by simultaneously binding to the TSG101 component of the ESCRT-I complex 
and CHMP4 (charged multivesicular body protein 4) [McCollough J, 2008], a component of ESCRT-III. 
MVBs can then fuse with the plasma membrane leading to exosome release or they can be degraded 
by lysosomes. The exact pathways behind these processes are still being researched as it is not clear 
what mechanisms determine the sorting of MVBs into those that are degraded versus those that are 
released from the cells. 
Interestingly, there are some reports suggesting that ubiquitination is not necessary for sorting the 
proteins into ILVs.  Baietti et al described involvement of syndecan protein in ESCRT III-driven 
exosome generation [Baietti MF, 2012]. A cytosolic protein called syntenin was shown to connect 
syndecan to Alix protein and clustering of syndecan  by heparanase  drives syntenin-ALIX-ESCRT-
mediated sorting and exosome generation [Roucourt B, 2015]. Intriguingly, this pathway mainly 
stimulates selective incorporation of CD63 into exosomes, rather than CD9 or CD81 and is regulated 
by the small GTPase ADP ribosylation factor 6 (ARF6) and phospholipase D2 (PLD2) [Ghossoub , 
2014]. Moreover, Trajkovic et al recently reported that ceramide (released from sphingomyelin by 
neutral sphingomyelinase 2 (nSMase2)) is involved in ILVs budding into MVBs by inducing negative 
membrane curvature [Trajkovic K, 2008].  
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These various generation pathways may target different exosome subpopulations and regulate 
different exosomal cargos which can define their biological function. Therefore, further insight into 
mechanisms regulating these pathways could have a significant effect into the potential use of 
exosomes in transitional medicine.  
As mentioned above, the MVBs can either fuse with the plasma membrane and release the 
exosomes into the extracellular fluid or fuse with lysosomes and undergo degradation. It is not 
currently understood what determines the fate of MVBs, but recent studies have provided some 
insight into potential regulatory mechanisms of this process. Fader et al reported that a change in 
the cellular conditions such as starvation can lead to decreased exosome release and increased 
fusion of MVBs with autophagosomes [Fader C, 2008]. Post-translational modifications were also 
shown to play a role in exosome secretion. Villaroya-Beltri et al demonstrated in in vivo and in vitro 
mice studies that conjugation of ISG15, an interferon (IFN)-α/β-induced ubiquitin like protein(UBL), 
to target proteins called “ISGylation” (ubiquitin-like modification) leads to decreased MVB number 
due to their co-localisation with lysosomes. This effect was shown on the TSG101 protein which led 
to MVB aggregation and degradation, and subsequently reduced exosome release from cells 
[Villaroya-Beltri C, 2016]. Additionally, the sumolyation of heterogeneous nuclear ribonucleoprotein 
A2B1 (hnRNPA2B1) was shown to play a role in the sorting of microRNAs into exosomes [Villarroya-
Beltri C, 2013]. 
The transport of ‘secretory’ MVBs to the plasma membrane is controlled along microtubules by 
various kinesin isoforms which are regulated by RAB7- and Arl8-dependent protein complexes 
[Raiborg C, 2015, Pu J, 2015].  Once ‘docked’ to the plasma membrane, MVBs bind to the SNARE 
complex (soluble N-ethylmaleimide-sensitive component attachment protein receptor), with small 
GTPases such as RAL-1 believed to play a role in this process [Hyenne V, 2015]. 
In recent years a variety of different SNARE proteins were described such as Synaptobrevin homolog 
YKT6, Syntaxin-1a, Syntaxin-4 and Syntaxin-5, SNAP23 (synaptosomal-associated protein 23), and 
VAMP7 (vesicle associated membrane protein 7) [Bebelman M, 2018]. The formation of SNARE 
complexes is controlled by various mechanisms such as their phosphorylation status and calcium-
sensing SNARE interacting protein synaptotagmin-7 [Bebelman, M, 2018]. 
1.3.2 Microvesicle secretion- the direct pathway 
This heterogeneous subtype of EVs is released directly in the process of vesicles budding from the 
plasma membrane which is the result of dynamic interaction between contractions of cytoskeletal 
proteins and phospholipid redistribution [Hugel B, 2005]. In a resting state the plasma membrane 
phospholipid bilayer consists of phosphatidylcholine and sphingomyelin primarily located in the 
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outer leaflet, and phosphatidylserine and phosphatidylethanolamine located in the inner leaflet 
[Seigneuret M, 1984].  The process of microvesicle secretion is controlled by enzymes: flippase (a 
translocase that moves the phospholipids from the outer leaflet to the inner leaflet of the plasma 
membrane), floppase (a translocase which moves the phospholipids from the inner to the outer 
layer) and scramblase (which can transfer the negatively charged phospholipids in both directions 
and does not require ATP). When the cell is activated, cytosolic calcium increases leading to 
increased activity of floppase and scramblase, and inactivation of flippase [Daleke D, 2003].  The 
subsequent reorganisation of the phospholipids in the plasma membrane by movement of 
phosphatidylserine to the outer leaflet leads to microvesicle secretion/ “budding” which is 
supported by cytoskeletal contractions [Hugel B, 2005, Akers C, 2017]. The  GTP-binding protein 
ADP-ribosylation factor 6 (ARF6), a member of the rho family,  is involved in the process of 
microvesicle secretion by inducing the signalling cascade from  the activation of phospholipase D, 
recruitment of the extracellular-signal regulated kinase (ERK) up to phosphorylation and activation 
of the myosin light chain by myosin light chain kinase (MLCK) [Muralidharan-Chari V, 2009]. Other 
proteins such as caspase and calpain are believed to play a role in this EV secretion pathway but the 
exact mechanisms behind it are not fully understood yet.  
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Fig.1.2: Extracellular vesicle generation pathways. 
Microvesicles are released directly from plasma membrane budding; exosome formation occurs 
within multivesicular bodies which subsequently fuse with the cell membrane. (Images courtesy of 
Dr K. Connolly, Cardiff Metropolitan University) 
1.4 EV content 
1.4.1 EV proteins 
EVs have been shown to contain a vast amount of various proteins with online databases available 
for reference which are continuously updated such as Vesiclepedia [Kalra H, 2012], EVpedia [Kim DK, 
2013] and ExoCarta [Simpson RJ, 2012]. Generally, EV-expressed proteins can be divided into those 
that are considered as EV markers and those that reflect the EV cellular origin, localisation and 
mechanisms of secretion. Cytosolic, cytoskeletal, plasma membrane and heat shock proteins have 
been found to be the most prevalent groups of EV proteins, although the data on EV proteomic 
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profile varies depending on the isolation and proteomic analysis techniques [Yanez-Mo M, 2015], 
which as discussed above are currently not unified and still being developed. 
Unfortunately, the EV proteins which are commonly used as markers often lack specificity but have 
been used in the literature due to the fact they are enriched in EV populations. These include 
tetraspanins (CD9, CD63, CD81 and CD82), 14-3-3 proteins, major histocompatibility complex (MHC) 
molecules and cytosolic proteins such as Alix, Tsg101 and heat shock proteins [Witwer KW, 2013]. 
Up until recently, it was believed that CD9, CD63 and CD81 could be used as exosome-specific 
markers but recent studies have shown that these tetraspanins are also present in apoptotic bodies 
and microvesicles [Tauro B, 2013, Crescitelli R, 2013]. 
EVs have also been found to contain an array of various cytokines such as Interleukin 1β (IL-1 β) , 
Interleukin 1α (IL-1 α), Interleukin 6 (IL-6), Interleukin 8 (CXCL8),  Transforming growth factor β (TGF 
β), Macrophage migration inhibitory factor (MIF) and vascular endothelial growth factor (VEGF) 
[Yanez-Mo M, 2015]. 
Table 1.1 demonstrates cell-specific markers used for EV analysis based on current experience from 
the literature. [Gustafson CM, 2015, Yuana Y, 2013] 
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Tab.1.1 Common markers used in EV analysis of biological fluids.  
 
 
Cell type 
 
 
Surface marker/antigen 
Erythrocytes CD235a, CD236 
Retikulocytes CD71 
Platelets 
 
CD41, CD42a, CD42b, CD61 
Leukocytes CD15, CD45 
Monocytes CD11b, CD14 
B cells B cell receptor, CD19 
T cells CD2, CD3, CD86 
Endothelial cells CD31, CD62E, CD144, CD146, 
CD105 
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1.4.2 Genetic material in EVs 
1.4.2.1.RNA in EVs 
The presence of functional RNA was first described in EVs just over a decade ago [Ratajczak J, 2006, 
Lotval J, 2007]. It typically consists of less than 700 nucleotides [Chen TS, 2010, Batagov AO, 2013] 
and can be in the form of intact mRNA and RNA fragments, miRNA, long-non-coding RNA, ribosomal 
RNA, piwi-interacting RNA and lastly, fragments of tRNA-, vault- and Y-RNA [Yanez- Mo M, 2015]. 
Batagov et al reported that exosomes secreted by human cells contain mostly mRNA fragments 
enriched in the 3'-untranslated regions rather than intact mRNA. These regions contain sites for 
regulatory miRNA binding which suggest that RNA delivered to the recipient cells by EVs may 
compete with cellular RNA for miRNA binding and play an important role in translation [Batagov AO, 
2013]. Secretion of RNA into EVs appears to be controlled by an active sorting mechanism as studies 
have shown that certain nucleotide motifs have been enriched in the  RNA isolated from EVs 
[Batagov AO, 2011]. The heterogeneous nuclear ribonucleoprotein (hnRNP) A2B1 appears to play an 
important role in this process as it recognises the EXOmotif (GGAG tetranucleotide) in miRNAs and 
controls the loading of these miRNAs into EVs [Villarroya-Beltri C , 2013]. 
EV-contained RNA has been shown to affect the recipient cells in a number of studies starting from 
the landmark discoveries by Ratajczak et al whereby murine bone marrow mononuclear cells treated 
with EVs derived from embryonic stem cells and enriched in Oct4 mRNA showed an increase in Oct4 
protein expression [Ratajczak J , 2006]; and by Lotvall  et al showing that mouse mast cell-derived 
EVs incubated with human mast cells transfer their murine RNA into the recipient cells leading to 
translation into murine proteins [Lotvall J, 2007]. Since then, numerous studies have shown a role 
for EV-contained RNA in biological processes such as angiogenesis, tissue repair, cell differentiation 
and proliferation, and immune regulation [Bruno S, 2009]. It also appears that the mRNA EV content 
is determined by the parental cell functional and physiological status as it was reported that EV RNA 
content differed in mast cell-derived EVs grown under normal conditions and oxidative stress [Eldh 
M, 2010].  
1.4.2.2. DNA content of EVs 
The physiological role of DNA present in EVs is currently not well understood. Nevertheless, various 
forms of DNA have been described in EVs so far: mitochondrial DNA (mtDNA), single-stranded DNA, 
double-stranded DNA (dsDNA) and oncogene amplifications (i.e. c-Myc) [Balaj J, 2011, Gruescini M, 
2010, Thakur BK, 2014, Waldenstrom A, 2012, Lee TH, 2014]. The analysis of DNA content of EVs 
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reflects the mutations in the parental tumour cells [Thakur BK, 2014] which may have potential use 
in development of novel biomarkers in oncological conditions.  
1.4.3 Lipids in EVs 
Lipids are believed to play an important role in EV physiology and there have been numerous studies 
in the last 2 decades aiming to describe EV lipid composition and the differences between various 
cells/ clinical conditions. Generally, compared to the cells of origin, EVs are enriched in 
sphingomyelin, cholesterol, PS and glycosphingolipids [Record M, 2014]. Lipids play a role in EV 
generation and release; these include cholesterol, ceramide, lysobisphosphatidic acid (LBPA) and 
phosphatidic acid [Yanez-Mo, 2015]. Moreover, EVs also act as cargos for bioactive lipids between 
cells such as eicosanoids, fatty acids and cholesterol [Record M 2014]. These EV-contained lipids 
were reported to play a role in angiogenesis [Kim CW, 2002], reproduction, [Palmerini CA, 2006] and 
inducing cell death in cancer cells [Beloribi S, 2012]. Interestingly, the composition and 
concentration of EV fatty acids alters during the different stages of their cell of origin’s growth and 
differentiation, with some fatty acid composition changes mimicking those occurring in the cells and 
some being unique to the EVs as previously shown by our research group [Connolly K, 2015]. 
1.5 EV uptake mechanisms and interaction with membrane receptors 
EVs are involved in intercellular cell signalling in a number of ways: by being internalised by the 
target cell, by surface receptor/ligand interaction and finally by transfer of active receptors such as 
CCR5 (C-C Chemokine Receptor type 5) [Mack M, 2000], EGFRvIII (the epidermal growth factor 
receptor variant iii) [Al-Nedawi K, 2008] or tyrosine-protein kinase Met [Peinado H, 2012]. EV 
internalisation can occur via phagocytosis [Morelli AE, 2004,], micropinocytosis or direct fusion, but 
the latter is limited to the low pH conditions common within the tumour microenvironment (as the 
fluidity of EVs and plasma membranes differs at neutral pH) [Parolini I, 2009]. 
Intriguingly, some molecules delivered by EVs are thought to be more biologically active than their 
free soluble forms. This was shown for Fas ligands and metalloproteinases [Tanaka M, 1998, 
Shimoda M, 2013]. 
The receptor-ligand reactions between EVs and target cells are regulated by EV-expressed proteins 
such as MHC I and II [Simons M, 2009, Fevrier B, 2004], tetraspanins [Nazarenko I, 2010] and 
transferrin receptors [Calzolari A, 2006], which trigger various communication pathways in the 
recipient cells such as mitogen-activated protein kinase (MAPK) [Calzolari A, 2006], integrins and 
calcium signalling or natural killer group 2D (NKG2D) signalling [Clayton A, 2008, Macario AJ, 2010]. 
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For instance, human natural killer (NK) cells and tumour cells have been shown to release EVs which 
express ligands triggering cell death in their target cells such as FasL, TNF-related apoptosis-inducing 
ligand (TRAIL) or perforin [Lugini L, 2012, Cai Z 2012, Andreola G, 2002 ]. Moreover, some of those 
tumour-derived EVs are capable of inducing lysis of lymphocytes that were programmed to kill the 
tumour cells [Andreaola G, 2002, Huber V, 2006] which has significant clinical implications in the 
context of malignant disease progression. 
Another example of important receptor-ligand interaction EVs participate in, is the role of platelet-
derived EVs (containing platelet-endothelium attachment receptors (CD41, CD61, and CD62), 
cytokine receptors (TNF-RI, TNR-RII, and CD05), and ligands such as CD40L and PF-4) in facilitating 
platelet adhesion and coagulation pathways [Baj-Krzyworzeka M, 2002]. Hence, it is not surprising 
that patients with established cardiovascular disease, acute strokes or vascular dementia were found 
to have increased levels of circulating platelet-derived EVs in blood [Del-Conde I, 2005]. 
1.6 EV isolation 
As mentioned above, EV research is a novel area and at present, there are lots of variations in 
approach to EV isolation which makes it challenging for direct comparison of work from various 
research groups. Therefore, the International Society of Extracellular Vesicles (ISEV) has focused 
efforts in the last few years on creating recommendations for standardisation of EV research 
methodology [Witwer K, 2013]. 
It has been stressed that for research questions aimed at characterisation of EV size, concentration 
and content, particular attention must be paid to the reproducibility of assays used and optimisation 
of their sensitivity.  
1.6.1 EV isolation from blood 
For studies on blood-derived EVs, basic anthropometric and clinical information should be available 
such as age, gender, ethnicity, smoking status, use of anticoagulants and current medication list. It is 
also important to standardise the sample collection protocols by using the same needle type and 
same type of collecting tube/vacutainer, appropriate sample handling and use of the same type of 
centrifuge, rotor and speed [Witwer K , 2013]. The effects of the circadian rhythm on EV 
concentration are not fully known but it is recommended to standardise the collection time for the 
purpose of the study. A similar rationale is applied to time intervals from the last meal, hence fasting 
samples are most likely to minimise unnecessary sample-to sample variations [Witwer K, 2013]. 
It is also believed that it is plasma rather than serum which is the medium for EVs in blood under 
physiological conditions. Hence, unless specific questions relating to platelet-derived EVs are being 
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addressed, plasma is the biological fluid of choice for blood-derived EV characterisation [Witwer K, 
2013]. 
The optimal anticoagulant is still debated. Whilst the use of heparin-based additives is generally 
contraindicated due to their potential effect on PCR- readings or potential heparin binding to EVs 
and blockage of their uptake [Yokata M, 1999, Beutler E, 1990], the choice between alternative 
anticoagulants such as EDTA [2,2',2'',2'''-(Ethane-1,2-diyldinitrilo)tetraacetic acid], sodium 
fluoride/potassium oxalate or sodium citrate is still not clear. Macey M et al suggested that the use 
of calcium chelators may lead to in vitro associations between platelets and EVs, and lower the 
overall EV count in blood collected into EDTA or citrate tubes, but further research is required to 
validate these findings [Macey M, 2002]. 
For sample collection, a 21-gauge needle or larger is recommended; the first few millilitres of blood 
should be discarded due contamination with fibroblasts and the platelet activation effect from the 
tourniquet pressure. Vacutainer tubes should be handled gently and processed promptly with the 
maximum time from venepuncture to centrifugation of 30 minutes [Jayachandran M, 2012].  
1.6.2 EV isolation - cell culture medium 
For the analysis of EVs released spontaneously from a certain cell type, collection of medium 
following a 24-48-hour incubation period is recommended. Shorter incubation periods may be 
required if an effect of a certain stimulus on cell-derived EV release is being analysed. As most tissue 
culture media are supplemented by sera (such as foetal calf serum (FCS) or human serum) 
contamination with those sera EVs and RNA is likely to occur. In order to eliminate this risk an 
overnight 100000g ultracentrifugation of the media should be performed, which should not contain 
more than 20% serum [Witwer K, 2013]. A second solution is to culture cells in serum-free media for 
a set period of time. The disadvantage of the first method is the need for additional experiments to 
ensure a lack of bovine proteins, whilst the second approach may stimulate stress response in cells 
by rapid nutrient depletion, thus the profile of EVs may not fully reflect the physiological milieu.  The 
percentage of dead cells in the culture should also be established as well as ensuring no microbial 
contamination [Witwer K, 2013]. 
1.6.3 EV isolation techniques 
There have been many approaches to EV isolation reported to date such as differential 
ultracentrifugation, filtration or immunoaffinity isolation, and the field continues to rapidly expand. 
The main disadvantage of current methods is the fact that they are usually time consuming which 
limits their adoption in clinical laboratories for rapid patient sample analysis.  
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Differential centrifugation is the most commonly used method of EV isolation. The aim of this 
method is to deplete the starting sample from platelets, cells and apoptotic bodies by at least one 
low speed centrifugation step, which is then followed by high speed centrifugation to pellet EVs 
(100000g-200000g). Some approaches suggest an interim speed centrifugation at 10000-20000g in 
order to pellet larger EVs [Witwer K, 2103]. The main limitation of this method is the inability to 
perform accurate EV separation based on size; during the procedure aggregation of different EV 
types may occur.  Secondly, the pellet may contain contamination from protein complexes or 
lipoproteins. [Webber J, 2013] Some advocate pellet resuspension in PBS and repeat 
ultracentrifugation. This may increase sample purity, but such an approach is likely to result in loss of 
the EV yield. Additionally, various inconsistencies in reproducibility of this method arise form 
differences in centrifugation speed, time, temperature and rotor type [Livshits MA, 2015]. However, 
when my study was commenced, differential ultracentrifugation was the most common EV isolation 
method and it was used in the majority of my experimental work.  
In order to address the issue of sample purity, various density gradient separating techniques were 
developed recently originating from sucrose density gradient studies [Thery C, 2006], which allow 
separation of protein and RNA aggregates from vesicles. The approaches to this method differ, with 
many variations in sample loading time and sucrose tube length which may affect the characteristics 
of the EV pellets obtained. Furthermore, the risk of contamination with protein aggregates is not 
fully overcome [Thery C, 2006, Witwer K, 2013]. 
Size exclusion for EV isolation is based on the assumption that by forcing sample passage through 
physical barriers such as filters or chromatography, separation of EVs based on their size will occur.  
This method allows exclusion of larger particles form the analysed sample. The downside of this 
method is the potential effect of forcing particles through filters leading to EV deformation and 
break up of large EVs  causing inaccuracies in final results [Witwer K, 2013]. Moreover, this method 
as I describe later in my results, leads to significant sample dilution/loss. Therefore, it is 
recommended that size exclusion is performed by gravity [Gyorgy B, 2011]. 
Immunoaffinity isolation is a method that uses the presence of certain characteristic surface 
proteins on EVs to select the desired EV population (immunoenrichment) or, in contrast, to deplete 
the sample of EV populations that are unwanted (immunodepletion) [Witwer K, 2013]. Antibodies 
are usually associated with beads (typically against tetraspanins (CD9, CD63, CD81) or immune-
regulator molecules (MHC I and II) present on the EV surface, which enables physical separation by 
magnetic techniques or low speed centrifugation [Oliveira-Rodríguez M, 2016, Lynch S, 2009]. The 
obvious advantage of this approach is its high specificity when analysing a particular EV 
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subpopulation, but this is compromised by lower EV yields as well as high cost and importantly, the 
potential loss of EV functionality [Thery C, 2006]. 
Polymeric precipitation is a method where biological samples are incubated with commercially 
available polymeric precipitation mixtures; subsequent centrifugation generates an EV precipitate, 
particularly exosomes. The potential disadvantage of this method relates to possible sample 
impurity, since the precipitating liquid may bind to non-EV particles such as lipoproteins [Witwer K, 
2016]. 
New methods on the horizon 
An affinity-based technique was recently described by Nakai et al which is based on Tim4 protein 
binding to phosphatidylserine (PS) which is present on the EV surface as described above. The 
authors used K562 cells and peritoneal macrophages to show enrichment in CD63, Flotillin2, CD9 
and CD81 markers in the small EVs (sEVs) in comparison to older isolation methods such as 
ultracentrifugation, with good recovery of the EV protein profile [Nakai W, 2016].  However, this 
method does not allow separation of exosomes from microvesicles and apoptotic bodies, since all 
these EV subpopulations can express PS.  
Microfluidic devices are another emerging alternative which have the advantage of being quick and 
requiring only a small amount of sample. They can be divided into sub-categories based on the 
methodology applied within them: sieving nanoporous membranes trapping EVs on porous 
structures, and immunoaffinity EV trapping [Liga A, 2015]. However, these devices also have 
numerous limitations at present and further improvements are required before they can be applied 
more widely. 
As all EV isolation methods available currently have some disadvantages, the combination of 
different isolation techniques is often performed in practice, such as ultracentrifugation and size 
filtration. However, this may again affect the final EV yield. With the rapidly developing 
improvements in EV methodology, a main focus over the next few years will be to develop a gold 
standard approach which can be reproduced easily and reliably across various laboratories. 
1.7 EV sample storage 
Should the biological fluid require a period of storage prior to EV isolation (as is the case with 
complex clinical studies requiring multiple samples), it is recommended that it should be rendered 
platelet- and cell-free prior to storage. There is no consensus, however, on the effects of different 
temperatures on EV recovery and characteristics. The work conducted by my colleague Dr K 
Connolly on the methods (4 Cͦ, -20 C̊, -80 Cͦ, liquid nitrogen) and length (1 day, 1 week, 1 month, 3 
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months) of storage of EVs revealed that EVs kept short term in the fridge (4 Cͦ) retained the closest 
concentration to that of fresh EVs and that long term storage irrespective of method increases EV 
concentration. [Connolly K, 2015] Therefore, the experimental work presented in this thesis 
evaluating EV characteristics is performed on samples which were stored for a maximum of 5 days at 
4 Cͦ following isolation from plasma/medium. 
The most widely used long-term storage temperature is -80 Cͦ and PBS is the diluent of choice [Thery 
C, 2006]. Moreover,  siliconised storing vessels should be used to prevent EV adherence to surfaces 
and their subsequent loss [Witwer K, 2013]. Whilst data on the effect of repeat freeze/thaw cycles 
on EV recovery are limited, this should be avoided nevertheless. If required, samples should be 
frozen and thawed rapidly for the best preservation of their function and morphology [Witwer K, 
2013]. 
1.8 EV characterisation methodology 
1.8.1 EV morphology 
Electron microscopy (EM) is a useful tool for visualisation of EV morphology and size measurement 
but cannot be used to assess EV concentration.  It can also be used to evaluate the presence of 
membrane markers when nanogold particles coupled with immunoglobulins are used [Witwer K, 
2013]. Atomic force microscopy is an alternative method to evaluate EV morphology [Gyorgy B, 
2011]. 
1.8.2 EV concentration and size 
Nanoparticle tracking analysis (NTA) is a technique where EV size and distribution can be established 
using commercial equipment, in which a laser beam scatters through a particle suspension and their 
Brownian motion are recorded by CCD camera.  The Stokes-Einstein equation is then applied to 
calculate the particles’ mean velocity. The limitation of this method is the fact that it cannot 
distinguish EVs from large protein complexes, hence the concentration calculated by the software 
may be skewed by the presence of such complexes.   
Resistive pulse sensing (qNano) is an alternative technique to NTA for measurement of size and 
concentration. This method is based on the assumption that transport of a vesicle through a 
nanoporous membrane will lead to a transient decrease of the ionic current. However, for 
characterisation of heterogeneous EV populations, various nanopore membranes may need to be 
used as each of those membranes only detects particles of a certain size [Witwer K, 2013].  
Flow cytometry (FC) enables quantitative and qualitative measurements of small particles but its use 
in EV research was until recently limited by the fact that most flow cytometers have detection 
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thresholds around 300-5000nm and are thus unable to detect small EVs such as exosomes. However, 
with the advent of new generation flow cytometers such as Gallios (Beckham Coulter) or DD-Influx 
(Becton Dickinson), smaller particles down  to100-200nm in diameter can now be detected which 
will likely result in more widespread adoption of this method for EV characterisation [Witwer K, 
2013]. 
1.8.3 EV  content 
Western Blot has been widely used to demonstrate the presence of proteins regarded as EV markers 
(such as CD9, CD63, CD81) or cytosolic proteins such as Alix or Tsg 101. The limitation of this method 
is that it does not allow measurement of EV quantity or distinguish between various EV 
subpopulations.  In addition, it may reflect the presence of contaminating proteins. 
Immunoaffinity assays can be used to detect the presence of an antigen of interest within the EV 
population. It has been adapted by our group based on the work of Webber J et al [Webber J, 2014] 
and is described in more detail in chapter 2.  
For functional EV studies, dose-response experiments should be included and density gradients for 
isolation are recommended, in order to ensure that it is the intrinsic content of EVs that is 
responsible for any observed effect. Labelling studies are also encouraged [Witwer K, 2013]. 
1.8.3.1 ISEV recommendations 
Given current limitations in EV isolation and processing as described above, ISEV created a set of 
minimal experimental criteria to define EVs and their function, in an attempt to standardise the wide 
variations reported in EV methodology [Lotval J, 2014]. 
Firstly, as mentioned above, EVs should be isolated from extracellular fluids such as cell culture 
medium, plasma or other bodily fluids and samples should be handled gently to prevent cell 
disruption which could contaminate the samples with vesicles from intracellular compartments. 
For EV characterisation and protein content/expression, at least a semi-quantitative method should 
be used and at least 3 proteins should be reported in an EV preparation. 
This should include various groups of protein: a) proteins that are expected to be present within the 
EV population such as tetraspanins or certain cytosolic proteins, and b) proteins that are not 
expected to be seen, and therefore their presence or absence in the analysed sample will give an 
indication of sample purity [Lotvall J, 2014]. 
19 
 
The use of EV protein databases such as Vesiclepedia is encouraged to compare the protein profiles 
of various samples. It is encouraged that negative controls are used to compare EV samples against 
EV-depleted fluids when various commercially available antibodies are used first [Lotvall J, 2014]. 
For the characterisation of a single vesicle, two main methods should be applied: size distribution 
such as NTA or dynamic light scattering, and electron or atomic force microscopy [Lotvall J, 2014]. 
The four main groups of proteins expected to be analysed in EV samples are summarised below: 
[Lotvall J, 2014] 
1. Transmembrane or lipid-bound extracellular proteins such as tetraspanins (CD9, CD63, 
CD81), heterotrimer G proteins, adhesion molecules/integrins, GH (Growth Hormone) factor 
or lactadherins  are proteins which are usually present/enriched in EVs/exosomes which 
prove the presence of a membrane  in the isolated sample. 
2. Cytosolic proteins with membrane or receptor binding capacity such as ALix, TSg101 or 
syntenins are also present or enriched in EVs/exosomes. 
3. Intracellular proteins  which are associated with other than membrane/endosomes cellular 
compartments and  should be absent or depleted in exosomes but can be present in other 
EV types. Examples include: Endoplasmic reticulum (Grp94=HSP90B1, calnexin=CANX),Golgi 
(GM130), Mitochondria (cytochrome C=CYC1), Nucleus (histones=HIST*H*)  or 
Argonaute/RISC complex (AGO*). 
4. Extracellular proteins which have variable associations with EVs as they can bind specifically 
or non-specifically to membranes and co-isolate with EVs. Examples include: cytokines, 
metalloproteinases, collagens, serum albumin, growth factors or acetylcholinesterase.  
At least one protein of groups 1-3 should be quantified in the EV preparation. 
 
The EV-TRACK knowledge base has recently been launched [van Deun J, 2017] which enables 
scientists to use various tools for effective EV research and to obtain an EV-METRIC for their 
manuscript on the methodology used. This facilitates transparency.  
ISEV recognised, however, that our knowledge on what the EV and non-EV proteins are, is still 
developing which may affect the ‘minimal criteria’ of EV characterisation. The Society also 
acknowledges that it sometimes may be difficult to perform all the protein expression experiments 
due to limited amount of EV material [Witwer K,  2017].  
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1.9 EV function 
EVs have been reported to be involved in numerous biological processes to date. EV biological roles 
can be broadly divided into 3 categories: remodelling and/or removal of cellular components; 
vectors of intercellular communication by direct EV content uptake by neighbouring and distal cells, 
transfer of cell surface proteins or receptor-ligand reaction, and finally regulation of the local or 
distal cell microenvironment by modification of immune reactions, cell migration and angiogenesis 
[Gonda D, 2013]. 
Interestingly, the proposed function of EVs in the context of certain pathologies can differ which may 
be due to variability in isolation and characterisation methodology between various research 
laboratories. However, it could also indicate biological plasticity of EVs and the fact that different 
intracellular compartments of origin subsequently lead to different EV function, reflected in a 
different EV composition. Therefore, tools for better separation of EV populations are essential in 
order to advance the potential use of EVs in clinical practice.  
Plasma-derived EVs comprise a heterogeneous group of EVs originating from cellular blood 
components as well as endothelial cells. In pathological conditions, however, other EV sources may 
also appear in the circulation, such as tumour-derived EVs in malignancy. Platelet-derived EVs are 
believed to be the most abundant circulating EV population, comprising around 25% of total blood 
EVs [Aatonen MT, 2014]. They are mainly involved in haemostasis and possess procoagulant 
properties, which may hold particular relevance in conditions such as cardiovascular disease, 
diabetes mellitus, sepsis or cancer [Aatonen MT, 2013].  Leukocyte-derived EVs seem to play an 
important role as paracrine messengers in both innate and acquired immunity. Along with platelet-
derived EVs, they are also involved in angiogenesis. Reticulocyte –derived EVs are involved in the 
erythrocyte maturation pathway. There is also a growing body of evidence for EV involvement in 
tissue repair and organogenesis, bone calcification, liver homeostasis and neuronal communication 
[Aatonen MT, 2013]. It is, however, important to state that at present the proportions of circulating 
plasma EV subpopulations described in various published manuscripts depend to a certain degree on 
the isolation and characterisation techniques used. As discussed previously these have various 
limitations and there is currently no method with 100% detection/capture rates that would ensure a 
true reflection of physiological plasma EV distribution. Moreover, circulating plasma EVs profiles are 
not static and change in response to various stages of acute illness. For instance, Chiva-Blanch et al 
compared the circulating EV profile from patients at various timepoints following an acute ischaemic 
stroke (within 48 hours of onset, day 7 and day 90) to EVs from a high cardiovascular risk control 
group. They reported increased EVs shedding from blood and vascular compartment cells and neural 
progenitor cells at all those timepoints in the stroke arm and also changes in the EVs proportion at 
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90-day follow-up in those with the largest post-stroke cerebral lesions – with decrease in neural
precursor cell derived EVs and increase in smooth muscle cell-derived EVs [Chiva-Blanch G, 2016]. 
EVs also play a role in cellular waste management as they may contain redundant intracellular 
material which is then secreted within EVs by the cells and removed from the circulation through 
phagocytosis by the other cells. The spleen is likely to be involved in clearing these EVs from the 
circulation [Davilla M, 2008]. 
Inflammation/immune system 
EVs have been found to modulate the immune response in a number of ways, exhibiting both pro-
and anti-inflammatory properties on the local microenvironment. With regard to anti-inflammatory 
responses, EVs were described to affect the expansion of T regulatory cells and stimulate their 
function which leads to suppression of the host immune reaction [Szajnik M, 2010]. They contain a 
variety of different cytokines such as interleukin 10, cytotoxic T-lymphocyte antigen-4, transforming 
growth factor-β1 and also Fas ligand, which initiates Fas-dependent apoptosis in lymphocytes [Kim 
JW, 2005].  In melanoma patients, tumour-derived EVs were shown to  hinder the differentiation of 
monocytes into dendritic cells (DCs) and stimulate the differentiation of myeloid cells with 
Transforming Growth Factor-β–Mediated Suppressive Activity on T Lymphocytes (CD14+HLA-
DR−/low) [Valenti R, 2006].  They were also found to contain annexin-1 which has anti-inflammatory 
properties [Dalli J, 2008].  
Interestingly, not only leukocyte- but also platelet-derived EVs have been found to be involved in 
modulation of immune responses by delivering CD40 ligands (also known and CD154) to promote 
adaptive immune responses via CD4+ T cells [Sprague DL, 2008]. 
Additionally, EVs are enriched in molecules involved in antigen presentation, such as major 
histocompatibility complex class I and II molecules [Androela G, 2002].  It has been shown that cells 
infected by various pathogens release EVs presenting the pathogen-derived antigens which leads to 
stimulation of T cells [Walker JD, 2009]. Berckmans et al showed that leukocyte-derived EVs from 
synovial fluid from patients with rheumatoid arthritis stimulate synoviocytes to secrete 
inflammatory molecules such as monocyte chemoattractant protein-1 (MCP-1), IL-8, IL-6, RANTES 
(regulated on activation, normal T cell expressed and secreted), ICAM-1 (Intercellular Adhesion 
Molecule-1) and VEGF (Vascular Endothelial Growth Factor) [Berckmans RJ, 2005]. 
Angiogenesis 
EVs have been shown to have both a pro- and anti-angiogenic role in studies evaluating endothelial- 
and platelet-derived EVs. Endothelial cell-derived EVs contain metalloproteinases such as MMP-2 
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and MMP-9 which play a role in matrix degradation and thus help to initiate formation of new blood 
vessels [Tarabolletti G, 2002].  EVs derived from platelets have also been shown to promote
formation of capillary-like structures in both in vitro [Kim KH, 2004] and in vivo mice models [Brill A 
2005]. This may be particularly important from the tumour biology point of view since platelet-
derived EVs play a role in tumour metastasis and angiogenesis by stimulating the expression of 
growth factors such as VEGF and HGF (hepatic growth factor), matrix metalloproteinases and 
interleukin-8 [Janowska-Wieczorek A, 2008]. Interestingly, tumour cell-derived EVs can also promote 
angiogenesis themselves as they are enriched in IL6, IL8 and angiogenin [Skog J, 2008]. 
Moreover, adipocyte-derived EVs (from 3T3-L1 cells and rat adipocytes) were recently shown to 
contain various angiogenic factors and exhibit angiogenic activity in vivo in obese mice.  They also 
stimulated cell migration and  tube formation of endothelial cells derived from human umbilical 
veins and promoted endothelial cell invasion through extracellular matrix [Aoki N, 2010]. 
 On the other hand, endothelial cell-derived EVs as well as lymphocyte-derived EVs have the ability 
to hinder angiogenesis by increasing the production of reactive oxygen species (ROS) and reducing 
nitrite oxide (NO) [Yang C, 2008, Burger JA, 2006].
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Coagulation 
The role of EVs in coagulation is not yet fully characterised though they have been widely reported 
to initiate and augment platelet aggregation. In 1999, Giesen et al reported that cell-derived vesicles 
obtained from plasma of healthy individuals expressed tissue factor (TF) which initiates coagulation. 
[Giesen PI, 1999]. As EVs also express phosphatidylserine (PS), they provide the catalytic surface for 
formation of the tenase (factors VIIIa, IXa, and X)  and prothrombinase (factors Va, Xa, and II)   
coagulation cascade complexes [Tripisciano C, 2017]. Moreover, PS might play a role in changing TF 
into its biologically active form [Spronk HM, 2014].  Interestingly, not only blood but also urine and 
saliva contain EVs expressing coagulant TF under physiological conditions [Berckmans RJ, 2011]. 
Numerous studies have reported the presence of procoagulant TF in EVs derived from patients 
suffering from malignancy-associated venous thromboembolism [Tesselaar ME, 2007], sepsis 
[Nieuwland R, 2000], coronary artery disease [Nieuwland R, 1997] or sickle cell disease [Shet As, 
2003].  On the other hand, in bleeding disorders such as Scott syndrome defective microvesicle 
formation was described secondary to impaired scramblase activity resulting from a calcium-gated 
ion channel mutation (TMEM16F) [Malvezzi M, 2013]. The decreased PS exposure and decreased 
procoagulant EV secretion is believed to lead to low prothrombinase activity in this condition [Toti F, 
1996]. 
1.10 Potential application of EVs 
Circulating EVs are elevated in numerous conditions including diabetes mellitus, cardiovascular 
disease, malignancies, liver disease and autoimmune disorders [Van der Pol E, 2012]. Given that they 
contain protein and miRNA derived from their parental cells, they may represent novel biomarkers 
for early disease detection and assessment of treatment response, particularly in cancer 
management [Kalluri R, 2016]. 
However, although specific EV subtypes are increased in various pathological conditions, their 
biological role under such circumstances appears to be ambivalent; they might promote the 
pathological process but might also promote protective and tissue repair pathways. Endothelial EVs 
are a good example of this plasticity and diversity; on the one hand, they have been found to impair 
endothelial function and dilatation, whilst on the other they can stimulate endothelial proliferation 
and repair [Digant-George F, 2011]. 
Of additional interest, EVs appear to be promising therapeutic agents within the field of 
nanomedicine. This potential is being explored in the context of cancer and infectious disease 
vaccinations, immunosuppressive and regenerative therapies and as drug-delivering nanovectors, 
with numerous trials already in progress  [Fais S, 2016]. 
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1.10.1 EV role as biomarkers 
EVs have a potential use as biomarkers in establishing the presence of disease, predicting the risk of 
developing it or evaluating response to therapy. For instance, the presence of leukocyte-, platelet- 
and endothelial cell- derived EVs was shown to affect the Framingham risk score (a risk assessment 
tool to estimate a patient's 10-year risk of developing CVD) in recent studies [Chironi G, 2006, Ueba 
T, 2010, Nozaki T, 2009]. In oncology, EV content seems to reflect tumour cell plasticity and 
molecular changes; samples are also easier /quicker to access than traditionally used methods such 
as repeated biopsies. This may be particularly important in the management of rapidly progressing 
tumours such as glioblastoma multiforme (GBM) as it may help to predict the effectiveness of 
planned therapy and/or development of resistance to therapy used. For instance, the microfluidic 
chip device developed recently showed that EVs isolated by this method from GBM patients 
expressed increase EGFR, EGFRvIII, podoplanin, and IDH1 R132H proteins compared to healthy 
volunteers. Higher levels of these proteins were associated with failure to respond to standard 
treatment with temozolomide and radiotherapy [Wykosky J, 2011].  
Gene expression analysis of EV-contained DNA, mRNA, miRNA, methylation status and proteins by 
microarray as well as sequencing of EV nucleic acids in a search for tumour-specific mutations offers 
another potential tool for clinical application but is currently hindered by  methodological 
limitations.  
1.10.2 EVs’ role in pharmacotherapy 
1.10.2.1 Modulation of EV secretion 
Given the multiple biological functions of EVs as described above, there are various possibilities to 
use them in modern pharmacotherapy. These can be broadly divided into blocking of EV secretion 
and uptake, and the use of EVs as cargos for immunotherapies or targeted gene/drug delivery.  
As discussed, EVs have been shown to be raised in numerous pathological conditions and affect 
various processes such as angiogenesis, immune responses, and tumour invasion and metastasis 
[Gonda D, 2013]. Therefore, development of mechanisms that stop their release from cells and their 
uptake could in theory help to stop the pathological processes mediated by EVs. Interestingly, some 
commonly used old generation drugs such as amiloride, imipramine and proton pump inhibitors 
(PPI) were shown to reduce EV secretion by various mechanisms: amiloride, a diuretic, decreases 
calcium influx into the cells [Bianco F, 2009]; the antidepressant imipramine inhibits 
sphingomyelinase [Bianco F 2009] and PPIs affect EV release by interaction with the tumoral acidic 
extracellular environment [Luciani F, 2004].  Iero et al showed that patients with cancer treated with 
amiloride had reduced EV production and tumour-mediated immunosuppression [Iero M, 2008] 
25 
whilst mice studies on melanoma showed that pre-treatment with PPIs leads to increased sensitivity 
to chemotherapy with cisplatin by reducing the efflux of the drug via EVs [Chalmin F, 2010]. Al 
Nedawi et al hindered EV uptake into surrounding cells by inhibiting their fusion to plasma 
membranes by reducing the horizontal propagation of the EGFRvIII oncogene using annexin V, a 
scaffolding protein that blocks phosphatidylserine exposure [Al Nedawi K, 2008].  
Other potential EV specific strategies include interference with the ESCRT pathway by silencing 
genes encoding proteins such as HRS, Rab27a, STAM, or TSG101 which are required for EV 
production [Savina A, 2003]. Bobrie et al also showed in their in vivo study on mammary carcinoma 
cells that blockade of Rab27a resulted in decreased exosome secretion and subsequent decreased 
primary tumour growth and lung dissemination of a metastatic carcinoma [Bobrie A, 2012]. 
Moreover, my colleague, Dr N Burnley-Hall showed that release of EVs from hypoxia-exposed human 
endothelial cells can be reduced by treating the cells with sodium nitrite (NaNO2) which increases 
HIF1α degradation.  This effect is further attenuated by the addition of allopurinol which inhibits 
xanthine oxidoreductase, thus stopping the conversion of nitrite to nitric oxide [Burnley-Hall N, 
2017]. 
1.10.2.2. EVs used as pharmacotherapy vectors 
EVs are promising vectors for novel therapies for a number of reasons and they appear 
advantageous over artificial nanoparticles that have been developed for drug delivery.  Firstly, EVs 
have the right biophysical properties in the form of a gel-like cytoplasm-derived core and 
deformable cytoskeleton [Hood JL, 2012], and near neutral, slightly negative zeta potential which 
enables them to exist longer the circulation [Zhao W, 2011]. Moreover, due to their size, EVs have 
the ability to cross the gap between endothelial cells in the tumour vasculature (which is typically 
around 400nm) and transfer into the tumour microenvironment [Hood JK, 2012]. Lastly, EVs are well 
tolerated by the immune system compared to synthetic nanoparticles and contain various ligands 
and co-receptors which enable intercellular signalling processes, as discussed previously. EV 
modification for the purpose of pharmacotherapy can be undertaken endogenously at the cellular 
level or exogenously following EV isolation. The latter can be modified by alteration of their surface 
molecules, loading of hydrophobic therapeutics into the EV membrane or loading of hydrophilic 
molecules into the EV core [Gonda D, 2013]. 
As discussed above, EVs are involved in modulation of various immune processes. The role of 
immunotherapies in oncology has recently gained considerable interest. The potential ability of EVs 
to stimulate cytotoxic T lymphocytes against tumour cells has made them a promising novel 
therapeutic vector which is already reflected by some recent preliminary studies both on animal 
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models and in phase I trials. For instance, Escudier et al reported that metastatic melanoma patients 
who received a 1-month weekly cycle of subcutaneous and intradermal autologous dendritic cell-
derived EVs pulsed with MAGE 3 (Melanoma associated antigen 3) showed promising results in 
terms of disease progression control with no major toxicity reported [Escudier B, 2005]. Similarly, 
Morse et al applied autologous dendritic cell-derived EVs loaded with MAGE-A3, -A4, -A10, and 
MAGE-3DPO4 peptides used as  4 treatment cycles for patients with advanced non-small cell lung 
cancer (n=9). They also demonstrated good response, no major side-effects and achieved long term 
stability of disease in some patients [Morse M, 2005].  Moreover, Dai et al showed that in patients 
with advanced colorectal cancer (n=40) subcutaneous injection of autologous exosomes isolated 
from ascitic fluid, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), 
induced a tumour-specific anti-tumor cytotoxic T lymphocyte (CTL) response [Dai S, 2008]. 
Finally, EVs can potentially be used as vectors for targeted delivery of therapeutic agents which is 
particularly important in the management of malignancies since systemic chemotherapy is 
associated with significant side-effects and damage to healthy cells. A proof-of-concept study by Dai  
et al on murine models showed that si-RNA was successfully delivered through the blood-brain-
barrier to neurons by EVs derived from dendritic cells which were engineered to express rabies viral 
glycoprotein (RVG) and Lamp2b protein,  a constituent of exosomes [Dai S, 2008]. Apart from 
transferring small RNAs, transfer of active signalling molecules is also being explored in order to 
affect cells’ response to therapy [Lachenal G, 2011]. 
Once the mechanisms of EV protein and miRNA sorting are fully elucidated, targeted drug delivery 
and potential modulation of the recipient cell’s gene expression could ultimately revolutionise future 
pharmacotherapy. 
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2. Adipose tissue
2.1  Overview 
Adipose tissue (AT) is now considered as an active endocrine organ secreting a variety of hormones 
and cytokines and playing an important role in modulation of various metabolic processes. This is in 
addition to the traditionally well-known role of AT in ‘energy storage’ by accumulation of neutral 
triglycerides (TG) via the lipogenic pathway.  AT consists of adipocytes and preadipocytes, 
fibroblasts, macrophages, endothelial cells and leukocytes. The storage of TGs in the adipocytes 
leads to increased size of lipid droplets and subsequent adipose expansion and development of 
obesity [Tan CY, 2008].  On the other hand, AT-stored TGs can undergo lipolysis into free fatty acid 
(FFA) and glycerol when energy expenditure is increased under conditions of starvation [Lafontan M, 
2009]. Under such circumstances, FFAs and glycerol are transported via blood to muscles, liver and 
other organs which modulates the energy homeostasis in the body [Frayn KN, 2002]. 
2.2 AT classification 
In general, AT can be divided into 2 types: white adipose tissue (WAT) and brown adipose tissue 
(BAT). The latter is mainly involved in the dissipation of surplus energy into heat via uncoupling 
protein 1 (UCP1). Interestingly, over the last few years it has emerged that WAT contains an 
adipocyte population described as beige or brite  (“brown-like-in-white”) in which UCP1 expression 
can be stimulated by cold stress or β3-adrenoceptor agonists [Barbatelli G, 2010, Bostrom P, 2012]. 
Given the thermogenic properties of beige and brown adipose tissue, there has been interest in 
recent years in their potential application in the management of obesity [Ishibashi J, 2010].  Mice 
studies have shown that an increase in circulating factors such as natriuretic peptides, Fibroblast 
Growth Factor 21 (FGF-21) and irisin can enhance the function of brown and beige AT depots [Harms 
M, 2013]. Therefore, therapies which enhance BAT activity or augment its content, or lead to trans-
differentiation of non-BAT progenitors into BAT-preadipocytes,  could potentially open a  new 
chapter in targeted therapies for obesity [Reddy NL, 2014]. 
White, brown and beige adipocytes differ in morphology, origin, mitochondrial content and 
thermogenic abilities. WAT mainly consists of white adipocytes varying from 25-200µm in size and 
containing a unilocular lipid droplet and very few mitochondria. They therefore have a low oxidative 
rate [Jeanson Y, 2015] but, as discussed above, have the ability to store energy in the form of TGs. 
White adipocytes originate from resident mesenchymal cells within WAT. Generally, there are 2 
main types of WAT based on their anatomical location: visceral adipose tissue (V-AT) such as 
mesenteric, retroperitoneal and perigonadal fat, and subcutaneous adipose tissue (S-AT). These two 
depots, however, differ by much more than location. Other differences include adipocyte 
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development, cell morphology, biological function and molecular signature [Berry DC, 2013].  S-AT 
appears to be morphologically more heterogeneous as it contains both mature unilocular and small 
multilocular adipocytes and increased interstitial tissue component. In contrast, V-AT mainly consists 
of large unilocular cells [Tchernof A, 2006].  S-AT also displays an increased rate of cell turnover, 
leading to an increase in new adipocyte formation. It is believed that ‘younger’ adipocytes are not 
associated with the risk of developing metabolic dysfunction [Salans LB, 1973]. There are also 
differences in lipolytic rates between these two depots in response to external stimuli such as 
steroid hormones. Shi et al demonstrated in human and mice studies that the accumulation of AT 
within the viscera or neck tissue is more responsive to glucocorticoids whereas the accumulation of 
adipose tissue in a subcutaneous location appears to be stimulated by oestrogens [Shi H, 2009]. 
Finally, there are differences in transcription factors such as members of the homeobox (HOX) and 
forkhead box (FOX) family [Gesta S, 2006], and in gene expression. For example, expression of leptin, 
angiotensinogen and glycogen synthase is increased in S-AT compared to omental fat, whereas the 
latter shows elevated expression of the insulin receptor, 11β hydroxysteroid dehydrogenase (11β 
HSD) and interleukin 6 (IL6) [Gesta S, 2007]. 
It is therefore believed that these two AT depots have distinct biological functions. Simplistically, S-
AT is thought to be the more protective “good fat” whilst V-AT may be considered as “bad fat” 
associated with the metabolic complications of obesity [Berry DC, 2013]. 
In recent years, ectopic fat accumulation around the heart (pericardial and epicardial fat depots) as 
well as the PVAT (perivascular adipose tissue) adjacent to adventitia of most arteries has gained lots 
of interest due to its effects on cardiovascular function [Iozzo P, 2011]. The morphology and 
physiology of PVAT depends on its location; for instance, adipose tissue surrounding thoracic aorta 
was found to resemble BAT [Fitzgibbons TP, 2011]  whilst PVAT in mesenteric arteries resembles 
WAT [Guzik B, 2013]. These fat depots apart from providing structural support secrete a variety of 
adipokines such as TNFα, MCP-1, PAI-1, IL-6 which affects the inflammatory responses [Salgado-
Somoza A, 2010],  vascular tone [Maenhaut N, 2011], migration and proliferation of smooth muscle 
cells [Miao C, 2012] and neointimal hyperplasia and formation [Takaoka M, 2010]. Obesity leads to 
an increase in PVAT mass [Greenstein AS, 2009] and to alterations in its function. Increased 
production of  pro-inflammatory and vasoconstrictive adipokines affects the vascular relaxation 
response [Gao YJ, 2005, Xia N, 2017] and contributes to the development of cardiovascular disease 
in obese subjects. In the clinical context, measurement of pericardial/epicardial fat and  perivascular 
fat by echocardiography or computed tomography (CT) was shown to correlate with visceral adipose 
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tissue mass, BMI/waist circumference, LDL cholesterol, insulin sensitivity and low plasma 
adiponectin [Iacobellis G, 2003, Gorter PM, 2008]. 
Brown adipose tissue (BAT) was initially believed to play a role predominantly in temperature 
regulation in the neonatal period [Spiegelman B, 2001] where the adipocytes are mainly located in 
the dorsal region between the scapulae [Cannon B, 2004].  However, studies using 18F-
fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) have since 
shown that BAT is also present in some adults in the supraclavicular and lower neck areas 
[Nedergaard J, 2007]. Brown adipocytes originate from the dermomyotome, a tripotent engrailed 1 
(EN1)-positive cell lineage from which brown fat fibres, myocytes and the dermis develop [Atit R, 
2006]. Interestingly, a subset of brown as well as white adipocytes descends from a myogenic factor 
5 (MYF5)-positive source [Sanchez-Gurmaches J, 2012]. Brown adipocytes are enriched in 
mitochondria, which gives them their characteristic colour, and contain specialised proteins such as 
UCP1 which collapses the electron gradient causing heat rather than ATP generation.  
Beige adipocytes are a distinctive cell line mainly arising from Myf5− progenitor cells (similar to 
WAT) but they have a multilocular morphology and positive UCP1 expression [Wu J, 2012]. Beige 
adipocytes can develop via a number of different pathways, but the exact mechanisms are still 
poorly understood. Firstly, they can arise from Myf5− progenitor cells de novo. PDGFRα+ adipocyte 
precursor cells have also been shown to differentiate into beige adipocytes when stimulated by 
interleukin 4 receptor α (IL4Rα) signalling [Lee YH, 2012], and Sca1+ progenitor cells can develop into 
beige AT when induced with bone morphogenetic protein 7 (BMP7) [Schulz TJ, 2011]. ’Browning’ of 
WAT has also been induced by cold stress or its mimics via β3-adrenoceptor agonists [Young P, 
1984]. 
2.3 Adipose tissue turnover 
Our knowledge on the formation of adipose tissue is predominantly based on in vitro cell culture 
models. In fact, the term “adipogenesis” was first used to describe the transition of confluent 3T3-L1 
fibroblasts into lipid-laden cells following incubation with artificial inducers [Green H, 1975]. It has 
subsequently been shown that adipogenesis  is a complex process of differentiation of committed 
preadipocytes into mature adipocytes, with peroxisome proliferator-activated receptor γ (PPARγ) 
believed to play a key role in its regulation [Rosen ED, 2000] and multiple other signalling molecules 
involved such as insulin, thyroid hormone, glucocorticoids and TGFβ superfamily members 
(BMP2/BMP4/GDF3) [Berry D, 2013].  
In response to positive energy balance, AT can expand from 2-3% up to 60-70% of body weight 
[Hossain P, 2007]. There are two main types of adipose tissue expansion: hypertrophy and 
30 
hyperplasia, with the relative contribution of each component depending on a variety of factors such 
as genetic background, hormonal milieu, diet and fat depot site [Berry D, 2013].  Adipocytes are able 
to increase their storage of TGs leading to a 2-3-fold increase in their volume [Hirsch J, 1976]. This 
has a range of biological consequences, ranging from increased rate of adipocyte apoptosis and a 
shorter lifespan [Strissel K, 2007], to reduced sensitivity to insulin [Hossain P, 2007] and increased 
local inflammation and secretion of cytokines [Osborn O, 2012].  
In contrast, adipose tissue hyperplasia may lead to formation of small adipocytes which may play a 
protective role [Strissel K, 2007]. Studies have estimated that some 8% of adipocytes in humans turn 
over each year [Spalding K, 2008]. This suggests that adipose stem cell proliferation replenishes the 
adipocyte pool but the exact mechanisms initiating and controlling this process are not clear,  
although it appears this may be AT depot-specific [Berry D, 2013, Joe A, 2009]. 
2.4. AT function 
2.4.1 Energy storage 
AT is a primary organ for the storage of excess energy in the form of fat which is determined by the 
balance between lipogenesis and lipolysis. Lipogenesis is the process of fatty acid synthesis which 
then serves as energy storage. It is a dynamic process which is responsive to dietary intake with 
glucose being the main substrate, hence fasting leads to inhibition of lipogenesis whilst an increase 
in plasma FFAs and a high carbohydrate diet lead to its stimulation and a subsequent increase in 
plasma triglycerides [Kersten S, 2001]. Glucose is taken up by adipocytes via the insulin-dependent 
glucose transporter 4 (GLUT-4) and undergoes glycolysis to provide the substrate required for 
lipogenesis, glycerol-3-phosphate (glycerol-3-P). Lipid droplets of triacylglycerols are synthetized by 
esterification of glycerol-3-P from FFAs delivered to AT from the liver within VLDLs (very low-density 
lipoproteins) and chylomicrons from the intestine [Coehlo M, 2012]. AT-secreted hormones are 
involved in the regulation of lipogenesis, playing either stimulatory (angiotensin, acylation 
stimulating protein (ASP)) or inhibitory (leptin) roles. The opposite process, termed lipolysis, 
describes the hydrolytic breakdown of fat stores in the form of triglycerides into FFAs and glycerol to 
create energy. FFAs can be used as an energy source by other tissues by β-oxidation which converts 
them into acetyl coenzyme A molecules [Bemhlor DA, 2002, Coehlo M, 2012]. The main enzymes 
involved in lipolysis are hormone-sensitive lipase (HS-L) which is inhibited by insulin and 
monoacylglycerol lipase. The HS-L breaks the ester bonds in position 1 and 3 of the triacylglycerol 
molecules, with 2-monoacylglycerol lipase catalysing the hydrolysis of the remaining ester, leading 
to release of the FFA molecules and glycerol. FFAs are then bound to plasma albumin and 
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transported to peripheral tissues (muscles, liver) where they undergo oxidation whereas glycerol is 
moved back to the liver where it can be utilised for gluconeogenesis or oxidation [Coehlo M, 2012]. 
2.4.2 Adipose tissue as a secretory organ 
As mentioned above, AT is now considered as a potent endocrine tissue which secretes a variety of 
molecules named adipokines. These play important roles in the regulation of metabolism and 
inflammatory responses. They can be broadly divided into those secreted mainly by adipocytes such 
as leptin, adiponectin, resistin and chemerin and those secreted by AT resident immune and 
endothelial cells such as TNFα, IL6, MCP1, PAI1 or visfatin [Coehlo M, 2012].  A detailed analysis of 
all of these secreted factors is beyond the scope of this chapter hence only selected adipokines are 
described below.  Table 1.2 summarises the main biological functions of the principal adipokines .
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Adipokine    Biological role 
Leptin  Food intake, energy expenditure, reproduction, immune response, β-cells function, angiogenesis, haematopoiesis  
Adiponectin   Insulin sensitivity, energy expenditure, inflammation suppression; protective role against T2DM and CVD 
Resistin   Possible role in insulin resistance; inflammation 
IL6   Pro-inflammatory; lipid and glucose metabolism; regulation of body weight 
TNFα   Affects insulin receptor signalling, insulin resistance, inflammation, lipolysis, cell survival, adipokine action 
Adipsin   Links complement pathway with AT metabolism 
IGF-1   Stimulation of proliferation of various cells; mediates effects of growth hormone 
PAI-1    Inhibits fibrinolysis by blocking activation of plasminogen; vessel wall remodelling; adipokine action 
Angiotensinogen    Regulation of electrolytes and blood pressure 
ASP   Affects the rate of triacylglycerol synthesis in AT 
VEGF   Angiogenesis stimulation 
FGF21   Browning of WAT, thermogenesis 
TGFβ    Regulation of AT differentiation, fibrosis and endocrine and metabolic functions 
Chemerin, 
apelin, 
visfatin, 
MCP-1   Inflammation 
TNFα – tumour necrosis factor α , IL-6 – interleukin-6, PAI-1 – plasminogen activator inhibitor 1, ASP – acylation stimulating protein, VEGF – vascular endothelial growth factor, IGF-1 – insulin-
like growth factor 1; TGFβ- Transforming Growth Factor β; MCP-1- monocyte chemoattractant protein  
Tab.1.2: AT secreted molecules and their biological relevance. 
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 Adiponectin 
Adiponectin has been found to have a number of beneficial metabolic effects such as cardiovascular 
protection, improvement of insulin sensitivity, anti-inflammatory potential and stimulation of fatty 
acid oxidation and glucose uptake by peripheral tissues [Tomas, 2002, Haluzik, 2004].  Adiponectin is 
related to the complement 1q family and also shares some sequence homology with collagen VIII 
and X [Weisberg SP, 2006]. It is found in significant concentrations in human plasma compared to 
other adipokines (between 10-30 µg/mL) with no significant fluctuation; this suggests that its release 
is not regulated acutely but rather is determined by long-term metabolic status [Kadowaki T, 2005].  
It circulates in the form of trimers (approx. 67kDa), hexamers (approx. 120kDa) and multimers 
(>300kDa) with the latter believed to have the strongest insulin-sensitising potential [Tsao T, 2002, 
Waki H, 2003].  Each monomer of adiponectin consists of 3 domains:  an α-helical stalk of multiple G-
X-X repeats, an approximately 140 amino acid distinctive globular C-terminal, and a variable N-
terminal [Galic S, 2010]. The interchange between various adiponectin isoforms does not occur once 
in the plasma as the isoform is determined at the stage of secretion from adipocytes [Schraw T, 
2008].  Interestingly, a globular form of adiponectin has also been described (gAd) which is involved 
in activation  of the AMPK pathway in skeletal muscles, leading to increased fatty acid oxidation and 
glucose uptake [Yamauchi T, 2002]. 
Adiponectin exerts its action on various tissues via adiponectin receptor 1 and receptor 2 [Yamauchi 
T, 2003, Yamauchi T, 2007] which each contain seven transmembrane domains, but which differ in 
structure and function and in binding to T-cadherin [Denzel MS, 2010]. Various metabolic pathways 
are activated following receptor binding which contribute to the insulin-sensitising effect: these 
include AMPK, calcium, PPARα, ceramide and S1P (sphingosine-1 phosphate) [Yamauchi T, 2007, 
Zhou L, 2009, Holland W 2011]. The liver is the crucial organ for adiponectin’s involvement in energy 
homeostasis and insulin sensitivity where it has been shown to work in a number of ways: by 
reducing the expression of gluconeogenic enzymes such as glucose-6-phosphatase and 
phosphoenolpyruvate carboxylase [Nawrocki AR, 2006]; by enhancing ceramidase activity thus 
reducing hepatic ceramide content; and by affecting the biology of growth factors such as heparin-
binding epidermal growth factor (HB-EGF), fibroblast growth factor (FGF), and platelet-derived 
growth factor [Wang Y, 2005]. Adiponectin concentration decreases in obesity  and correlates 
inversely with BMI, triglycerides, glucose and insulin as well as visceral fat accumulation [De Rosa A, 
2013]. It plays an important role in preserving endothelial function and vascular remodelling, thus 
exhibiting antiatherogenic properties [Iwashima Y, 2004, Di Chiara T, 2014]. 
34 
Leptin 
Leptin was the first adipokine to be described [Zhang Y, 1994]. It is known as the “satiety hormone”  
as it has the ability to cross the blood-brain barrier to work on the hypothalamus and regulate food 
intake [Zhang Y, 1994, Morton GJ, 2011].  Following leptin’s binding with its receptors, orexigenic 
neuropeptide Y (NPY) and agouti-related protein (AgRP) neurons are inhibited [Schwartz MW, 1996]. 
Feeding is also controlled by regulation of other orexigenic neuropeptides, such as melanin-
concentrating-hormone (MCH), galanin, orexin and galanin-like peptide [Schwartz MW, 1996], and 
anorexigenic ones such as POMC, cocaine and amphetamine-regulated transcript (CART), 
neurotensin, corticotropin-releasing hormone and brain-derived neurotrophic factor (BDNF) [Liao 
GY, 2012]. Mice studies have shown that ob/ob mice (with deficiency of leptin) or db/db (with leptin 
receptor dysfunction) suffer from decreased energy expenditure and early onset obesity [Zhang Y, 
1994]. Plasma and AT leptin levels are dependent on the overall energy balance, hence obese 
individuals have higher concentration of plasma leptin and similarly fasting leptin levels are lower 
than in the post-prandial state [Coehlo M, 2012]. Females have been found to have higher levels of 
plasma leptin which can be explained by the inhibitory effect of androgens and stimulating effect of 
oestrogens but also by AT depot-related differences in leptin synthesis, which is greater in 
subcutaneous fat (higher in females) [Coehlo M, 2012]. 
Interestingly, apart from involvement in the regulation of energy expenditure and appetite, leptin 
receptors are expressed in various peripheral tissues suggesting its role is much more complex. For 
instance, leptin also has the ability to affect pancreatic β cells modulating insulin secretion [Marroqui 
L, 2012], to regulate immune responses [Naylor, 2016] and to act on reproductive organs [Perez-
Perez A, 2015].  
Despite its huge potential use in the management of obesity, the results from the use of 
recombinant leptin have thus far been disappointing [Farooqi IS, 1999] whilst clinical trials of the 
leptin sensitizer pramlintide demonstrated an unacceptable side-effect profile [Bluher M, 2014]. 
TNFα 
Adipocytes are capable of synthesising and secreting TNFα, but it is the stromal-vascular fraction 
containing macrophages that is the main source of this cytokine within AT [Coehlo M, 2012]. 
Interestingly, visceral AT contains more macrophages than subcutaneous AT [Trzeciak-Ryczek A, 
2011] which is one of the reasons visceral AT is believed to play a more important role in obesity 
pathogenesis. TNFα was the first described link between obesity, chronic inflammation and diabetes 
as this cytokine has been shown to impair insulin signalling in hepatocytes and adipocytes [Cai D, 
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2005], and decrease insulin-stimulated glucose uptake in skeletal muscles [Galic S, 2010]. Rodent 
studies revealed that neutralisation of TNFα improves insulin sensitivity in individuals without 
established T2DM, but it does not exhibit this action once T2DM is established [Galic S, 2010]. TNFα 
activates serine kinases such as the c-Jun-N-terminal kinase (JNK) or inhibitor of NF-κB kinase (IKK) 
and increases expression of suppressor of cytokine signalling 3 (SOCS3) which leads to inhibition of 
the signalling capability of insulin receptor substrate (IRS) [Coehlo M, 2012].  TNFα also reduces fatty 
acid oxidation in the liver which leads to accumulation of bioactive lipids such as diacylglycerols, in 
turn activating protein kinase C and inhibiting IRS [Galic S, 2010]. 
TNFα has been shown to have various effects on adipose tissue biology through activation of 
numerous signalling pathways: it induces insulin resistance in AT through suppression of PPARγ and 
GLUT4 mRNA expression, affects expression of genes encoding proteins involved in responses to 
oxidative stress, decreases production of insulin-sensitising adipokines and promotes secretion of 
those with proinflammatory properties. It also inhibits FFA uptake and lipogenesis, stimulates 
lipolysis and supresses the recruitment and differentiation of new adipocytes, thus diminishing AT 
lipid storage capacity [Cawthorn WP, 2008]. 
Interleukin 6 (IL-6) 
AT contributes to approximately 30% of circulating plasma IL-6, with V-AT producing more IL6 than 
S-AT [Coehlo M, 2012]. IL-6 secretion stimulated by IL-1 and TNFα is increased in obesity, correlating
with body weight and plasma free fatty acid concentration [Coehlo M, 2012].  Similarly to TNFα, the 
majority of AT- derived IL6 is secreted by the stromal-vascular fraction, with only around 1/3 
produced by adipocytes. IL6 impairs insulin signalling by upregulation of SOCS3 and it also induces 
lipolysis, inhibits lipoprotein lipase and increases glucose uptake [Galic S, 2010]. 
Fatty Acid Binding Protein 4 (FABP4) 
Fatty Acid Binding Protein 4 (FABP4), also known as aP2, belongs to a family of intracellular lipid 
chaperons that are involved in intracellular lipid trafficking and responses [Furuhasi M, 2008]. The 
expression of this protein is induced during adipogenesis and controlled by PPARγ, FFAs, insulin and 
dexamethasone [Amri E, 1991, Distel RJ, 1992, Kletzien RF, 1992,Cook JS, 1998, Melki S, 1993]. 
Within AT, FABP4 accounts for about 1% of all soluble proteins [Baxa C, 1989]. FABP4 has also been 
found in macrophages and dendritic cells [Makowski L, 2001], and also in endothelial cells within 
small vessels in the heart and kidneys [Elmasri H, 2009].  
Interestingly, it has been shown that FAPB4 can be secreted from adipocytes via ER-Golgi 
independent pathways: through activation of lipolysis by phosphorylation of HSL and the NPR-A-
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mediated GC-PKG (natriuretic peptide receptor A guanyl cyclase protein kinase G) pathway [Furuhasi 
M, 2014], and also through secretion by EVs [Nickel W, 2009]. Both of these mechanisms are 
upregulated by ionomycin which increases intracellular calcium and is downregulated by insulin 
[Kralisch S, 2014]. 
FABP4 has been shown to exert multiple extracellular roles such as enhancing hepatic glucose 
production [Cao H, 2013] and glucose-mediated insulin secretion from pancreatic β cells [Wu LE, 
2014] or supressing cardiomyocyte contractions in vitro [Lamounier-Zepter V, 2009].  In recent years 
plasma FABP4 has also emerged as a potent biomarker of metabolic dysfunction. It correlates 
positively with insulin resistance, waist circumference and blood pressure [Xu A, 2006], thus subjects 
with established T2DM, hypertension, cardiac dysfunction and atherosclerosis have higher 
circulating plasma levels than healthy controls [Yeung DC, 2007, Xu A, 2006]. FABP4 also appears to 
be a promising marker to predict future risk of developing cardio-metabolic dysfunction in 
apparently healthy individuals, as shown by recent 5- and 10-year prospective studies by Xu et al and 
Tsao et al [Tsa A, 2007, Xu A, 2007]. Therefore, pharmacological modifications of FABP4 could lead 
to development of a new class of drugs targeting obesity and its complications. Indeed, trials are 
currently being conducted to evaluate various strategies to inhibit or neutralise FABP4 [Furuhasi M, 
2007, Sulsky R, 2007]. 
Fibroblast growth factor 21 (FGF21) 
FGF21 has gained lots of attention in recent years due to its diverse biological functions as a hepato- 
adipo- and myokine [Luo L, 2016]. However, its exact mechanisms of action are not yet fully 
understood.  As discussed above, cold exposure induces FGF21 which, via its receptor 1c and 
coreceptor β-klotho [Itoh N, 2010], affects the expression of thermogenic genes in the BAT and 
inguinal WAT [Fisher FM, 2012, Adams AC, 2013]. Though FGF21 ‘browning’ and thermogenic effects 
are likely to have anti-obesogenic potential, circulating levels of this adipokine in obese subjects are 
elevated, suggesting possible resistance to its action in the presence of obesity [Chen W, 2008]. 
Resistin 
As its name implies, resistin is believed to be implicated in the development of insulin resistance. It is 
secreted by adipocytes [Savage D, 2001] as well as monocytes and macrophages [Patel L, 2003] and 
circulates as low molecular weight complexes and hexamers, with the latter being its active form 
[Patel S, 2004].  Resistin secretion is stimulated by inflammation, LPS (lipopolysaccharide), 
hyperglycaemia or IL6. The effects of resistin on glucose metabolism is through its negative 
modulation of insulin signalling on glucose uptake and by increasing hepatic gluconeogenesis 
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[Coehlo M, 2012]. It is likely to play a role in adipogenesis as its expression is higher in preadipocytes 
than in mature adipocytes [Steppan C, 2007]. 
 In rodents, resistin levels are significantly elevated in obesity and T2DM [Steppan C, 2001] but the 
results from human studies have been somewhat confusing, with some studies reporting similar 
associations [Oliver P, 2003, Gerber M, 2005] and others showing no significant correlation [Lee JH, 
2003, Iqbal N, 2005]. Nonetheless, resistin has been shown to stimulate the production of pro-
inflammatory cytokines and adhesion molecules such as Il6, TNFα, ICAM1, VCAM1 [Verma S, 2003], 
and to downregulate adiponectin signalling [Benomar Y, 2016]. 
Visfatin 
Visfatin, also known as pre-B cell colony-enhancing factor (PBEF), is mainly produced by visceral 
adipocytes and visceral AT resident macrophages, with only small quantities being made in 
subcutaneous AT. Its expression is increased in mature adipocytes compared to preadipocytes 
[Coehlo M, 2012]. Visfatin is considered a pro-inflammatory cytokine which has the ability to 
activate leukocytes and increase secretion of IL6 and TNFα [Coehlo M, 2012]. On the cellular level, 
visfatin is involved in regulating energy metabolism by affecting NAD+ biosynthesis and the activity of 
NAD+/NADH dependent enzymes [Manolescu B, 2008]. Interestingly, visfatin can act as an insulin 
mimetic: in in vitro studies as well as mice studies it was shown to lower glucose levels after binding 
to the insulin receptor [Wang P, 2009]. 
Other adipokines 
Amongst other AT secreted molecules, angiotensin, acylation stimulation protein (ASP) and 
plasminogen activator inhibitor 1 (PAI-1) are also worth mentioning given their potent biological 
roles. Angiotensin II was found to stimulate adipocyte differentiation, lipogenesis and prostacyclin 
synthesis, hence is thought to regulate adipocyte growth and differentiation [Coehlo M, 2012]. 
Interestingly, all components of the RAAS system are expressed by AT, including renin, 
angiotensinogen, angiotensin I-converting enzyme and the angiotensin II type 1 receptor [Ahima RS, 
2000]. This suggests that in obese individuals these AT-derived peptides play a role in blood pressure 
regulation [Carey A, 2006]. 
PAI-1 is a serpin predominantly secreted by endothelial and vascular smooth muscle cells but other 
sites including AT, stromal cells, monocytes and macrophages have been shown to produce it as 
well. Visceral AT is more involved in PAI-1 production and the contribution of AT -derived PAI-1 into 
the total plasma circulating pool is determined by the total fat mass [Coehlo M, 2012].  As PAI-1 is 
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mainly involved in fibrinolysis and its levels correlate with visceral fat it is often considered as an 
important link between CVD and obesity [Coehlo M, 2012].  
 ASP (acylation stimulating protein) stimulates triacylglycerol synthesis in AT and augments glucose 
transport by affecting the  translocation of glucose transporter type 4 (GLUT4). It also inhibits the 
actions of hormone specific lipase [Cianflone K, 2003]. Circulating plasma ASP levels are therefore 
increased in the postprandial state, obesity T2DM and CVD, whilst weight loss, exercise and 
starvation decrease circulating concentrations. Post-prandially, it is the subcutaneous AT depot that 
is involved in increased ASP production [Coehlo M, 2012]. 
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2.5 AT dysfunction and obesity- overview 
AT dysfunction leads to development of obesity and numerous related comorbidities such as 
cardiovascular disease (CVD), diabetes mellitus type 2 (T2DM) and malignancies. Obesity is 
considered as a state of chronic systemic low-grade inflammation [Itoh M, 2011]. The expansion of 
adipocytes leads to AT hypertrophy. Circulating monocytes are attracted to AT by a variety of 
cytokines secreted by adipocytes such as monocyte chemotactic protein (MCP-1), macrophage 
migration inhibition factor (MIF-1), macrophage inflammatory proteins (MIP-1α), chemokine CCL5 
(RANTES) and macrophage colony stimulating factor (M-CS F) [Ouchi N, 2011].  The proinflammatory 
cytokines are secreted from M1 macrophages infiltrating the AT originating from circulating 
monocytes, with the number of macrophages infiltrating the AT correlating with fat mass [Coehlo M, 
2012]. This leads to dysregulated adipokine secretion, with an increase in the pro-inflammatory 
cytokines IL-6 and TNFα, as well as leptin, resistin and free fatty acids, and a decrease in adiponectin. 
These secreted adipokines work not only in a paracrine and autocrine manner but also affect 
systemic metabolic homeostasis by decreasing insulin sensitivity in liver and muscles. This results in 
increased gluconeogenesis and glycogenolysis in the liver, and low glucose uptake and fatty acid 
oxidation in the muscles [Coehlo M, 2012]. Repeated cycles of these processes eventually lead to an 
increase in plasma glucose, insulin resistance and its clinical sequelae. (Fig.1.3) 
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Fig.1.3: Development of metabolic complications of obesity. 
Expansion of AT results in adipocyte hypertrophy and release of chemokines that lead to 
macrophage infiltration of AT, which further enhances local inflammation due to 
increased release of cytokines. This is accompanied by increased release of FFA and 
dysregulated secretion of leptin, adiponectin and resistin. These local AT changes lead at 
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the systemic level to increased ectopic lipid deposition and inflammation, which results in 
decreased muscle and liver insulin sensitivity and increased hepatic gluconeogenesis and 
glycogenolysis. This is accompanied by reduced glucose uptake and low FFA oxidation in 
the muscles leading to increased availability of glycerol as a substrate for liver. 
Subsequently, plasma glucose rises, and insulin resistance increases. (Adapted from: Galic 
S et al., 2010) 
2.6 Obesity  
2.6.1 Epidemiology 
The prevalence of obesity is rising worldwide, placing a significant burden on health care systems. It 
is estimated that by 2030 there will be 11 million more obese adults in the UK which will be 
associated with additional health care costs of £1.9-2billion/year [Wang C, 2011]. This is due to the 
fact that obesity leads to numerous chronic debilitating health conditions such as T2DM, CVD, 
malignancies, mobility problems and decreased quality of life.  
It is estimated that 26% of the adult population in the UK is obese (Body Mass Index (BMI) 
>30kg/m2), with the most prevalent regions being the North of England and the Midlands, and most
prevalent age groups being 45-74 yrs for men and 45-84 yrs for women [Niblett P, 2018]. Wales has 
a reported prevalence of obesity of 23%, with a further 36% of the population being reported as 
overweight. Being obese or overweight is more prevalent amongst men in Wales (65%vs 53%) with 
obesity rates highest in the most deprived areas and in 54-64 years olds (67%) [Baker C, 2018]. 
According to the National Health Service (NHS) statistics, in England in 2016/17 there were 10,705 
hospital admissions with a primary diagnosis of obesity and 617,000 admissions where obesity was a 
factor, representing an increase of 8% and 18% respectively compared to the previous year [Niblett 
P, 2018].  Interestingly, in both cases there was a clear predominance of female patients (72% and 
66% respectively).  
2.6.2 Pathophysiology 
Obesity is a complex condition resulting from numerous metabolic disturbances driven by excess 
energy provision from the diet and inadequate energy expenditure, which leads to disturbed glucose 
and lipid metabolism. In evolutionary terms, food storage in the form of fat ensured substrate 
provision at times of starvation. The change in food accessibility in many societies and change in 
42 
behaviours and attitudes to food, including binge eating and food addiction disorders as well as 
sedentary lifestyle, have led to excessive fat storage resulting in obesity.  
Excessive fat storage in the form of triacylglycerol leads to increased lipolysis (enhanced by 
increased sympathetic drive) which releases FFAs from the fat depots and causes oxidative stress to 
the mitochondria and endoplasmic reticulum (ER) of various tissues such as AT, pancreas and liver; 
this contributes to development of the metabolic syndrome [Redinger R, 2007, Hutley L, 2005]. 
Moreover, circulating FFAs then inhibit lipogenesis with subsequent development of 
hypertriglyceridaemia secondary to decreased clearance of serum triacylglycerol. FFAs are also 
released by endothelial lipases from circulating triglycerides which exacerbates the lipotoxicity 
further and eventually leads to dysfunction of insulin receptors, insulin resistance and subsequent 
hyperglycaemia [Redinger R, 2007]. This is further exacerbated by enhanced hepatic 
gluconeogenesis and decreased utilisation of glucose by muscles. Eventually the prolonged 
lipotoxicity from excess FFAs leads to gradual β cell exhaustion in the pancreas [Redinger R, 2007]. 
2.6.3 Obesity and inflammation 
Various forms of immune dysfunction have been described in obesity ranging from higher infection 
rates and impaired wound healing through to changes in white blood cell counts, with higher 
leukocytes, neutrophils, monocyte and lymphocyte counts but diminished T and B cell mitogen-
induced proliferation and decreased antigen production in vaccinated obese patients [Marti A, 
2001]. 
As mentioned previously, adipose cells, particularly visceral adipocytes and resident AT immune 
cells, secrete a range of active adipokines. These play an important role in the development of the 
metabolic consequences of obesity due to paracrine as well as systemic actions, since they are 
transported via the systemic circulation to various peripheral sites and reach the liver via the portal 
vein.  Elevated levels of cytokines such as CRP, IL6 and TNFα have been described in obese and 
overweight individuals. Plasma levels correlate with measures of visceral adiposity such as waist 
circumference or waist:hip ratio (WHR) [Festa A, 2001], including in lean individuals [Lapice E, 2009]. 
Interestingly, white adipocytes and immune cells share a common embryonic origin. Moreover, AT 
has been described as a site for formation and maturation of immune cell precursors [Poglio S, 
2010]. Rodent studies have shown that adipose tissue in obese mice is more significantly infiltrated 
by macrophages compared to lean ones [Weisberg SP, 2003]. Furthermore, 2 types of AT resident 
macrophages were described : the proinflammatory M1  (classically activated) and the anti-
inflammatory M2 (alternatively activated) with the shift from M2 to M1 phenotype observed in 
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obesity [Lumeng C, 2007]. The proinflammatory macrophages secrete monocyte chemoattractant 
protein 1 (MCP-1), macrophage migration inhibiting factor (MMIF) and resistin, which enhance 
insulin resistance. As immune stimulators, they enhance the mitogen activated protein kinase family 
and activate NFkB, leading to dephosphorylation of IRS-1 and 2 (Insulin Receptor Substrate 1 and 2) 
docking proteins, inhibition of GLUT4 and consequent insulin resistance [Tham D, 2002, Redinger R, 
2007].  Apart from macrophages, other resident immune cells within AT include: IL-10 producing 
invariant natural killer T (iNKT) cells and  T regulatory cells (Tregs), IL-4 producing eosinophils and Ig-
M producing B cells with loss of iNKT and Tregs described during adipose tissue expansion in obesity 
[Exley MA, 2014]. 
The exact mechanisms linking obesity with chronic systemic inflammation are not clear but are likely 
to involve various pathways. Firstly, as discussed earlier, in obesity there is an imbalance between 
the levels of the anti-inflammatory ‘protective’ adipokine adiponectin and pro-inflammatory leptin, 
which has a feedback effect on the production of other AT-secreted adipokines. Increased levels of 
FFAs can also induce inflammation through lipotoxic effects on other tissues. Furthermore, 
differences in FFA composition have been described between lean and obese individuals [Pietilainen 
KH, 2011].  FFAs can affect the production and secretion of adipokines and also act directly on cell 
receptors involved in inflammatory pathways, particularly through acting as ligands for PPARγ. 
PPARγ is a transcription factor with a number of metabolic effects including modulation of adipocyte 
differentiation and M2 to M1 macrophage transition, regulation of cell metabolism and transcription 
factor activity such as that of NF-kB [Coll T, 2010].  Subsequently, a vicious cycle of metabolic 
processes develops whereby increased proinflammatory cytokines raise circulating FFAs with 
upregulated lipolysis and diminished lipogenesis within AT, and concomitantly increased lipogenesis 
in muscles and liver [Mei M, 2011, de Heredia FP, 2012]. 
ER stress has also been implicated in the development of the chronic inflammation of obesity. As the 
ER is the main site for protein and triacylglycerol droplet synthesis within cells, a state of excessive 
nutrient availability puts stress on this cellular structure which leads to activation of ‘the unfolded 
protein response’ (UPR) which is a mechanism leading to increased production of reactive oxygen 
species and thus increased oxidative stress.  This then activates inflammatory pathways leading to 
secretion of proinflammatory cytokines such as TNFα, Il6 and IL8 or MCP-1 [de Heredia FP, 2012]. 
Adipose tissue hypoxia resulting from inadequate vascular supply to hypertrophied adipocytes also 
leads to production of proinflammatory molecules to stimulate local angiogenesis. These processes 
are regulated by HIF1α (Hypoxia Inducible Factor 1) which, as indicated by its name, is a 
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transcription factor unstable in normoxia but stable in hypoxia that regulates a variety of genes 
involved in metabolism and inflammation [Trayhurn P, 2010]. 
 Proinflammatory macrophages accumulate around hypoxic areas in AT, whilst increased lactate 
production from anaerobic glycolysis also stimulates inflammatory responses [de Heredia FP, 2011] 
and increases ER stress. As a consequence of these processes, AT becomes fibrosed which then 
further exacerbates AT dysfunction [Halberg N, 2009]. 
 All of these mechanisms appear to act synergistically to stimulate chronic systemic inflammation, 
and feedback positively on each other.  
2.6.4. Adiposity and atherosclerosis 
Chronic low-grade inflammation is also involved in the development of atherosclerosis which 
subsequently leads to the development of CVD,  the leading cause of death globally [Mentis S, 2014]. 
Adipokines, including perivascular fat depots such as PAI-1, VEGF, angiotensinogen, renin and 
angiotensin II, are implicated in the development of vasomotor dysfunction and endothelial injury. 
This subsequently leads to formation of foam cells resulting from uptake of oxidised low density 
lipoproteins, FFAs and other lipid metabolites into endothelium. Furthermore, a decrease in nitric 
oxide (NO) in obesity secondary to increased oxidative stress and the effects of proinflammatory 
cytokines, leads to vasoconstriction and increased vascular resistance [Poirier P 2005]. Moreover, 
proinflammatory cytokines such as IL6 inhibit the activity of endothelial and adipose lipoprotein 
lipase which results in increased plasma triglyceride levels [Redinger R, 2007]. Macrophages 
infiltrating smooth muscle cells secrete MCP-1, MMIF and endothelin-1 which further fuels the 
inflammation within the atheromatous plaque. This is further exacerbated by adipokines with 
prothrombotic properties such as TNFα, PAI-1, TGFβ, and IL6 and matrix metalloproteinases, also 
secreted by WAT which take part in collagen remodelling. The cascade of events finally leads to 
thinning of the atheroma cap and plaque rupture, release of tissue factor and intravascular 
thrombosis which leads to clinical presentation of CVD in the form of acute coronary syndrome or 
stroke.  
2.6.5 Metabolic syndrome and cardiovascular disease in obesity 
The main complication of the chronic low-grade systemic inflammation triggered by obesity is the 
development of metabolic syndrome which consists of impaired glucose metabolism exacerbated by 
TNFα and other inflammatory adipokines, hypertension resulting from enhanced endothelial 
vasomotor tone affected by AT-secreted renin, angiotensinogen and angiotensin II, and 
dyslipidaemia (hypercholesterolaemia and hypertriglyceridemia) [Redinger R, 2007]. These 
conditions combined with ongoing lipotoxicity form FFAs finally lead to the development of  
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atherosclerosis and cardiovascular disease, as discussed previously. Moreover, the effects of adipose 
tissue mass on the cardiovascular system contribute further to the development of comorbidities 
since the total adipose tissue mass can constitute a significant proportion of total body weight in 
obese individuals, which has a significant effect on an increase in cardiac output, total metabolic 
demand and cardiac workload [Alpert MA, 2001]. The increase in left ventricle filling pressure and 
volume leads to chamber dilatation, increase in cardiac wall stress and muscle mass, and eventually 
eccentric hypertrophy [Meserli FH, 1986]. Left atrial dilatation is also commonly observed which is 
linked with a risk of atrial fibrillation in obesity [Wang TJ, 2004]. Obese subjects are therefore 
susceptible to develop both systolic and diastolic left ventricular dysfunction [Poirier P, 2000]. 
Furthermore, adipositas cordis (“fatty heart”) which develops secondary to excessive epicardial fat 
and fatty infiltration of the myocardium leads to cardiac conduction defects due to replacement of 
the sinus node musculature, atrioventricular node and right bundle branch by fat [Balsaver AM, 
1967]. Additionally, fat infiltration also leads to development of a restrictive cardiomyopathy 
[Dervan JP, 1991].  Apart from increased risk of acute coronary syndrome and ischaemic stroke, 
obesity is also associated with increased risk of venous thromboembolism, pulmonary emboli, 
hypertension, sleep apnoea and pulmonary hypertension [Poirier P, 2005]. 
2.6.6. Obesity and Cancer 
Obesity is an important risk factor for many types of cancers such as colon, breast, endometrium, 
prostate, hepatocellular, renal and oesophageal malignancies [Redinger R, 2007]. Various 
mechanisms appear to be involved in this process depending on the type of malignancy, including  
chronic low-grade inflammation, angiogenesis, perturbed cellular proliferation, dedifferentiation and 
apoptosis, with adipokines such as leptin and insulin growth factor-1 believed to play an important 
role [Kim S, 2006]. The first insight into the causative relationship between obesity and cancer was 
provided by Schoen et al who reported that hyperinsulinaemia in obese patients is a risk factor for 
bowel cancer [Schoen RT, 1999].  Non-alcoholic fatty liver disease (NAFLD) which is common in 
obesity and can progress to liver cirrhosis, is associated with the development of hepatocellular 
carcinoma, with high circulating levels of leptin in obesity believed to play a stimulating role for the 
growth of these malignant cells [Wang SN, 2006]. The chronic oesophageal inflammation resulting 
from acid reflux, again common in obesity and exacerbated by hiatus hernia, is a consequence of 
decreased oesophageal sphincter tone from pressure from visceral adiposity. This leads to Barrett’s 
oesophagus and subsequently oesophageal metaplasia [Chow W, 1998]. Chronic pancreatic 
inflammation resulting from gluco- and lipotoxicity leads to pancreatic dysplasia and development of 
pancreatic adenocarcinoma [Calle E, 2004]. Genetic and environmental factors are also likely to play 
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a role in the development of various malignancies in obese individuals. More information to explain 
the pathogenesis of these cancers is still needed. 
2.7 Obesity management 
2.7.1 Lifestyle modification 
The aim of lifestyle intervention is to aid weight loss by decreased caloric intake in order to create a 
negative energy balance and increased energy expenditure through exercise. According to the 
American Heart Association, in order to maintain health, moderate exercise of 30 minutes 5 times a 
week is required [Haskell W, 2007]. Numerous studies to date have evaluated the effects of lifestyle 
intervention on various health markers/outcomes. Though dietary intervention alone is likely to lead 
to weight loss, the results are difficult to maintain without the addition of regular exercise [Tate D, 
2007] and the long-term cardiovascular benefits are not clear. The recent LookAhead trial was 
designed to compare intensive lifestyle intervention (ILI) to Diabetes Support and Education (DSE) in 
obese T2DM patients with regard to CVD risk over time. It consisted of 175 minutes /week of 
unsupervised exercise and reduction in caloric intake to either 1200–1500 Kcal/day with 40–50 gm 
of fat for initial weights of <250 lbs or  1500–1800 kcal/day with 50–60 gm of fat for initial weights 
>250 lbs [Wadden T, 2006].  ILI led to 8.6% weight reduction in the first year which was maintained
at 6% at the end of intervention (median 9.6 years). It was accompanied by improved glycaemic 
control and lipid profile, reduction in liver fat and severe kidney disease, improvement in OSA and 
sexual dysfunction, reduced need for diabetes medications, maintenance of physical mobility and 
overall care costs, as well as improved quality of life. Surprisingly, however, there was no effect on 
cardiovascular outcomes between the groups [Pi-Sunyer X, 2014]. 
 Unfortunately, adherence to lifestyle modification in obese subjects is quite poor and often limited 
by various social and psychological barriers. The long-term maintenance of weight following weight 
loss is usually low, ranging from 2 to 20% [Blackburn G, 2005]. Therefore, alternative treatment 
modalities, as described below, have been intensively explored in recent years.  
2.7.2 Pharmacotherapy for obesity 
The development of a safe and effective pharmacotherapy approach to treat obesity has been quite 
challenging, partly because obesity as discussed above is a complex condition affecting various 
metabolic pathways, hence monotherapy with an agent targeting a single protein or mechanism will 
have limited efficacy. According to Federal Drug Agency (FDA) criteria a weight loss agent is believed 
to be effective if it induces >5% loss of body weight compared to placebo or if >35% of study 
participants lose >5% of their initial body weight [Narayanaswami V, 2017].  Generally, 
pharmaceutical agents in obesity management can be divided into 3 groups: a) medication that acts 
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centrally to decrease food intake b) medication that decreases fat absorption peripherally c) agents 
that increase energy expenditure [Narayanaswami V, 2017]. Unfortunately, many of the therapies 
that appeared promising in recent years were terminated due to unfavourable cardiovascular or 
psychiatric side-effects.  Therefore, at present there are only 5 effective FDA-approved therapeutic 
agents used for the treatment of obesity: orlistat, liraglutide, phentermine/topiramate, lorcaserin 
and naltrexone/bupropion [Homayoun A, 2016].  
Phentermine (2-methyl-1-phenylpropan-2-amine) is a sympathomimetic that has been available for 
over 50 years for short-term (less than 12 weeks) obesity management in addition to lifestyle 
modifications. The most common side-effects are insomnia, dry mouth, palpitations/tachycardia and 
hypertension but data from long safety and efficacy trials are not available. A recent placebo-
controlled study by Kang et al on slow release 30mg phentermine used in obese individuals , showed 
improvement in their lipid profile (cholesterol and LDL) and mean body weight reduction by 8kg 
(compared to 2 kg in the placebo group) [Kang JG, 2010]. 
Since 2012, phentermine immediate release has been also available in combination therapy with 
topiramate (2, 3, 4, 5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate), a GABA agonist 
initially developed for the management of epilepsy but found to have appetite-supressing properties 
aiding weight loss [Ben-Menachem E, 2003].  It is not clear whether the results observed are due to 
increased GABA-A receptor stimulation, and/or inhibition of AMPA ( α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor)/kainite glutamate receptors or the effects on voltage gated ion 
channels [Richard D, 2000]. Topiramate has since been effectively used in treating binge eating 
disorder [McElory S, 2007]. The combination of 46mg of topiramate with 7.5mg of phentermine led 
to 7.8% weight loss compared to 1.2 % in the placebo arm after 1 year of treatment [Gadde K, 2011] 
and was also shown to improve glycaemic control in patients with T2DM as well as lipid profile and 
blood pressure control [Allison D, 2012]. 
Orlistat ((S)-((S)-1-((2S, 3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-
methylpentanoate) is a lipase inhibitor that impairs absorption of dietary fat by inhibiting 
gastrointestinal lipases (gastric and pancreatic). Therefore, it is commonly associated with 
gastrointestinal side-effects such as flatulence, bloating, abdominal pain and diarrhoea. Treatment 
can also lead to deficiency of fat-soluble vitamins (A, D, E, K) hence supplementation is 
recommended [Padwal RS, 2007]. Cases of severe liver failure and acute kidney injury have also 
been rarely reported [Karamadoukis L, 2009]. 
Lorcaserin ((1R)-8-chloro-1-methyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine) is a selective 5-HT2C 
agonist approved for use in conjunction with lifestyle modification at a dose of 10mg twice daily in 
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people with BMI of ≥30, or ≥27 kg/m2, with at least one weight-related comorbidity, such as 
hypertension, T2DM or dyslipidaemia [Narayanaswami V, 2017].  However, it should be discontinued 
if weight loss of >5% is not achieved after 12 weeks. Lorcaserin acts centrally on 5-HT2C receptors in 
POMC (proopiomelanocortin) neurons of the arcuate nucleus and promotes hypophagia by 
increasing satiety [Lam D, 2008].  A 1-year, randomised, double-blind, placebo-controlled trial by 
O’Neill et al in obese patients with T2DM showed that 38% of the participants in the intervention 
arm achieved >5% body weight loss. After 52 weeks of treatment the intervention group lost 4.5% of 
initial body weight compared to 1.5% in the placebo arm [O’Neill, 2012]. 
Side-effects include back pain, headache, cough and hypoglycaemia, hence modification of diabetes 
treatment regimen is required in patients with diabetes. As it stimulates the serotonergic system, 
lorcaserin can also potentially lead to serotonin syndrome, especially in patients using other 
serotonergic drugs which are quite commonly prescribed, hence more safety studies are required. 
The lorcaserin side-effect profile is, however, significantly better than that of dexfenfluramine (a 
non-selective 5HT agonist) which led to hallucination, cardiac valvopathies and pulmonary 
hypertension, and was eventually withdrawn [Narayanaswami V, 2017]. 
Naltrexone (((4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-
4,12-methanobenzofuro[3,2-e]isoquinoline-7-one) and Bupropion (((±)-2-(tert-butylamino)-1-(3-
chlorophenyly)propan-1-one)  is another new combined therapy option for obesity management. 
Naltrexone is a non-selective opioid receptor antagonist whilst bupropion inhibits DA (dopaminergic) 
and NE (norepinephrine) transporters. Both agents were previously used in the therapy of 
addictions. It is not exactly understood how weight loss is achieved by using these agents, but the 
proposed mechanisms of action include modulation of homeostatic (hypothalamic melanocortin 
system) and non-homeostatic systems (mesolimbic DA reward system) [Narayanaswami V, 2017]. 
The first proposed mechanism suggests that bupropion stimulates release of α-MSH (melanotropin) 
which binds to MC4Rs (melanocortin 4 receptors) leading to decreased oral intake and increased 
energy expenditure. Simultaneously, β-endorphins are secreted which normally act by negative 
feedback to prevent further α-MSH secretion. However, as naltrexone blocks opioid receptors, the 
negative feedback mechanism is impaired and POMC activity is increased which causes subsequent 
weight loss [Billes S, 2014]. The DA reward system is also likely involved as shown by an fMRI study 
by Wang et al where obese subjects treated with bupropion/naltrexone for 4 weeks showed 
reduced activation in the hypothalamus and increased activation in regions involved in inhibitory 
control (anterior cingulate), internal awareness (superior frontal, insula, superior parietal) and 
memory (hippocampal) when exposed to food cues [Wang G, 2014]. 
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 Apovian et al showed in their double-blind, placebo-controlled randomised study that obese 
individuals with hypertension and/or dyslipidaemia following 56 weeks of therapy with naltrexone 
32 mg/day and bupropion 360 mg/day achieved weight loss of 6.4% compared to 1.2% in the 
placebo group which was also associated with improvement in cardiometabolic risk factors and 
quality of life [Apovian C, 2013]. The side-effect profile consisted of nausea and vomiting , dizziness, 
constipation/diarrhoea and headache, but a black box warning has also been issued regarding 
increased risk of suicidal behaviour and neuropsychiatric symptoms [Narayanaswami V, 2017]. 
Liraglutide is a long-acting GLP-1 receptor analogue given subcutaneously, initially developed for the 
therapy of T2DM (dose 1.2 and 1.8mg) which has later been approved  to be used at 3mg daily as a 
weight loss agent in individuals with at least one weight-related comorbidity [Narayanaswami V, 
2017]. A 56-week randomised trial showed reduction of body weight of 8.1% compared to 2.7% in 
the placebo group with associated improvement in cardiometabolic risk factors, glycaemic variables, 
and β cell function and insulin sensitivity [Pi-Sunyer X, 2015]. The side-effect profile includes 
dizziness, nausea and vomiting, headache, constipation/diarrhoea, dyspepsia and fatigue with 
serious side-effects including acute pancreatitis, bronchitis and chest pain [Narayanaswami V, 2017]. 
Rodent studies indicate that this agent may lead to the development of medullary thyroid cancer 
though there are no data from human subjects on this to date [Narayanaswami V, 2017]. 
2.7.3 Bariatric surgery 
Bariatric surgery is the only treatment modality for obesity at present which is shown to have 
established long-term efficacy. The most frequently performed procedures are: gastric banding (GB), 
Roux-en Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (SG) [Samuel I, 2006]. Weight 
loss is achieved by a reduction in caloric intake through restrictive and malabsorptive consequences 
of the procedures, but the exact mechanisms involved are complex and include neurophysiological 
and neuroendocrine pathways [Zhang Y, 2014]. The RYGB procedure, the most complex of the 
bariatric interventions, has been extensively evaluated in order to define all the metabolic changes 
leading to rapid weight loss postoperatively. It was shown that it affects the gut peptide profile with 
a reduction in ghrelin and increase in GLP-1 and PYY (peptide YY) which promotes satiety and 
diminishes hunger [Bose M, 2010]. Interestingly, however, changes in brain activation, taste 
preferences and desire to eat have also been reported. Functional MRI studies (fMRI) by Ochner et 
al in female patients 1-month post-RYGB  revealed a reduction in brain activation within the 
mesolimbic reward pathway in response to high calorie food cues as well as diminished visual and 
auditory whole-brain activation [Ochner C, 2011]. The altered perception of reward may play a role 
here as some RYGB patients report that high-fat and /or high-carbohydrate foods are no longer 
enjoyable post-surgery [Halmi K, 1981].  
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The long-term effects of bariatric surgery are accompanied by improved cardiovascular outcomes in 
this group of individuals which was also observed in our local population.  My colleagues and 
collaborators, Min et al showed that bariatric surgery in individuals with impaired glucose 
metabolism, leads to significant reduction in predicted 10-year and lifetime CVD risk evaluated by 
QRISK score (24 and 24.5 % reduction, respectively) [Min T, 2017]. 
2.7.4 Faecal microbiota transplantation 
In recent years more evidence has emerged regarding an important role of gut microbiota in the 
regulation of metabolism, insulin signalling and low-grade inflammation, suggesting involvement in 
the development of obesity [Baothman O, 2016]. Patients with T2DM were shown to have gut 
microbial dysbiosis: an increase in opportunistic pathogens and decrease in butyrate-producing 
bacteria [Qin J, 2012]. Interesting results from rodent studies showed that germ-free mice develop 
increased total body fat mass when colonised with microbiota from obese mice, compared to those 
colonised with ‘lean’ microbiota [Backhead F, 2004]. Results of human studies are unclear, not least 
due to the impracticalities and acceptance of this treatment. Hence, faecal transplantation is 
currently used in clinical practice only in the treatment of refractory, severe Clostridium difficile 
infection. However, van Reenen et al, conducted a double-blind, controlled trial in men with 
metabolic syndrome (n=18) who either received faecal transplant of their own faeces (placebo) or 
faeces donated by lean volunteers (intervention) which led to reduced fasting triglycerides and 
improved peripheral insulin sensitivity in the intervention arm [van Reenen,  2011]. Given the advent 
of ‘natural’ therapies in recent years, faecal transplantation may become more common in the near 
future once more evidence emerges. 
2.8 Study hypothesis and aims 
As discussed above, EVs are increasingly recognised as markers of diseases and potent biological 
vectors. Due to the lack of gold standard methods for EV isolation, and the inability to separate EV 
subpopulations of interest, more studies are required to understand the role of EVs in various 
processes such as the development of obesity and its associated complications. Although EVs have 
been found to be elevated in various conditions associated with obesity such as CVD and cancer, 
very few studies have examined EVs in the healthy state, and the effects of surgical or non-surgical 
treatment modalities on EV characteristics. Moreover, due to technical challenges, there are very 
few studies evaluating adipocyte-derived EVs obtained from human AT explants.  Given how active 
AT is as an endocrine organ, characterisation of this particular population of EVs could provide 
valuable information regarding complex pathways behind obesity-driven systemic complications. 
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I hypothesised that EV profile in plasma from healthy subjects may vary regarding EV concentration, 
cellular origin and adipokine content depending on the BMI/waist circumference and that individuals 
who are overweight or obese as per the WHO criteria [WHO, 1995] may show subtle differences in 
their EV profile before overt metabolic consequences of increased adiposity develop. In particular, I 
postulated the obese subjects have increased expression of FABP4-expressing EVs (this adipokine 
has been used by our research group as a marker of AT-derived EVs in circulation) as well as platelet- 
and endothelial cell-derived EVs. I believed these changes would be accompanied by differences in 
circulating free adipokine levels such as adiponectin, IL6 and FABP4.  
Secondly, I hypothesised that the circulating EV concentration, cellular origin and content of healthy 
subjects would differ significantly from that in individuals suffering from morbid obesity with 
established metabolic complications.  
I also postulated that intervention aimed at reducing weight in morbidly obese subjects would lead 
to alteration in the EV concentration, cellular origin and EV-expressed adipokines, with decreased 
expression of those with proinflammatory properties.  
Finally, given the differences in the biological properties of V-AT and S-AT, I hypothesised that EVs 
derived from these fat depots may show differences in their adipokine content. 
To address this, the main aims of this thesis are: 
• To evaluate circulating EVs in a cohort of metabolically healthy volunteers across a range of
BMI 
• To compare the EV profile of healthy versus severely obese subjects
• To assess the effects of weight loss on circulating EVs:
a) In patients undergoing bariatric surgery
b) In patients undergoing a lifestyle modification programme
Additionally, using in vitro experiments on subcutaneous and visceral AT explants I sought: 
• To harvest and characterise human adipose tissue-derived EVs (ADEVs) from subcutaneous
and visceral AT depots
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Chapter 2 
General Methods 
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2.1 Study approvals 
All studies presented in Results Chapters (3-6) have received relevant ethical approvals, the details 
of which are described later.  
2.2 Study support 
The research work conducted for this MD thesis was supported by a Lewis Thomas Gibbon Jenkins of 
Britton Ferry Fellowship from the Royal College of Physicians, Wales. The research work was 
conducted at the following sites: Cardiff University (Wales Heart Research Institute; Centre for 
Endocrine and Diabetes Sciences), Cardiff Metropolitan University (Department of Biomedical 
Sciences), and Cardiff and Vale University Health Board (Out-patient and Biochemistry Department 
at University Hospital Llandough). 
2.3 Study participants 
As the study cohorts in each results chapter differ, their characteristics and exclusion and inclusion 
criteria are described in the relevant results chapters. All participants provided written informed 
consent. 
2.4 Anthropometric measurements 
For the cohort of healthy volunteers, the anthropometric measurements took place at the Clinical 
Research Facility, Wales Heart Research Institute, whilst for the patient cohorts they were 
undertaken as part of clinical evaluation in the relevant clinical centres. Height was measured using a 
Seca 242 measuring rod [Seca, Birmingham, UK] to the nearest cm and weight with Seca stand on 
scales [Seca, Birmingham, UK] to the nearest 0.1kg. Waist circumference was measured at minimal 
respiration by positioning the measuring tape immediately above the iliac crest in parallel to the 
floor. Hip circumference was established in the same manner around the widest portion of the 
buttocks.  
Body Mass Index (BMI) was calculated as weight (kg) divided by height (meters) squared.  The Waist-
Hip Ratio (WHR) was established by dividing the waist circumference by the hip circumference (both 
in cm).  
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2.5 Isolation and characterisation of plasma-derived extracellular vesicles (EVs) 
2.5.1 Differential ultracentrifugation 
2.5.1.1 Background 
EVs were predominantly isolated by differential ultracentrifugation (chapters 3-6) but additional 
isolation technique- size exclusion chromatography was used for the research work conducted in 
chapters 5 and 6 as described later. Differential ultracentrifugation was the most commonly used
isolation approach at the time the research work described in this thesis was commenced. 
Centrifugation leads to sedimentation of particles that are heavier than the solvent. Hence, 
differential centrifugation is a technique that selectively isolates the components of interest by 
using increasing centrifugation forces and duration. 
Sedimentation coefficient depends on the mass and size of the particle and the viscosity of the 
medium that the particle is suspended in. The bigger the particle, the higher the sedimentation 
coefficient therefore sedimentation occurs faster. Differential centrifugation separates the particles 
of different sedimentation coefficient. The application of higher forces/spinning time allows smaller 
particles (with low sedimentation coefficient) to be obtained in the pellet [Livshits MA, 2015]. 
It is recommended that for differential centrifugation fixed angle rather than swinging bucket rotors 
are used due to a shorter particle migration path in the former. This facilitates a shorter running 
time which is more practical when running multiple samples [Livshits MA, 2015]. 
2.5.1.2. Experimental methodology 
In my studies, venous blood from healthy volunteers and patients undergoing medical/surgical 
obesity management was drawn from a large peripheral vein using a 21G butterfly needle (Hospira, 
UK) into 3.2% (v/v) sodium citrate vacutainers which is the recommended anticoagulant by the 
Scientific Standardisation Committee of the International Society on Thrombosis and Haemostasis 
[Lacroix A, 2013]. The collected blood was handled gently, and the first centrifugation was typically 
performed within 10mins of venepuncture to avoid any artificial increase in EV levels associated 
with lengthy incubation prior to processing [Ayers L, 2011]. Acellular plasma was obtained following 
2 centrifugation steps at 3000g for 10mins at room temperature (RT) (21ºC). The obtained 
supernatant was then ultracentrifuged at 100000g for 1 hour at 4ºC and the pellet was resuspended 
in 100µL of 0.22µm filtered x1 Phosphate Buffered Saline (PBS). (Fig. 2.1) 
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Fig.2.1:  Isolation of EVs by differential centrifugation. 
2.5.2 Size exclusion chromatography columns 
2.5.2.1 Background 
Due to developments in the EV research area when this study was ongoing, new methodologies 
were being implemented in order to improve EV sample purity. One such method was size exclusion 
chromatography (SEC), which was initially described in the 1950s and has gained renewed interest in 
recent years due to good reproducibility and speed [Hong P, 2012]. SEC has been ’re-invented’ for 
the purpose of EV isolation with numerous commercially available ready-made SEC column kits. It is 
a technique where molecules in a solution are separated based on their size to porous polymer 
beads packed into a column. 
The thermodynamics of the chromatographic process are described by the following equation: 
∆𝐺° = ∆𝐻° − 𝑇∆𝑆° = 𝑅𝑇𝑙𝑛 𝑘 
where ΔG0, ΔH0, and ΔS0 are the standard free energy, enthalpy, and entropy differences, 
respectively; R is the gas constant: T is absolute temperature, and k is the partition coefficient. 
However, in SEC the entropic processes are the ones driving the partitioning as there ideally should 
be no adsorption hence enthalpy is 0. Therefore, the equation describing SEC is: 
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𝑙𝑛𝐾𝑑 =  −∆𝑆°/𝑅 
Kd= thermodynamic retention factor
The thermodynamic retention factor is the fraction of intraparticle pore volume that is accessible to 
the analyte and is defined by:  
Kd= 
𝑉𝑟−𝑉𝑜
𝑉𝑖
With VR, V0, and Vi representing the retention volumes of the analyte of interest, the interstitial 
volume, and the intra-particle volume.  When the analyte is completely excluded from the pores of 
the stationary phase, Kd will equal 0, whilst when it fully accesses the intraparticle pores, it will be 
equal to 1 [Hong P, 2012]. In simple terms, in the SEC columns, sample components with small 
hydrodynamic radii pass through the pores in the column which results in late extraction, whilst 
those with large hydrodynamic radii are excluded from entering the pores [Li P,2017].  
2.5.2.2 Experimental methodology 
This method of EV isolation from plasma was applied to samples from a cohort characterised in 
chapter 5 where Exo Spin Midi Columns (Cell Guidance Systems) were used as described by 
colleagues from our research group [Welton J, 2015]. Figure 2.2 illustrates the principles of this 
isolation technique. (Fig.2.2) 
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Fig.2.2: Schematic principle of SEC columns. 
Fractions are 
collected at 500µL 
volume intervals (1-
30) and are then
analysed for protein
concentration,
particle count and
EV marker presence.
Larger particles 
cannot pass 
through the pores 
in the beads 
therefore they pass 
quickly through the 
column. The small 
particles pass 
through the pores 
therefore their 
passage through 
the column is 
slower.
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Validation experiments were performed before this method was used to ensure the EV-rich 
fractions were being extracted in fractions 5-10 as described previously [Welton J, 2015]. Briefly, 
following equilibration of columns with 2x500µL filtered x1 PBS, 1mL of double spun (at 3000g for 
10mins) acellular plasma was applied to the columns and fractions 1-30 x 500µL were collected. 
Initial analysis of particle concentration was undertaken using Nanoparticle Tracking Analysis 
software and each fraction’s protein concentration measured by Nanodrop as described below. 
Figure 2.3 illustrates the peak of EVs eluting in the early fractions which is followed by a peak of 
protein in the later fractions.  (Fig. 2.3) 
a)
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b) 
Fig.2.3: Validation experiment of plasma EV isolation from healthy donors: a) protein 
(mg/mL) (Nanodrop) and nanoparticles/mL concentration (NTA) of 30 fractions obtained 
by SEC showed an early peak of EVs in fractions 5-10 followed by a protein peak in
fractions 15-20 b) particle: protein ratio (concentration of nanoparticles divided by protein 
concentration) reveals a peak in early fractions which identifies the EV-rich fractions as 
described previously [Welton J, 2015]. 
These confirmatory experiments allowed me to run later experiments on clinical samples by 
focusing on fractions 5-10 where the majority of EVs should be present. These fractions were then
pooled, and further analysis was performed as described in chapter 5 (section 5.3.5.1). 
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2.5.3 Storage of extracellular vesicles 
For short-term (1-3 days) studies, EVs were stored at 4ºC. When long-term storage was required, 
samples were frozen at a rate of -1ºC/minute using a Mr Frosty (Thermo Fisher Scientific, UK) 
container and stored in -80ºC. The latter appears to be an optimal storing temperature for 
preserving EVs as confirmed in the EV literature [Jayaram A, 2018, Lőrincz A, 2014] and the work of 
our colleague from the research group, Dr K Connolly [Connolly K, 2016].   
2.5.4 Size and concentration analysis of extracellular vesicles 
2.5.4.1 Background 
EV size and concentration were established by Nanoparticle Tracking Analysis (NTA) using Nanosight 
LM10 (Malvern), software version 3.1. This method has proven to be very popular within the EV field 
in recent years in that it provides robust and repeatable results and enables data comparison 
between various research centres. 
NTA enables direct real time visualisation of nanoparticles by using a finely focused laser beam to 
illuminate the EV sample in a suspension. (Fig. 2.4) The laser beam travels through a glass prism at a 
low angle which creates a thin beam of laser light at the interface of the glass-liquid layer and leads 
to illumination of the nanoparticles which as a result, scatter light. The light is then collected by 2 
lenses connected to a sensitive electron multiplying charge coupled device (EMCCD) camera. This 
camera system is able to record videos of the particle movements at 30 frames per second with a 
view field of 100 µm x 80 µm [Carr B, 2014]. 
Fig.2.4: NTA operation: laser beam goes through a glass prism and is then refracted into 
particles containing fluid suspension which allows the particles to scatter light. A 
microscope with the attached camera then visualises the particles and traces their 
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Brownian motion over a set time which allows calculation of the size and concentration of 
EVs (adapted from Malvern, UK). 
NTA determines the size and concentration of EVs by analysing the Brownian motion and light 
scattering properties of the nanoparticle suspension illuminated by a laser beam using a modified 
Stokes-Einstein equation where temperature (T) and viscosity (ŋ) are constant parameters: [Dragovic 
RA, 2011] (Fig.2.5) 
(x,y)2=Dt=
𝐊𝐛𝐓𝐭𝐬
𝟑𝜫𝜼𝒅
Fig.2.5:  The modified Stokes-Einstein equation. 
The modified Stokes-Einstein equation used in NTA software to analyse the size of 
individually tracked particles from their motion in 2 dimensions where kB is the 
Boltzmann constant and (x,y)2 is the mean-squared speed of a particle at a diluent 
temperature T, in a medium of viscosity η; ts=sampling time (ms); d= sphere equivalent 
hydrodynamic diameter (particle size).  
Each individual particle is tracked during 60 second videos and, as smaller particles move faster than 
the bigger ones, NTA provides high resolution size distribution data. Moreover, concentration 
measurements are also undertaken based on a set volume of particle solution injected for each 
analysis. For biological samples, the lower limit of particle size detected using this method is 30nm 
[Carr B , 2014].  
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2.5.4.2 Experimental methodology 
NanoSight LM10 software v 3.1 (Malvern, UK) was used with a 488nm (blue) laser installed. Prior to 
each set of measurements, a calibration measurement of 100nm polystyrene beads diluted 1:1000 
was performed to ensure the results were reproducible. The pre- and post-analytical setting 
parameters were kept constant as described in Table 2.1 to allow comparison between various 
samples. 
Setting Value 
Pre-analytical Camera shutter 450 
Camera level 12-16
Camera gain 200-300
Post-analytical Temperature 21-26 ͦC
Screen gain 10-15
Detection threshold 5-8
Tab.2.1: Pre- and post- analytical settings used for EV sample analysis by NTA. 
For each sample, 60 seconds videos were recorded in replicates of 5. The system was flushed with 
sterile water between sample measurements. Depending on starting plasma volume, EV samples 
were diluted in ultrapure water (Fresenius Kabi, UK) between 1:10000 to 1:50000 prior to NTA with 
the aim of obtaining a concentration of 108 -109 particles/mL. The concentration of plasma EVs is 
presented as EVs/mL. Size distribution graphs were created by totalling the concentration of EVs/mL 
of plasma in each 100nm range (bin width).  
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2.5.5.Immunophenotyping of extracellular vesicles 
2.5.5.1 Background 
A Time Resolved Fluorescence (TRF) Immunoassay for EV characterisation was developed by our 
colleague, Prof Aled Clayton (Cardiff University) and has since been used by our EV research groups. 
[Webber J, 2014, Connollly K, 2015] It enabled me to establish EV cellular origin, cytokine and 
adipocyte-marker expression. This technique utilises lanthanides which are long-life fluorophores 
which following excitation emit light over a longer period of time compared to standard fluorophores 
(microseconds vs nanoseconds). Consequently, the background signal is reduced as the measurement 
commences after the background noise has decayed. (Fig.2.6) TRF using lanthanides rather than 
standard fluorophores is therefore more sensitive. 
Fig.2.6: The principle of TRF using a long half-life fluorophore. Following excitation, the 
background fluorescence diminishes quickly in relation to the signal from lanthanide which 
allows a delay time before measurement of the emission signal is undertaken. Hence , 
background auto fluorescence is minimised (adapted from Perkin Elmer). 
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2.5.5.2 Experimental methodology 
 In the adaptation of this method by our group, high affinity protein binding ‘sticky bottom’  96 well 
plates (Greiner Bio-One) were loaded with 5x1010 EVs/well (as established by NTA) diluted to a total 
volume of 100µL with x1 filtered PBS and incubated overnight at 4˚C. Following a wash with Delfia 
Buffer (Perkin Elmer, Waltham, USA), non-specific sites were blocked with 1% (wt/vol) Bovine Serum 
Albumin (BSA) in PBS for 2 hours. After a further wash, primary antibodies were added in duplicates 
at 3µg/mL concentration (anti-CD41, anti- CD11b, anti-CD235a, anti-CD144, anti-CD9, anti-IL-6, anti-
TNFα, anti-interferon ɤ, anti-adiponectin, anti-FABP4 and anti-PPARγ, Tab.2.2). After overnight 
incubation in the cold room on a plate shaker and a further 3 washes, the secondary antibody (anti-
rabbit IgG Biotin labelled, 1:2500 in 0.1 % (wt/vol) BSA in PBS) (Perkin Elmer, UK) was added for 1 hour 
(room temperature (RT), plate shaker), followed by 3 further washes and staining with 
Europium-labelled Streptavidin for 45 mins (RT, plate shaker) (Perkin Elmer, UK). After the final 6 
washes, Delfia Enhancement Solution (Perkin Elmer, UK) was then added  to allow formation of 
fluorescent chelates. The resulting fluorescence emission was measured using a Clariostar 
spectrometer (BMG Labtech Ltd, Aylesbury, UK) configured to Time Resolved Fluorescence (TRF) 
where a narrow emission peak is produced with a large Stokes’ shift and long decay time, 
thereby giving a good signal-to-noise ratio (each well received 400 flashes; measurement 
commenced after 400µs after the last flash and continued for 400µs; Fig 2.6).  
During each experiment a set of Europium standards was applied in duplicate in order to set the gain 
adjustment, thus allowing comparison between various plates/experiments. MARS software (BMG 
Labtech, UK) was used for data analysis and results are presented in arbitrary TRF units (aTRF). All 
samples/markers were run in duplicate and the final aTRF value was calculated as the mean of 2 
readings adjusted by subtracting the mean of negative control/background (signal from the EV-loaded 
wells where no primary antibody was added). Figure 2.7 illustrates the principle of the above 
described method. 
All primary rabbit monoclonal antibodies were supplied by Abcam (Cambridge, UK) apart from anti-
CD9 antibody which was provided by Cell Signalling Technology (Danvers, USA). For the analysis of 
internal EV content (IL6, TNFα, Interferon γ, adiponectin, FABP4, PPARγ), RIPA Lysis Buffer (Santa 
Cruz Biotechnology Inc., USA) containing protease inhibitor, sodium orthovanadate and 
phenylmethyl sulfonyl fluoride (PMSF) was added for 1 hour (RT, plate shaker) before the addition of 
primary antibodies to enable the disruption of the EV membrane.  
The optimal concentration of primary antibodies for this experiment was previously established by 
our group by comparison of TRF signals at 4 different concentrations of each primary antibody of 
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interest (10µg/ml, 3 µg/ml, 1 µg/ml and 0.1 µg/ml) added to a set number of EVs (5x1010) with 
results indicating that saturation of TRF signal was achieved with 3 µg/ml and provided a reliable and 
replicable concentration for the purpose of this assay. 
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Primary marker Source Relevance 
CD41 Abcam ab134131 Platelet marker 
Cd11b Abcam ab52478 Monocyte/macrophage 
marker 
CD235a Abcam ab129024 Erythrocyte marker 
CD144 Abcam ab40772 Endothelial cell marker 
CD9 Cell Signaling D3H4P Exosomal marker 
Interleukin-6 Abcam ab32530 Inflammatory pathway 
TNFα Abcam ab53450 Inflammatory pathway 
Interferon ϒ Abcam ab133566 Inflammatory pathway 
Adiponectin Abcam ab75989 Adipocyte marker 
FABP4 Abcam ab92501 Adipocyte marker 
PPAR ϒ Abcam ab191407 Adipocyte marker 
CD63 Exosomal marker 
Tab. 2.2:  Primary antibodies used in the EV immunophenotyping by TFR. 
 Santa Cruz Biotech.sc-15353 
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   Excitation source  
 Emission fluorescence 
 
  Primary antibody 
a) 
b)
Fig. 2.7: TRF Immunoassay: a) the steps involved in TRF immunoassay: EVs are loaded into 
96 well plates and exposed to primary antibodies. These then bind to a biotinylated 
secondary antibody and this complex is stained with Europium-labelled streptavidin. 
Finally, fluorescent chelates are formed.  b) Fluorescence is measured in TRF mode by a 
Clariostar plate reader. 
EV 
Straptavidin-Europium 
conjugate  
Biotinylated secondary 
antibody 
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2.5.6 Electron microscopy 
Electron microscopy of plasma-derived EVs isolated by differential centrifugation was performed in 
collaboration with Dr Christopher von Ruhland (Central Biotechnology Services, Cardiff University). 
Transmission electron microscopy was used to confirm EV presence and morphology following 
isolation. EVs were isolated as described above and resuspended in x1 sterile PBS and stored at 4 Cͦ 
until analysis was undertaken. EV droplets (50µL) were then adsorbed onto a carbon-coated grid for 
30 mins and were later fixed with 1% glutaraldehyde (v/v) for 1 hour (RT). Following 3 washes in PBS 
for 1 minute and 6 washes of 10 minutes duration in water, EVs were stained negatively with 2% 
(w/v) uranyl acetate for 20 minutes. Following removal of excess stain, samples were air dried at RT 
and EVs were then visualised by a Philips CM12 TEM microscope (FEI Ltd, UK) at 80 kV. (Fig. 2.8) 
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a) 
b) 
c) 
Fig.2.8: TEM images of plasma-derived EVs isolated (fresh) by differential centrifugation 
from 3 healthy donors (a-c); EVs are marked with red arrows; scale 500nm as marked with 
orange arrows. 
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2.6 Plasma measurements 
For all the following assays, venous blood was collected into EDTA vacutainers and spun x2 at 3000g 
for 10mins immediately. Acellular plasma was then aliquoted and stored at -80ºC until further 
analysis.  
2.6.1  Measurement of plasma adipocytokines 
An array of adipokines and cytokines was measured as described below using commercial kits. All 
samples were assayed in duplicate. A BMG Clariostar was used to determine the optical density at 
each assay’s recommended wavelength.  
2.6.1.1  Human plasma FABP4 
The concentration of FABP4 in human plasma was established by a Quantikine ELISA Human FABP4 
Immunoassay (DFBP40, R&D Systems, UK) which is a quantitative sandwich enzyme immunoassay 
with a mean minimum detectable (MDD) concentration of human FABP4 of 6.55pg/mL (range 2.7-
14.2pg/mL).  The reported assay range was 62.5 - 4,000 pg/mL and cross-reactivity was <0.5%. The 
assay only required 10µL of plasma.  
Plasma samples were diluted 20-fold using Calibrator Diluent RD6-68 and assayed in duplicate. 
Samples and standards (4000pg/mL, 2000pg/mL, 1000pg/mL, 500pg/mL, 250pg/mL, 125pg/mL and 
62.5pg/mL) were added to 96 well microplates pre-coated with immobilised antibody which binds to 
FABP4 present in the sample. Following a wash with the wash buffer, a human FABP4 enzyme-linked 
polyclonal antibody was added. After a second wash, a substrate solution was added which led to 
colour development in the light protected wells in proportion to the amount of FABP4 present. Once 
the stop reagent had been added, the colour intensity was measured immediately at 450nm with the 
correction wavelength set at 570nm (BMG Clariostar, UK). 
The duplicate readings for each standard, control and sample were averaged and the average zero 
standard optical density (O.D.) was subtracted from them. Following standard curve creation, a best 
fit curve was drawn through the points on the graph and the concentration of FABP was calculated. 
2.6.1.2 Human Plasma PPARϒ 
The concentration of human PPARϒ was measured using a Human PPARG Sandwich ELISA Kit (LSBio, 
Inc, USA, LS-F12376) with a detection range of 0.156-10ng/mL, lower limit of detection of less than 
0.056ng/mL, intra-assay CV of <6.1% and inter-assay CV of <11.2%.  Standards were set up at the 
following concentrations: 10ng/mL, 5ng/mL, 2.5ng/mL, 1.25ng/mL, 0.625ng/mL, 0.313ng/mL, 
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0.157ng/mL and 0ng/mL.  Standards and undiluted plasma samples (100µL volume) were then 
added to pre-coated plates to allow binding to the capture antibody  and incubated for 2 hours at 
37ºC. Following a wash, 100µl of biotin-conjugated antibody was added and after the excess 
antibody was washed away, Avidin-Horseradish Peroxidase (HRP) was added to bind with the biotin. 
Finally, a TMB ( 3,3’,5,5’-tetramethylbenzidine) substrate solution was added which led to reaction 
with the HRP enzyme and colour development. This was then stopped by the addition of the sulfuric 
acid stop solution and measurement of the optical density (OD) at 450nm was undertaken. The 
standard curve was constructed by plotting the mean absorbance for each standard  against the 
concentration and a best fit curve was drawn. The final concentration was calculated in the same 
manner as for FABP4. 
2.6.1.3 Plasma IL6, interferon γ, TNFα and adiponectin 
Assays for evaluation of  IL6, TNFα, interferon γ and adiponectin concentration in human plasma 
were supplied by Abcam, UK (ab46042, ab100537, ab46087, ab99968, respectively). The 
characteristics of each kit are summarised in Table 2.3. 
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IL6 TNFα Interferonγ Adiponectin 
Detection 
method 
Colorimetric Colorimetric Colorimetric Colorimetric 
Sample type Serum, plasma, 
cell culture 
supernatant 
Plasma, serum, 
cell culture 
supernatant 
Plasma, cell 
culture 
supernatant 
Plasma, serum, 
cell culture 
supernatant 
Sensitivity <0.8 pg/mL <10pg/mL <15pg/mL <25pg/mL 
Range 1.56-50 pg/mL 25-800pg/mL 20.6-
15000pg/mL 
Not provided 
Recovery (mean% 
(range) 
93%(72-123) 81%(74-90%) 86.82%(81-102) 90.29%(80-103) 
Assay time 3hr 45mins 3hr 40min 5hr 30 mins 5hr 30mins 
Species reactivity Human Human Human Human 
Tab.3.3:  The specifications of commercially available Abcam kits used for estimation of 
plasma concentration of IL6, TNFα, interferon γ and adiponectin.  
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Similarly to the above described methods, these were colorimetric ‘sandwich’ quantitative ELISA 
assays using the same methodology, including incubation steps and measurement settings. 
Undiluted plasma samples were measured in duplicate for IL6, TNFα and interferon γ, whilst plasma 
adiponectin measurement required 1:30000 dilution using a  reagent provided. Absorbance was 
read by a BMG Clariostar spectrophotometer using 450nm as the primary wavelength and 620nm as 
the reference wavelength.  
The table below summarise the concentrations of standard solution for each adipocytokine which 
was used for the standard curve preparation (Tab.2.4). 
Standard 
# 
IL6 (pg/mL) TNFα(pg/mL) Interferonϒ(pg/mL) Adiponectin(pg/mL) 
1 50 800 15000 18000 
2 25  400 5000 6000 
3 12.5   200  1666.7 2000 
4 6.25   100  555.6   666.7 
5 3.125   50 185.2 222.2 
6 1.56   25  61.7 74.07 
7  20.6 24.69 
Zero standard 0  0   0 0 
Tab.2.4: The concentration of standards used in the Abcam  assay kits used for 
measurement of plasma IL6, TNFα, interferon γ and adiponectin. 
The final concentration of each adipokine was calculated from the standard curve as described 
above.  
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2.6.3 Plasma insulin measurement 
A human insulin ELISA Kit (Abcam, UK, ab100578) was used to determine fasting insulin 
concentration using the same methodology as described above. Plasma samples were diluted 1:2. 
The kit had a detection range of 178.5-10713pg/mL with a minimum detectable dose of insulin 
of<50pg/mL and mean recovery of 99.03% (range 73-128). Standards were set at 167.47pg/mL, 
334.96pg/mL, 669.91pg/mL, 1339.8pg/mL, 2679.67pg/mL, 5359.35pg/mL and 10718.71pg/mL. The 
plate was read at 450nm as previously. 
2.6.4 Plasma glucose measurement 
Fasting glucose concentration was established by the glucose oxidase method as previously 
described. [Dietzler DN, 1980] Briefly, this is a colorimetric method where glucose in the presence of 
air is oxidised by glucose oxidase to glucuronic acid which results in concomitant hydrogen peroxide 
release. The latter then undergoes decomposition by the peroxidase enzyme which results in oxygen 
release leading to oxidisation of the chromogen which is then measured colorimetrically. Fifty 
microlitres of fasting plasma were assayed in duplicate for each healthy volunteer. The absorbance 
of samples and standards was read at 510nm using a Jenway 6705UV/Spectrophotometer. The 
glucose concentration of the samples (mg/dL) was calculated using the following formula:  
𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
  𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
∗ 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
The following calculation was used to convert glucose concentration (mg/dL) to mmol/L: mg/dL x 
0.0555 = mmol/L. 
2.6.5  HOMA-IR 
The HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) was calculated as per the 
formula: HOMA-IR= fasting insulin(mIU/L)*fasting glucose (mmol/L)/405. [Matthews DR, 1985] 
2.7 Protein concentration 
The protein concentration of the columned plasma-derived EVs and adipocyte-derived EVs from 
tissue culture was established using a NanoDrop 2000 microvolume spectrophotometer (Thermo 
Fisher Scientific, UK) with a protein detection range of 0.1-400mg/dL. Following calibration with 
ultrapure water, 1µL of each column fraction was carefully pipetted onto the Nanodrop pedestal and 
following the arm closure, a sample column was formed and the optimal path length (0.05-1mm)  
found by the pedestal automatic movement. Each sample was assayed in duplicate. This method 
was chosen because of its time efficiency and small volume of sample required without any need to 
perform serial dilutions. 
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2.8 The isolation and characterisation of adipocyte-derived EVs (ADEVs) from primary 
adipocyte culture 
Samples of subcutaneous (abdominal wall) and visceral (omental or perinephric) fat were obtained
from patients undergoing open or laparoscopic elective surgery at the University Hospital of Wales, 
Cardiff (REC ref. 06WSE03/37). Written informed consent was obtained from all study participants.  
2.8.1. Sample preparation 
Peri-operative samples were collected into sterile universal containers with no additives and  
immediately transferred to the tissue culture laboratory, where they were processed the same day. 
Firstly, fat tissue lumps were dissected into fine pieces using a disposable scalpel blade (size 11), 
(Swann Morton, UK).  The tissue was then added to a mixture of  collagenase type 2 (Gibco, 17101-
015), 7.5% BSA (Bovine Serum Albumin, Sigma-Aldrich, A7906) and  HbSS (Hank’s balanced Salt 
Solution, Thermo Fisher, UK, 14025092)  in order to perform tissue “digestion”. The volume of each 
ingredient depended on the size of the fat tissue, with the following volumes required typically for a 
0.7g sample: 7mLs HbSS, 3mLs 7.5%BSA, 1mL collagenase. The mixture was then incubated in a 
water bath at 37ºC for 1 hour and shaken manually every 5 mins. Following this step, samples were 
centrifuged at 1500rpm for 5mins at 4ºC which allowed separation of preadipocytes and RBC from 
mature adipocytes, oil and lipids. (Fig.2.9) Once oil, lipids and mature adipocytes were gently 
removed, the remaining preadipocyte pellet was resuspended in control medium and transferred to 
T25 tissue culture flasks.  
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a) 
 b) 
Fig.2.9: Schematic illustration(a) and photograph (b) of separation process during 
preadipocyte isolation following adipose tissue digestion and 1500rpm centrifugation. 
*Preadipocytes are pelleted at the bottom of the universal container.
Preadipocytes and red blood cells 
Lipids 
Mature  adipocytes 
Oil 
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Preadipocytes were maintained in control medium which was changed every 3-5 days at a maximum 
of 70-75% confluence between passages, and underwent differentiation following passage 3. 
(Fig.2.10)  The components of control (CM) and differentiation medium (DM)(x2) are summarised in 
Table 2.5.  
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Component CM DM 
DMEM (high glucose 4.5g/L, no 
glutamine, Lonza, BE12-614F) 
85mLs 44.5mLs 
Ham’s F12 nutrient mix, Lonza, BE12-
615F) 
85mLs 44.5mLs 
Sodium pyruvate 2mLs 1mL 
Sodium bicarbonate 3mLs 1.5mL 
FCS, Lonza 20mLs 20mLs 
Penicillin/Streptomycin (Thermo-
Fisher Scientific, 15140122) 
4mLs 2mLs 
Insulin (Sigma Aldrich, I-1882) x 500nM (570µL) 
Hydrocortisone (Sigma Aldrich, H-
2270) 
x 1µM (20µL) 
Panthetonate (Sigma-Aldrich, P-5155) x 17µM(200µL) 
Biotin (Sigma Aldrich, B-4639) x 33µM(64µL) 
Triiodothyronine (Sigma Aldrich, T-
5516) 
x 1nM(1.4µL) 
Pioglitazone x 1µM(20µL) 
Amphotericin B (Sigma Aldrich, 
A2942) 
2mLs 1mL 
Tab.2.5:  Ingredients and their respective volumes required to prepare 200mLs of 
complete medium with 10%FCS and 100mLs of x2 differentiation medium mix.
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The above described medium composition has been widely used by Prof Ludgate’s group working on 
adipocyte tissue derived from orbits within the Centre for Endocrine and Diabetes Sciences, Cardiff 
University. However, I observed early on in my experiments that the visceral and subcutaneous 
tissue from my experiments was very prone to fungal infection, hence I modified my media by the 
addition of amphotericin B as a prophylactic measure.  
Typically, it would take around 4-6 weeks from the day the sample was obtained to start the 
differentiation process. Preadipocytes were kept in differentiation medium for up to 21 days. 
(Fig.2.10) 
2.8.2  Commercial preadipocyte culture 
In addition to samples obtained from volunteers undergoing elective surgery, commercial visceral 
preadipocytes were obtained from Lonza, UK (PT-5005). This was due to the fact that the surgically 
obtained samples grew quite slowly and often developed fungal or bacterial infection towards the 
end of the experiments which led to sample loss at a great time and resources expense. The Lonza 
preadipocytes were grown in the same medium but showed faster growth rate between passages 
and no problems with sample contamination was noted. 
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Fig.2.10:  Timeline of primary adipocyte culture experiments from subcutaneous and 
visceral fat depot.
Day 0
• Preadipocytes obtained from visceral and subcutaneous adipose
tissue lumps and placed in control medium in T25 flasks
Day 1-7
• Medium changed 24 hours later and every 3-5 days thereafter
• Cells split into x4 T25 flasks once confluence exceeds >75%
Days 7-21
• Medium changed every 3-5 days
• Cells split into x4 T75 flasks once confluence exceeds >75%
Days 21-36
• Medium changed every 5 days
• Cells split into x4 T50 flasks once confluence exceeds >75%
Day 36-55
• Medium changed every 5 days
• Once confluence exceeds 75%, differentiation process started
Day 56-77
• Differentiation medium changed every 5 days
• 'Starvation' (FCS free) medium added at day 21 of differentiation
Day 78-
• Starvation medium  collected and differentially centrifuged  to
obtain EVs
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2.8.3 Adipocyte-derived EV isolation 
2.8.3.1 Differential centrifugation 
As mentioned above, prior to EV isolation, adipocyte cultures were pre-incubated in serum-free 
media for 24 hours. This is due to our observation [Connolly K, 2015] that was also described in the 
literature [Shelke V, 2014, Faure J, 2006] that isolating EVs from FCS- containing media may lead to 
overestimation of EV amount.  
The removed FCS-free medium was first spun at 500g for 5 mins to remove any cells which was 
followed by a 15 mins spin at 5000g  to remove cell debris and larger vesicles/apoptotic bodies. The 
final step was the same as for plasma derived EVs, namely ultracentrifugation at 100000g for 1hour 
at 4 Cͦ. The EV pellet was then resuspended in x1 filtered PBS. (Fig.2.11) 
5mins, 500g      15mins, 5000g  1h, 100000g 
Conditioned culture medium 
Fig.2.11:  Differential centrifugation steps used to isolate adipocyte derived EVS (ADEVs). 
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2.8.3.2 Size exclusion chromatography columns 
Exospin columns (Cell Guidance Systems, UK, EXO-01) were used to purify ADEV samples obtained 
by differential centrifugation prior to their content analysis. Due to smaller sample volume available, 
smaller SEC columns were chosen. One hundred µL EVs in x1 PBS samples were added to the 
columns after initial equilibration with x1 PBS and 6 fractions of 100µL were collected. NTA revealed 
that EVs typically occur in fraction 3-4 with this column and sample type.  
2.8.4 ADEV concentration and size 
NTA was used as described above to establish ADEV size and concentration. Samples were diluted 
between 1:200-1:1000 in  ultra-pure water prior to analysis. 
2.8.5 Proteome Profiling 
Human Adipokine Proteome Profiler Array Kit (R&D Systems, UK, ARY024) was used to establish 
adipocytokine expression in the adipocyte-derived EVs. In this method, capture antibodies for 58 
human adipokines (Tab.2.6) are present in duplicate on a nitrocellulose membrane which also 
contains 3 duplicates of reference spots and 1 duplicate for negative controls. EV samples were first 
incubated with RIPA (1:1 volume ratio) and added to a 30µL cocktail of biotinylated detection 
antibodies and diluted up to the volume of 1.5mL with supplied array buffers. The mixture was then 
added to wells where nitrocellulose membranes had been pre- incubated for 1 hour on a rocking 
platform shaker in 2mLs of an array buffer. Following overnight incubation on a rocking platform, 
membranes were washed x3 and incubated with Streptavidin-HRP for 30mins. Following 3 further 
washes, 1mL ChemiReagent Mix  was pipetted onto each membrane and incubated for 1min. Films 
were then developed in a dark room  in the autoradiography cassette following 1-hour exposure 
using photographic film (AmershamTM Hyperfilm ECL, GE Healthcare), KodakTM -D19 developer  and 
fixer by Sigma-Aldrich. Chemiluminescence signals were proportional to the amount of the adipokine 
bound (Fig. 2.12). This exposure time was chosen after validation experiments showed that shorter 
exposure time gives low signal which cannot be reliably read after scanning the membranes.   
Developed films were then scanned and the average signal (pixel density) for each pair of adipokines 
was established using Quick Spots HLImage+++ software (Western Vision, USA) which automatically 
subtracts the average signal of each pair of duplicate spots from the average signal of the negative 
spots. 
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Adiponectin FGF basic M-CSF
Angiopoietin-1 FGF-19 MIF 
Angiopoietin-2 Fibrinogen Myeloperoxidase 
Angiopoietin-like 2 Growth Hormone Nidogen-1/Entactin 
Angiopoietin-like 3 HGF Oncostatin M 
BAFF/BLyS ICAM-I Pappalysin-1/PAPP-A 
BMP-4 IGFBP-2 PBEF/Visfatin 
Cathepsin D IGFBP-3 PCSK9 
Cathepsin L IGFBP-4 Pentraxin-3 
Cathepsin S IGFBP-6 Pref-1/DLK-1/FA1 
CCL2/MCP-1 IGFBP-rp1/IGFBP-7 RAGE 
CCL5/RANTES IL-1 beta Resistin 
Chemerin IL-6 Serpin A12 
Complement Factor D IL-10 Serpin A8/AGT 
C-Reactive Protein IL-11 Serpin E1/PAI-1 
CXCL8/IL-8 LAP (TGF-ß1) TIMP-1 
DPPIV/CD26 Leptin TIMP-3 
Endocan LIF TNF-alpha 
EN-RAGE Lipocalin-2/NGAL VEGF 
Fetuin B 
* BAFF/BLyS (B Cell Activating Factor/ B Lymphocyte Stimulator), BMP-4 (Bone Morphogenetic Protein 4),
CCL2/MCP-1 (C C motif chemokine ligand 2/Monocyte Chemoattractant Protein 1), CCL5/RANTES (C C motif 
chemokine ligand 5/ Regulated Upon Activation Normal T-cell Expressed and Secreted), CXCL8/IL-8 (CXC 
motif ligand 8/Interleukin 8), DPPIV/CD26 (Dipeptidyl peptidase-4/cluster of differentiation 26), EN-RAGE 
(Extracellular Newly identified Receptor for Advanced Glycation End-products binding protein), FGF 
(Fibroblast Growth Factor), HGF (Hepatocyte Growth Factor),ICAM-1 (Intercellular adhesion molecule-1), 
IGFBP (Insulin Like Growth Factor Binding Protein), LAP (TGF-ß1) (Latency Associated Peptide (Transforming 
Growth Factor β1)), LIF (Leukaemia Inhibitory Factor), NGAL (Neutrophil Gelatinase-associated Lipocalin), M-
CSF (Macrophage Colony Stimulating Factor), MIF (Macrophage Migration Inhibitory Factor), PAPA-A 
(Pregnancy-associated Plasma Protein A), PBEF (Pre B cell Enhancing Factor), PCSK9 (Proprotein convertase 
subtilisin/nexin type 9), Pref-1/DLK-1/FA1 (Preadipocyte Factor 1/delta like 1/ foetal antigen 1), RAGE 
(Receptor for Advanced Glycation Endproducts), AGT (angiotensinogen), PAI-1 (Plasminogen Activator 
Inhibitor-1), TIMP (tissue inhibitor of metalloproteinases), VEGF (Vascular endothelial growth factor). 
Tab.2.6:  
Alphabetical list of adipokines detected using the Proteome Profiler Assay. 
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Fig.2.12: Example of a result obtained following incubation of visceral adipose tissue 
derived EVs obtained at day 21 of differentiation using the adipokine proteome profiler 
assay.  
2.8.6 Oil Red O staining 
Oil Red O was prepared from a 0.5% stock solution (w/v in isopropanol) at 3:2(v/v) dilution with 
distilled water (dH2O) and filtered after 15mins through Whatman paper. 
For this measurement, human adipocytes were cultured in 6 well plates and washed in sterile PBS 
before staining.  Formaldehyde (10%, v/v in PBS) was then used to fix the cells over a 15 minute 
period at room temperature (RT) which was followed by a wash with dH2O. Cells were then stained 
for 15 mins at RT with prepared Oil Red O solution as described above. Sixty percent isopropanol 
(v/v in PBS) was used to remove excess stain and following 2 washes with sterile PBS, cells were 
photographed (Nikon Diaphot microscope, Nikon) at 10x magnification (View Finder, Software, 
version 3.0.1, Better Light Inc. USA). The intracellular stain was extracted following two further 
washes with PBS by using 100% isopropanol. A BMG Clariostar was used to measure optical density 
at 490nm. 
Reference 
spots 
Negative control 
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2.9 Statistical analysis 
Graph Pad Prism (versions 6.0 and 7.0, GraphPad Software Inc. USA) software was used for statistical 
analysis and graph creation. Details of specific statistical analysis are described in the relevant results 
chapters. Data are presented as mean (SD) unless stated otherwise. A p value of <0.05 was accepted 
as statistically significant. 
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Chapter 3 
Characterisation of circulating 
extracellular vesicles and plasma 
adipocytokines in healthy lean and obese 
subjects 
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Perspective 
At the time this study was commenced, our group had established standardised protocols of EV 
isolation from plasma of various patient groups by differential centrifugation, which was then the 
most commonly used approach in the literature. We also had regular access to Nanosight (NTA) 
equipment, and developed Time Resolved Fluorescence Immunoassay for analysis of EV content and 
cellular origin. Moreover, our research group recently characterised adipocyte-derived EVs (ADEVs), 
and subsequently developed an interest in developing evidence for the presence of ADEVs in the 
circulation and validation of potential ADEV markers in plasma.  Pilot results at that time confirmed 
by Western blotting the presence of FABP4 and PPARϒ in human plasma-derived EV samples, 
corresponding with findings from 3T3 (adipocyte) cells and 3T3-derived EVs.  I therefore decided 
that a natural follow-up would be to analyse plasma EV samples from healthy volunteers across a 
range of BMIs and to evaluate them for the presence of the proposed adipocyte markers: 
adiponectin, FABP4 and PPARϒ as described by Connolly KD et al [Connolly K, 2015], in addition to 
‘traditional’ markers of cellular EV origin relating to the principal blood components: erythrocytes, 
leukocytes and platelets as well as endothelial cells.  
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3.1 Introduction 
Extracellular vesicles have emerged as potential disease biomarkers in recent years but relatively 
little is known about their characteristics in a healthy state.  Most papers to date have 
predominantly used healthy cohorts as controls to the diseased populations, looking at expression of 
particular disease markers relevant in given clinical contexts, such as early detection of malignancy 
or autoimmune disorders, or for treatment response monitoring. 
Over the last two decades it has become apparent that EVs are very heterogeneous; hence, in order 
to advance their use in the clinical setting, not only must a more standardised approach to their 
isolation and analysis be introduced, but also an understanding of the ‘normal’ EV profile and 
reference ranges should be established.  
In the recent ISEV statement paper, Witwer et al [Witwer K, 2013] placed an emphasis on the 
importance of an organised, reproducible approach to sample collection and processing  in order to 
minimise the effects of extraneous factors on study findings. Furthermore, little is known about the 
effects of the circadian rhythm, food and prior exercise/resting status, age and gender on circulating 
EV concentration and subtype.  Until our understanding of the effects of these factors on circulating 
plasma EVs is improved, the application of EV measurements in clinical practice should not 
commence. One of my first study goals was therefore to characterise circulating plasma EVs in a 
cohort of healthy volunteers. 
There is also relatively little research on plasma-derived EVs in the context of obesity per se. Given 
the growing interest in circulating EVs as disease biomarkers and the rising prevalence of obesity, 
with its well established cardiometabolic and inflammatory consequences [Redinger R, 2007], I 
wanted to evaluate if differences in circulating plasma EVs could be observed between healthy 
volunteers across the BMI range. If such differences were observed, this might help distinguish early 
obese ‘at risk’ individuals from those with so-called ‘healthy obesity’. In time, this might translate 
into stratification of cardiovascular disease prevention and treatment.  
I therefore aimed to characterise circulating plasma EVs from a cohort of metabolically healthy 
volunteers with no overt indicators of disease using a structured approach to sample collection and 
analysis. I also utilised an array of EV cellular origin markers, based on the established literature, for 
platelets, monocytes/macrophages, erythrocytes and endothelial cells (CD41, CD11b, CD235a, 
CD144, respectively), as well as new markers proposed by our group for the detection of circulating 
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ADEVs in plasma (FAPB4, PPAR and adiponectin) and EV-expressed cytokines (IL6, TNFα, 
interferonϒ). 
3.2 Aims 
The aims of this chapter were to characterise a cohort of  volunteers without known cardio-
metabolic complications across a range of BMI (lean, overweight, obese) with respect to:
1. Anthropometric measurements (BMI, weight, waist, waist-hip ratio (WHR), age,
gender)
2. Glucose metabolism (fasting glucose, fasting insulin, HOMA-IR) and circulating plasma
adipokines (IL6, TNFα, Interferon ϒ, adiponectin, FABP4, PPARϒ)
3. EV concentration, cellular origin and adipokine content using the same panel of
adipokines as for ‘free’ plasma measurements
4. Evaluation of the effect of increased BMI on circulating EV profile
5. Evaluation of gender-related differences in circulating EVs and plasma adipokine
profile
3.3 Scientific question/hypothesis 
Does EV concentration and content alter in response to increased BMI in healthy individuals with 
no formal diagnosis of cardiometabolic disorder? 
Does gender affect the circulating EV profile? 
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3.4 Methods 
Disclosure: Recruitment of volunteers, consenting, anthropometric measurements, sample 
collection and laboratory analysis were performed by myself. Thus, I was not blind to BMI category 
or gender whilst undertaking the laboratory work.  However, such an approach ensured 
standardisation of the research protocol and minimised inter-user variability whilst performing the 
laboratory assays. 
3.4.1 Recruitment/ Ethics 
Healthy non-smoking volunteers on no regular prescribed/ ’over the counter’ medications or herbal 
supplements were invited to take part in this study. Ethical approval was obtained from the School 
of Medicine, Cardiff University (SoMRec 14/53).  
 All volunteers attended the Clinical Research Facility at the Wales Heart Research Institute between 
the 9 and 11am to avoid any potential variation in EV concentration and profile due to circadian 
rhythm.  They underwent anthropometric measurements and donated a fasting venous blood 
sample. 
 The inclusion criteria were: 
- No known chronic illness
- Non-smoking
- Not on any regular medication
- Able to provide written, informed consent
- Able to attend following an 8 hour overnight fast.
Exclusion criteria included: 
- Pregnancy/post-partum
- Recent surgery or major illness
- Recent/current viral/bacterial infection
- Unable to provide written, informed consent
- Unable to attend in a fasting state
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3.4.2 Anthropometric measurements 
3.4.2.1. BMI (Body Mass Index) 
Body Mass Index was calculated as weight (kg) divided by height (m) squared.  Height was 
established using a Seca 242 measuring rod [Seca, Birmingham, UK] and weight was measured by a 
Seca floor scale [Seca Birmingham, UK]. 
3.4.2.2 Waist: Hip Ratio 
The Waist: Hip Ratio (WHR) was determined by dividing the waist circumference (cm) by the hip 
circumference (cm). Waist circumference was measured by a tape measure positioned parallel to 
the floor immediately above the iliac crest at minimal respiration. The hip circumference was 
measured around the widest portion of the buttocks. 
3.4.3 Blood Pressure Measurement 
Following a brief period of rest, 2 blood pressure readings were obtained 5 minutes apart using a 
validated Omron HEM-9907 blood pressure monitoring device [Omron Healthcare UK Ltd, Milton 
Keynes, UK]. The blood pressure cuff was inflated on the non-dominant arm of each subject. The 
mean of 2 readings was then calculated. 
3.4.4 Venepuncture 
Venepuncture was performed using a 22G ‘butterfly’ needle inserted into a large peripheral vein 
(typically in the antecubital fossa). Samples for plasma markers were taken into EDTA vacutainers 
whilst samples for EV isolation were taken into citrate vacutainers as heparin-based anticoagulants 
are discouraged by the International Society of Extracellular Vesicles (ISEV) as heparin can bind EVs, 
affect platelets activation and give false-negative PCR readings [Witwer K, 2103]. 
3.4.5 Plasma analysis 
Following a double centrifugation at 3000g for 10 minutes at 4°C, acellular plasma was stored at -
80ºC until recruitment was completed. All samples were analysed simultaneously in duplicates.  
3.4.5.1 Fasting glucose 
Glucose concentration was measured using a glucose oxidase assay as previously described in 
Methods chapter section 2.6.4 [Dietzler DN, 1980]. Fifty microliters of fasting plasma were assayed 
in duplicate for each healthy volunteer.  
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3.4.5.2 Fasting insulin 
A human ELISA sandwich kit was used (Abcam, ab100578) as per the manufacturer’s instructions. 
The same methodology was applied as for the human adipokine measurements (Methods chapter, 
section 2.6.3). Plasma was diluted 1:2 for this assay. 
3.4.5.3 HOMA-IR 
HOMA-IR was calculated as described in the Methods chapter, section 2.6.5 
3.4.5.4 Plasma adipokines 
Sandwich ELISA assays were used for these measurements as described in chapter 2 section 2. 
Samples were assayed in duplicate. Plasma IL6, Interferonϒ, TNFα  and adiponectin were evaluated 
using Human ELISA kits provided by Abcam (ab46042, ab100537, ab46087, ab99968 respectively). 
Plasma FABP4 concentration was evaluated by a Human Quantikine FABP4 ELISA kit (R&D Systems, 
DFBP40). A human PPARϒ Sandwich ELISA kit was used for plasma PPARϒ evaluation (LifeSpan 
BioSciences, Inc, LS-F12376). Plasma samples were diluted 1:20 for FABP4 and 1:30000 for 
adiponectin assays whereas it was measured undiluted for the remaining ones.  A BMG Clariostar 
plate reader was used to determine optical densities at 450nm wavelength (with 540nm correction). 
3.4.6 EV isolation and analysis 
3.4.6.1 EV isolation 
EVs were isolated by differential centrifugation as described in the Methods chapter, section 2.5.1.2. 
3.4.6.2 EV concentration and size 
Nanoparticle Tracking Analysis (NTA) was undertaken using NanoSight LM10 as described in 
Methods, section 2.5.4. All samples were measured within 48 hours of isolation. Following that, 
samples were gradually frozen to -80ºC (1°C/hr using a ‘ Mr Frosty’ cell freezing device) and stored 
for further analysis which was typically performed within 1-3 weeks of sample collection. 
3.4.6.3 EV cellular origin and content 
Time Resolved Fluorescence –based immunoassay was used for this analysis as described in 
Methods, section 1.3. Samples were assayed in duplicates and fluorescence was measured using a 
BMG Fluorostar Optima plate reader.  
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3.4.7 Statistical analysis 
GraphPad version 6.0 was used for statistical analysis. Normally distributed variables are presented 
as mean (SD) whereas non-normally distributed variables are shown as median (range). The Shapiro-
Wilk test was used to test for normality.  A P value of <0.05 was accepted as statistically significant. 
When comparing normally distributed variables, t-test was used whilst for not normally distributed 
ones- the Mann Whitney test. The Kruskall Wallis test was used when more than 2 groups were 
compared with post-test Dunn’s analysis. The Spearman correlation analysis was applied to test for 
correlations. 
3.5 Results 
3.5.1 Baseline anthropometric and metabolic characteristics of the healthy cohort 
A total of 49 healthy subjects were recruited:  26 female (mean age 33.8±11.5 years) and 23 male 
(mean age 33±7.6 years), p=ns. Of these, 22 subjects had BMI <= 25kg/m2 (range 16-25kg/m2), 13 
had BMI between 25-30kg/m2 (overweight) and 14 had BMI above 30kg/m2 (obese; range
30.3-42kg/m2). Therefore 55% of the evaluated cohort were overweight or obese. 
The anthropometric and metabolic characteristics are summarized in Table 3.1. 
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Age (years) Lean 
(BMI<=25kg/m2) 
Overweight (BMI 
25-30kg/m2) 
Obese 
(BMI>30kg/m2) 
P value 
Gender (M/F) M=9, F=13 M=6, F=8 M=8, F=5 
BMI (kg/m2) 21.86 (2) 27.7 (1.56) 35.3 (3.8) a,b,c p<0.005 
Weight (kg) 64.2 (9) 79.5 (11.4) 105.9 (16.8) a,b,c p<0.005 
Waist 
circumference 
(cm) 
F: 76.9 (9.9) 
M: 82.2 (4) 
F: 84.6 (8.8) 
M: 100.5 (6.75) 
F: 109.4 (19.3) 
M: 118.5 (11.9) 
F: ap=ns, b,cp<0.01 
M:  a,b,cp<0.01 
WHR (waist:hip 
ratio) 
F: 0.76 (0.05) 
M: 0.835 (0.03) 
F: 0.77 (0.08) 
M: 0.92 (0.07) 
F: 0.91 (0.06) 
M: 0.98 (0.07) 
F: ap=ns, b,cp<0.01 
M: ap<0.05, 
bp<0.005, cp=ns 
Resting systolic BP 
(mmHg) 
123.6 (12.9) 121.1 (13.4) 124.5 (15.7) a,b,c p=ns 
Fasting glucose 
(mmol/L) 
5.5 (0.7) 4.8 (1.7) 5.7 (0.87) a,b,c p=ns 
Fasting insulin 
(mIU/mL) 
3.36 (3.26) 4.6 (6.8) 5.4 (8.7) a,b,c p=ns 
HOMA-IR 0.82 (0.75) 1.08 (1.5) 1.31 (1.95) a,b,c p=ns 
Age (years) 32.6 (12.5) 33.5 (8.1) 34.7 (5.4) a,b,c p=ns 
Tab.3.1:  Anthropometric and metabolic characteristics of the healthy volunteer cohort. 
Waist circumference and WHR ratio are presented separately for male and female 
volunteers.  a overweight vs lean     b obese vs lean   cobese vs overweight 
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The average BMI in the female cohort was 25.7±5.5kg/m2 compared to 28.6±6.4 kg/m2 in the male 
cohort, with the average weight and WHR 70±15.5kg vs 90±23kg and 0.79±0.08 vs 0.9±0.08, 
respectively. 
The distribution of BMI in male and female cohorts is presented in Figure 3.1a and 3.1b respectively. 
Fig.3.1: The BMI distribution: a) percentage BMI distribution in the healthy female cohort 
b) percentage BMI distribution in the male cohort.
3.5.2 Glucose homeostasis 
The mean fasting glucose concentration remained within the normal range for evaluated subjects 
(Table 3.1). Fasting plasma insulin, as expected, was low in this cohort. Although, there are no clearly 
agreed cut-off values for HOMA-IR which define insulin resistance (since it is influenced by gender, 
age and ethnicity), it is notable that the average HOMA-IR  in my obese cohort was below cut-off 
thresholds conventionally used for diagnosing insulin resistance in the literature (which vary from 
1.5 to 2.77) [Gayoso-Diz P, 2013]. 
3.5.3 Circulating plasma cytokine and adipokine profile 
Measurements of these adipocytokines were performed in 40 out of 49 subjects; reasons include 
not enough plasma available, sample compromised or failure of assay. 
50%
31%
19%
Female cohort
Lean
Overweight
Obese
39%
22%
39%
Male cohort
Lean
Overweight
Obese
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3.5.3.1 Interleukin 6 
The median IL6 concentration was 1.49 pg/mL (0.43-7.4pg/mL). IL6 was significantly higher in 
healthy male volunteers compared to females (1.9 vs 1.1pg/mL, p<0.05).  Plasma IL6 correlated with 
fasting insulin and HOMA-IR. Moreover, positive correlations were observed with EV 
concentration/mL and WHR (r= 0.35 and r=0.4  respectively, p<0.05) and negative correlation with 
plasma adiponectin (r=-0.47, p<0.005). There were no correlations observed with BMI, age or EV- IL6 
expression (r= 0.29, p=0.0.065, r=0.14 p=0.39 and r=0.39, p=0.076).  
3.5.3.2 TNFα 
As expected, plasma TNFα concentration in this cohort of metabolically healthy volunteers was low, 
with a median concentration of 47.7pg/mL (range 2-833pg/mL) and no differences between males 
and females (49pg/mL vs 47pg/mL, p=0.82). In 6 subjects the concentration of this cytokine was 
below detection threshold of the assay used therefore they were excluded.   
3.5.3.3 Interferon γ 
Circulating plasma interferon γ was expected to be very low and difficult to detect in plasma of 
healthy donors. In our cohort, only 17 subjects had detectable levels of this cytokine with a median 
concentration of 98pg/mL (range 10-604pg/mL) with the assay’s sensitivity threshold being 
15pg/mL. 
3.5.3.4 Adiponectin 
In contrast to the above, all subjects had detectable levels of circulating adiponectin, with a median 
concentration of 203.4 µg/mL (range 115.1-822.9). 
Interestingly, plasma adiponectin was higher in women than in men (272.3µg/mL vs 128 µg/mL, 
p<0.005). However, no difference was observed between lean, overweight and obese BMI cohorts as 
plasma adiponectin did not correlate with BMI (r=-0.2, p=0.2), neither did it correlate with HOMA-IR, 
fasting insulin or age (respectively r=-0.2, r=-0.19, r=-0.04, p=ns). However, it did correlate negatively 
with WHR and waist circumference (r=-0.46 and r=-0.35, p<0.05). As discussed above plasma 
adiponectin correlated negatively with plasma IL6 concentration but no relationship with other 
plasma adipocytokines was observed. Similarly to above described adipocytokines, there was no 
correlation observed between plasma and EV-associated adiponectin (r= -0.12, p=0.45). Interestingly 
however, plasma adiponectin correlated negatively with various EV markers as summarised in Figure 
3.2. 
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Fig. 3.2 Spearman correlation analysis of plasma adiponectin and EV concentration/mL of plasma  (a) and EV expressed cellular markers 
(b,c) and adipokines (d-g).
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3.5.3.5 Fatty Acid Binding Protein 4 
Similarly to the adiponectin assay, all healthy subjects had detectable levels of circulating plasma 
FABP4 with a mean concentration of 19.9 ±9.07ng/mL.  There were no gender differences observed 
(mean plasma FABP4 concentration in women vs men: 21.8±7.8 vs 18.1 ±9.8 ng/mL, p=ns) but 
significant differences between healthy lean and healthy overweight and obese volunteers were 
observed(13.5 ±6.4 vs 19.2 ±6.7 vs 28.5 ±6.3 ng/mL, all p<0.05) (Fig.3.3a). Therefore, as expected, 
plasma FABP4 concentration correlated significantly with BMI (Fig. 3.3b), weight and waist  (r=0.68, 
r=0.56, r=0.59 all p<0.0001,) as well as WHR and age ( r=0.36, p<0.05 for both). There were no 
correlations observed with any of the glucose metabolism measurements, other plasma 
adipocytokines or EV concentration or markers, including EV FABP4 (all p=ns). 
a)
H
ea
lth
y 
le
an
H
ea
lth
y 
ov
er
w
ei
gh
t
H
ea
lth
y 
ob
es
e
0
10
20
30
40
*
Plasma FABP4 concentration
**
***
n
g
/m
L
99 
b)
Fig.3.3. a) Plasma FABP4 concentration (mean (SD)) in healthy lean, overweight and 
obese volunteers. *p<0.05, **p<0.01, ***p<0.005 b) Spearman analysis of correlation
between plasma FABP4 and BMI from all cohorts evaluated in this thesis
3.5.3.6 PPARγ 
The presence of free PPARγ in plasma was expected to be very low however the assay was 
performed to mirror the EV expressed PPARγ analysis.  Unfortunately, in 29 out of 40 subjects the 
levels were below the detection threshold of the assay which had a sensitivity threshold of  
0.156ng/mL according to the product data sheet.  Amongst those 11 subjects who had detectable 
levels of plasma PPARγ  (M=8, F=3, lean=4, obese= 7) the median concentration obtained was 
0.37ng/mL (0.09-6.3).  
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3.5.4 Characterisation of circulating plasma EVs in the healthy population 
3.5.4.1 EV concentration and size distribution 
There was no statistically significant difference in median EV concentration between healthy lean 
and healthy overweight and obese individuals (3.3x1011EVs /mL (2.2-12.15) vs 4.1x1011EVs/mL (2.3-
8.7) vs 4.7 x1011EVs/mL (2.3-11.2), p=0.64). 
The size distribution analysis did not reveal any differences either. In contrast, male volunteers had a 
higher concentration of EVs within a subgroup ranging from 100 to 200nm in diameter (p<0.01, 
Fig.3.4) though no differences were seen in the median plasma concentrations (4.5x10 11EVs/mL(2.2-
12.5) vs 3.7x10 11EVs/mL(2.3-8.7), p=0.3). 
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Fig.3.4 a-b Differences in size distribution of plasma EVs between male and female healthy 
volunteers. Male subjects had significantly higher EV concentration within the exosomal 
range (100-200nm in diameter).  ***=p< 0.005. 
The correlations between EV concentration/mL of plasma and other parameters are summarised in 
Table 3.2. 
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EVs conc./mL of plasma  r P value 
BMI   0.15      0.33 
WHR   0.14      0.37 
Age   0.15      0.34 
HOMA-IR   0.39      0.01 
Glucose 
Plasma IL6 
EV-IL6 
Plasma Adiponectin 
EV-adiponectin 
Plasma FABP4 
EV FABP4 
EV PPARϒ 
  0.007 
  0.35 
  0.4  
-0.37
0.14
0.12
0.17
0.13
0.96 
0.02 
0.01 
0.01 
0.39 
0.42 
0.27 
0.42 
Tab.3.2: Spearman correlation analysis between EV concentration/mL of plasma and other 
evaluated parameters. 
3.5.4.2. EV cellular origin 
The expression of the following cell-of-origin markers was evaluated : CD41(platelets); CD11b 
(monocytes/macrophages) , CD235a (erythrocytes) and CD144 (endothelial cells) as well as the 
exosomal marker: CD9.  
There were no differences in the expression of these markers between healthy lean, overweight and 
obese individuals (p=0.96, p=0.31, p=0.26, p=0.97, p=0.84, respectively) (Fig 3.5a). It is likely related 
to the large individual variations in expression of those markers across the analysed groups of 
healthy volunteers which given the sample size makes it difficult to detect any obvious differences. 
Interestingly, when results were compared by gender, the expression of CD144 was significantly 
higher in males vs females, whilst there was no statistically significant difference for CD41 (p=0.07). 
103 
There was no difference in the expression of the erythrocyte marker or CD9 (p=0.14 and p=0.37, 
respectively)  but female subjects had higher CD11b signals (p=0.02)(Fig 3.6a). 
3.4.3.3 EV adipocytokine expression 
Analysis of the expression of the following adipocytokines was performed: Interleukin 6, TNFα, 
Interferon γ, adiponectin, FABP4 and PPARγ- to match the plasma adipocytokine analysis.  
No differences were observed with regard to expression of these adipocytokines in EVs isolated from 
lean, overweight and obese individuals (p=0.75, p=0.95, p=0.53, p=0.36, p=0.35, p=0.7, respectively). 
This remained true even when obese and overweight healthy individuals were grouped together or 
waist circumference rather than BMI was used to define body habitus.  
Interestingly, gender differences were observed with significantly higher signals from EV-expressed 
IL6, Interferon γ and FABP4 in males (p= 0.01, p=0.0006, p=0.0013) but no differences for TNFα, 
adiponectin or PPARγ (p=0.57, p=0.15, p=0.44 respectively)(Fig. 3.6b). 
The higher expression of EV-IL6 in male subjects was in keeping with higher plasma-free IL6 
expression but correlation between plasma and EV IL6 was not significant (p=0.07). As mentioned 
above, no direct correlation was observed between the plasma and EV-expressed TNFα, Interferon γ, 
adiponectin, FABP4 (p=0.2, p=0.86, p=0.74 and p=0.71). This suggests that the process of EV 
packaging with adipocytokines is controlled by mechanisms different to those that regulate 
secretion of plasma ’free’ adipocytokines.   
Adiponectin-Receptor- 1 was also found to be expressed within plasma derived EVs with median TRF 
signals of 19542 (478-50485 a.TRF) but it did not correlate with plasma or EV-expressed adiponectin 
or BMI (p=0.93, p=0.23, p=0.39 respectively). 
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Fig.3.5 a) Expression of cell of origin markers (CD41 platelets, CD11b monocyte/macrophages, CD235a erythrocytes, CD144 endothelial 
cells) in plasma EVs isolated from healthy lean, overweight or obese individuals. b) EVs adipocytokine expression in lean, overweight and 
obese individuals. 
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 Fig.3.6 a) Effects of gender on expression of cell-of-origin markers (CD41 platelets, CD11b monocyte/macrophages, CD235a erythrocytes, 
CD144 endothelial cells). *p<0.05, ***p<0.005 b) Effects of gender on EV adipokine expression. *p<0.05, ***p<0.005
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3.5.4.4 Expression of the exosomal marker CD9 
There was no difference in expression of CD9 between healthy volunteers, irrespective of their BMI 
or gender.  However, interesting significant correlations were observed between CD9 and EV-
expressed FABP4, interferon γ, and adiponectin across the BMI range, suggesting that exosomes 
(rather than microvesicles) may be the primary vesicular carriers for these molecules (Fig.3.7). 
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Fig.3.7: Spearman correlation analysis of the exosomal marker CD9 with EV-expressed 
interferon γ, adiponectin and FABP4 (a-c). 
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3.6 Discussion 
3.6.1 Anthropometric measurements and glucose metabolism 
Body Mass Index (BMI) and Waist-Hip Ratio (WHR) correlate strongly with body fat and the cut-off 
point for the healthy volunteers in this study dividing them into healthy weight/lean, overweight and 
obese groups was based on the World Health Organisation  (WHO) and National Institute for Health 
and Clinical Excellence (NICE) definitions [WHO, 1995, NICE, 2006]. These cut-off points were chosen 
based on established relationships between mortality and increased BMI; current guidelines suggest 
that health intervention is required when BMI is 25kg/m2 or more [WHO, 1999, NICE, 2005]. 
However, a significant limitation in using BMI is the fact that it reflects ‘overall’ adiposity, whilst it is 
visceral adiposity in particular that has emerged as an independent predictor of health outcomes 
[WHO, 1999, NICE, 2006]. The latter is  easily measured by waist circumference. However, since 
commonly used cut-off points to define cardiometabolic risk differ for men and women (102cm and 
88cm, respectively), I decided to use BMI rather than waist circumference to divide my cohort into 
subgroups. The recruited subjects were well matched with regard to age and despite significant BMI, 
weight and waist circumference differences, no differences were observed between them with 
respect to glucose metabolism (fasting glucose, insulin and HOMA-IR). On the one hand, this 
observation confirms the ‘healthy obese’ status of the recruited subjects. On the other, it shows that 
changes in glucose metabolism in obese subjects may be a late sign of underlying metabolic 
dysfunction. This would be  in keeping with the current assumption that about half of the estimated 
415 million of people with type 2 diabetes worldwide are unaware of their condition [Beagley J, 
2014]. In recent years, the term ‘metabolically healthy obesity’ has gained lots of attention following 
observations that some obese individuals may be somewhat protected from developing the 
cardiometabolic consequences of increased adiposity. However, it is presently unclear how best 
such subjects can be distinguished at an early stage from ’high risk’ obese subjects using traditional 
markers of metabolic health [Stefan N, 2013].  A recent meta-analysis by Lotta et al which evaluated 
a total of 140845 individuals from various studies according to lean, overweight and obese BMI 
categories, showed that current traditional binary markers of metabolic health reported in literature 
(such as the presence or absence of metabolic syndrome, insulin resistance or both, or 
cardiorespiratory fitness) have limited predictive performance in establishing the long-term risk of 
developing type 2 diabetes [Lotta L, 2015]. The so-called metabolically healthy obese subjects still 
had a high absolute risk of developing type 2 diabetes (10-year cumulative incidence 3.1% [95% CI 
2.6–3.5]) [Lotta L, 2015]. Therefore, greater emphasis has been placed in recent years on developing 
more complex machine learning algorithms to predict the risk of cardiometabolic disease [Olivera A, 
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2017] as well as the development and introduction to clinical practice of more complex and 
individualized metabolomics/proteomics profile [Peddinti G, 2017]. This aligns with the aims and 
results of my study as discussed below. 
3.6.2 Plasma adipocytokines 
As discussed in chapter 1, adipose tissue is an active endocrine organ secreting a variety of 
molecules playing a crucial role in the regulation of metabolic homeostasis. The chronic low-grade 
systemic inflammation associated with obesity is likely to occur secondary to the imbalance in 
secretion of pro-inflammatory vs. anti-inflammatory cytokines from adipose tissue [Ouchi N, 2011]. 
These adipokines are believed to play an important role in the intercellular cross-talk regulating 
inflammation and metabolism. However, the pathways regulating these processes are not yet fully 
understood.  Below, I discuss the relevance of my analysis of plasma IL6, TNFα, adiponectin and 
FABP4 concentration. As plasma Interferon γ and PPARγ levels were very low and measurable in only 
a small proportion of subjects, I will not discuss them further in the context of this study. 
3.6.2.1 Plasma IL6 
Plasma IL6 levels are well known to be increased in metabolic syndrome/obesity and type 2 diabetes 
mellitus (T2DM). Indeed, IL6 concentrations may help predict the risk of type 2 diabetes 
development [Pradhan AD, 2001]. Moreover, IL6 levels decrease following a lifestyle intervention 
aiming at weight reduction (which also leads to increase in plasma adiponectin levels) [Esposito K, 
2003]. It is believed that around one third of circulating IL6 is secreted by adipose tissue and this 
cytokine correlates with adiposity [Fried SK, 1998], which was shown by its correlation with WHR in 
our cohort.  IL6 also has an effect on insulin signalling as it exacerbates insulin resistance in 
hepatocytes [Senn JJ, 2003]. 
IL6 and TNFα hinder the secretion of adiponectin [Kern PA, 1996], which was supported by the 
negative correlation observed between IL6 and adiponectin in my cohort. In my study, apart from 
association between IL6 and overall plasma EV concentration, we did not observe any correlation 
with any other EV markers. However, a previous study by Ueba et al evaluating Japanese healthy 
volunteers showed that platelet-derived EVs correlated with plasma IL6 concentration as well as CRP 
[Ueba T, 2010]. 
There do not appear to be gender-related reference ranges for IL6 but in my cohort, interestingly, 
plasma IL6 was marginally higher in men. In contrast to my subjects, who were relatively young, a 
study by Campesi et al revealed that plasma IL6 (after correction for body weight) was significantly 
higher in post- vs. premenopausal women and also higher compared to men >45 years of age 
[Campesi I, 2016]. 
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3.6.2.2. Plasma TNFα 
Similarly to IL6, plasma levels of TNFα are increased in obese individuals and decrease following 
weight loss interventions [Kern PA, 1995]. Many animal models have shown that this cytokine plays 
a crucial role in regulation of insulin sensitivity as it attenuates insulin-stimulated tyrosine 
phosphorylation of the insulin receptor in muscle and adipose tissues, which leads to insulin 
resistance [Hotamisligil GS, 1994]. It is therefore not surprising that in my data as well as in the 
literature [Hivert MF, 2008] plasma TNFα correlates with markers of insulin resistance, even when 
HOMA-IR is still within normal range (as it is in this cohort). This indicates the involvement of this 
cytokine in processes regulating metabolic homeostasis.  
Plasma cytokines did not correlate with BMI or age in my cohort, which as stated above was 
relatively young and there were not many severely obese volunteers recruited (the highest BMI was 
42kg/m2). 
3.6.2.3. Plasma Adiponectin 
Adiponectin is an anti-inflammatory, anti-atherogenic adipokine that is known to be present in 
abundance in the circulation. Though this protein is primarily secreted by adipocytes, it paradoxically 
decreases in obese subjects and is reduced in patients with T2DM [Hotta K, 2000] suggesting its 
secretion is disturbed in those clinical circumstances. The secretion of this adipokine is in fact 
decreased by IL6 and TNFα (which are elevated in obesity driven chronic systemic inflammation) 
[Ouchi N, 2011] and  reduced levels of adiponectin can be considered as a marker of visceral 
adiposity.  Indeed, in our cohort plasma adiponectin showed negative correlation with WHR 
(Fig.3.2). It also correlated negatively with FABP4- expressing EVs, which we believe, are 
predominately secreted by adipocytes. 
Moreover, hypoadiponectinaemia is associated with insulin resistance: in previous studies on Rhesus 
monkeys, a decline in plasma adiponectin concentration occurred before hyperinsulinaemia 
developed [Hotta K, 2001]. This might explain why no correlation was observed with HOMA-
IR/fasting insulin in my healthy volunteers who even in the obese arm had no apparent biochemical 
evidence of disturbed glucose homeostasis suggestive of impending insulin resistance. 
Interestingly, men had significantly lower plasma adiponectin levels compared to women in my 
study. This is in keeping with findings from a study by Nishizawa et al who in an attempt to explain 
this phenomenon showed that in vitro testosterone reduces adiponectin secretion from 3T3 cells 
and that castration leads to increase of this adipokine in the mice models [Nishizawa H, 2002]. This 
has led to a conclusion that androgens are involved in reducing circulating plasma adiponectin levels 
and might thus contribute to the known increased risk of cardiovascular disease and insulin 
113 
 
resistance in male subjects. The interplay between adiponectin and hypothalamo-pituitary-gonadal 
(HPG) axis has only begun to be explored in recent years.  In fact, it has been shown that adiponectin 
and adiponectin receptors are present in HPG axis cells participating in gameto- and steroidogenesis 
and regulated by factors such as age, gender, nutrition and hormonal status [Rak A, 2017]. 
Finally, I also found interesting correlations between plasma adiponectin and EV markers. Firstly, 
plasma adiponectin correlated negatively with circulating EV concentration. This might suggest a 
possible negative feedback mechanism between the two as adiponectin is known as the ‘anti-
inflammatory’ adipokine whereas increased circulating EVs concentration are found in various 
pathological disorders associated with increased inflammation such as CVD  [Agouni A, 2008, Helbing 
T, 2014]. EV secretion is known to be affected by a rise in intracellular calcium [Pasquet JM, 1996] 
hence calcium ionophores directly trigger EV release [Hess C, 1999]. On the other hand, recent 
studies have shown that increased concentrations of extracellular calcium and phosphate also 
stimulate EV release (from macrophages) which have high calcification potential and can be involved 
in excessive intimal and medial calcification which subsequently leads to CVD development [New SE, 
2013].  It was also reported by Kapustin et al that vascular smooth muscle cell calcification is 
affected by exosome secretion regulated by sphingomyelin phosphodiesterase 3 that is induced by 
increased extracellular calcium levels [Kapustin A, 2015]. Thus both in vitro and in vivo (in chronic 
kidney disease patients) high extracellular calcium levels were associated with increased secretion of 
EVs with a ‘calcifying’ potential [New SE, 2013]. High plasma adiponectin levels have anti-
atherogenic potential as they suppress TNF-α-induced mRNA expression of various adhesion 
molecules, decrease lipid accumulation in macrophages and decrease proliferation of vascular 
smooth muscle cells [Ouchi N, 1999]. Adiponectin is known to lead to increase in intracellular 
calcium [Ouchi N, 2011]. Therefore, its higher levels possibly inhibit secretion of those EVs 
subpopulation that have detrimental effects on the vascular endothelium, with a consequent 
protective effect against CVD development. This would be in keeping with the findings by Zoccali et 
al who reported that plasma adiponectin inversely correlates with the incidence of ischaemic heart 
disease in CKD patients (who are known to have high plasma calcium levels) [Zoccali C, 2002]. The 
mechanism behind the inverse relationship between plasma adiponectin and EV concentration is 
likely to be more complex but I believe that alterations in calcium homeostasis may play an 
important role here.  
 In my study, I also found that plasma adiponectin correlated negatively with endothelial- and 
platelet-derived EVs subpopulations which are known to be increased in subjects with CVD [Agouni 
A, 2008, Helbing T, 2014]. This suggests that this adipokine may have an important effect on EV-
driven intracellular communication affecting/protecting the vascular endothelium.  
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A previous study by Kranendonk et al evaluating correlations between plasma adiponectin and 
“atherothrombotic” EV markers (cystatin C, CD14, serpin G1 and F2) in subjects with clinically 
evident cardiovascular disease did not reveal any relationship between adiponectin and those 
specific EV expressed markers [Kranendonk ME, 2014]. This may indicate that once overt 
cardiovascular disease is present (which is associated with hypoadiponectinaemia), the negative 
feedback between adiponectin and the release of EVs, which have proinflammatory and 
proatherogenic potential, is disturbed.  
It should also be noted that the plasma EVs in my cohort were expressing adiponectin receptor-1 by 
TRF immunoassay which may suggest that this adipokine is not only involved in regulating EV 
secretion but may directly affect EV biology by binding to its receptor on them. More detailed 
studies in this area are required which were outside the scope of this project. 
3.6.2.4 Plasma Fatty Acid Binding Protein 4 (FABP4) 
FABP4 is emerging as an early and potent biomarker of cardiovascular and metabolic disease and has 
been detected not only in adipocytes but also in macrophages [Furuhasi M, 2015]. High circulating 
levels of this adipokine are associated with insulin resistance, type 2 diabetes and atherosclerosis. 
[Furuhasi M , 2015]. It is involved in intracellular lipid cargo, glucose metabolism and inflammatory 
response [Furuhasi M, 2015, Hotamisligil GS, 2015]. My data showed a strong correlation between 
BMI, weight and waist circumference and plasma FABP4. Moreover, changes in plasma 
concentration of this adipokine were observed between metabolically healthy lean, overweight and 
obese individuals before any changes in traditional glucose metabolism markers such as HOMA-IR or 
fasting glucose or proinflammatory cytokines associated with obesity such as IL-6 are seen. This 
suggests that plasma FABP4 could be utilised in the future as a marker of impending cardiometabolic 
dysfunction. It would be of great interest to follow up my healthy cohort over a 5- or 10-year period 
to evaluate the predictive value of high plasma FABP4 for the development of cardiovascular disease 
or type 2 diabetes mellitus. Evidently, this was not possible due to time restrictions in my project but 
interesting data from other research centres on the use of this adipokine are emerging. A study by 
Miedema et al evaluated the association between plasma free fatty acids (FFA) and plasma FABP4 
and total and cardiovascular mortality in older adults (mean age=75, n=4770, median follow up 11.8 
years). Interestingly, they found that it was plasma FFA and  not plasma FABP4 that was better 
associated with cardiovascular and non-cardiovascular mortality [Miedema MD, 2014]. However, the 
study by Xu et al where 495 non-diabetic adults were followed up for 5 years showed that subjects 
with higher baseline plasma FABP4 levels developed a progressively worse cardiometabolic risk 
profile and increasing risk of metabolic syndrome independently of adiposity and insulin resistance 
[Xu A, 2007]. Also, von Eynatten et al showed that plasma FABP4 in subjects with clinically overt CVD 
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was, over a 10-year follow-up, associated with increased risk of secondary cardiac events and 
cardiovascular death [von Eynatten M, 2012]. Therefore, there is a growing interest in clinical 
application of this adipokine in various risk stratification approaches. A recent study by Lindt et al 
evaluating various proteomics that could be used to predict the risk of atrial fibrillation (AF) 
highlights the ‘predictive’ potential of plasma FABP4  [Lind L, 2016] whilst  Ningh et al suggest it 
could also be a useful biochemical marker to estimate the risk of developing gestational diabetes 
[Ningh H, 2016]. Moreover, a recent study by Tu at al suggests that plasma FABP4 can also be used 
to predict the outcome from an acute ischaemic stroke [Tu W, 2017]. It is therefore quite likely that 
plasma FABP4 may soon become incorporated into risk stratification pathways given that it is 
relatively easy to measure using commercially available assays. However, the important research 
questions that remain unanswered are: 1) whether lowering plasma FABP4 can affect primary and 
secondary CVD outcomes and 2) how this can be achieved pharmacologically. Advances in our 
understanding of this protein may, in my opinion, have a significant impact on our approach to the 
management of cardiometabolic disorders in years ahead. 
3.6.3 Circulating plasma EVs in healthy volunteers 
My study has shown that in metabolically healthy individuals the circulating EV profile is unaffected 
by increasing BMI/weight. It was observed not only with regard to the expression of markers of 
cellular origin of the main plasma-derived EV families (platelets, monocytes/macrophages, 
erythrocytes, endothelial cells) but also with regard to their adipokine content. This indicates that EV 
secretion and packaging could be controlled by mechanism(s) maintaining metabolic homeostasis in 
the healthy state and until this is disturbed, EV profiles of so called “healthy obese” individuals do 
not differ from  “healthy lean” individuals. As discussed earlier, EVs have gained lots of attention in 
the recent years as potential disease biomarkers but it must be remembered that cells release EVs in 
both health and disease states and the fact that increase in various EVs has been associated with 
many pathological disorders may have slightly drawn the attention away from the fact that EVs 
probably also play an important role in physiological intercellular signalling in order to maintain 
health. Therefore, in contrast to what I initially hypothesized, circulating EVs cannot at present, at 
least using current methodology, be used as biomarkers of impending metabolic disorder if obesity 
alone is present. They do, however, appear to reflect overt cardiometabolic disease as evident in the 
literature and by my further work described in chapter 4 and 5 which characterises EVs in severely
obese subjects who developed obesity driven comorbidities.
Interestingly, I observed that within a healthy cohort there are differences in circulating plasma EV 
profiles that suggest EVs in men have more pro-inflammatory potential which would be in keeping 
with the increased CVD risk associated with male gender. Although there were slightly more males in 
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my study in the overweight or obese category (Fig.3.1), the lack of correlation between EV 
characteristics and BMI/WHR suggest that there are different mechanisms, other than adiposity 
alone, influencing these gender-related differences. This observation, apart from potential 
interpretation in the CVD risk stratification context, is hopefully a useful addition to the knowledge 
required to establish accurate gender-related reference ranges for healthy plasma EV profiles.  
Below, I have discussed some recent studies, which further elaborate on this in the context of my 
results. 
3.6.3.1 Plasma EVs and obesity 
As mentioned previously, Kranendonk et al recently evaluated a cohort of 1012 patients with 
clinically manifest vascular disease.  Isolated plasma EVs were evaluated for the expression of 
cystatin C, serpin G1 (C1-inhibitor), serpin F2 (alpha-2-antiplasmin) and CD14 (monocytes) markers 
[Kranendonk ME, 2014]. This study, in keeping with my findings, showed that it is not the adipose 
tissue excess but rather adipose tissue dysfunction and the presence of metabolic complications that 
drives the differences in circulating plasma EVs. When vascular disease subjects in this study were 
divided into subgroups based on BMI (<30 and >30kg/m2), visceral obesity (waist circumference 
>88cm for females and >102cm for males) or visceral adipose tissue thickness, no differences in the
concentration of the above 4 EV-expressed markers were observed between the groups 
[Kranendonk ME, 2014]. Only when overt metabolic complications occurred (such as dyslipidaemia, 
presence of metabolic syndrome or T2DM), the EV profile started to differ, showing positive 
correlations between EVs expressing cystatin C and high CRP, and negative associations with HDL. 
Moreover, the EV –cystatin C levels were associated with 57% higher odds for developing the 
metabolic syndrome. There were, however, no gender-related differences in the EV profiles 
observed [Kranendonk ME, 2014]. 
Similarly, Zhang et al evaluated the impact of type 2 diabetes and obesity in combination and 
separately on absolute EV concentration as well as EV expression of platelet, leukocyte and 
monocyte markers. They showed that subjects with diabetes had higher concentrations of platelet- 
derived as well as fibrinogen-positive, tissue factor-positive and P-selectin positive EVs, with no 
differences in monocyte or leukocyte markers. Obesity did not affect any of the EV profile and even 
within subjects with diabetes, the concentration of platelet-derived EVs did not differ between lean 
and obese diabetic patients [Zhang X, 2014]. 
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3.6.3.2 Plasma EVs and gender 
A recent study by Baek et al characterised EVs from healthy males and females over 40 years of age 
using a sandwich ELISA-based EV array developed by this group [Baek R, 2016]. Samples were 
evaluated for 37 various EV markers/EV associated proteins (which apart from CD9 differed from 
those used in my study). The results showed that there was a wide variation in expression of 
markers amongst individuals. There was no effect on the EV profile of gender per se, but smoking 
appeared to increase CD9 expression as well as CD151 (another tetraspanin), and decreased 
Epithelial Cell Adhesion Molecule expression (EpCAM). However, when gender was further split by 
smoking status, it was seen that male smokers had higher level of CD171 (L1CAM) (cell adhesion 
molecule), PD-L1 (Programmed Death Ligand-1) and TSG101 (Tumor susceptibility gene 101 
proteins) compared to female smokers or male non-smokers. Female smokers had also significantly 
lower TSG101 and CD146 (MUC18; cell surface glycoprotein) compared to non-smokers. Certain 
proteins were also significantly lower in female compared to male smokers such as AREG 
(amphiregulin), MUC1 (polymorphic epithelial mucin), CD146, CD13 (membrane alanyl 
aminopeptidase) and TSG 101. Aging was associated with a decrease in oestrogen receptor (AREG) in 
both genders but only significantly in males [Beak R, 2016]. 
Gustaffson et al evaluated gender-related differences in plasma EVs from healthy men and women 
(aged 20-70) isolated by differential centrifugation and evaluated by flow cytometry (hence only 
identifying EVs>200um in diameter) [Gustaffson CM, 2015]. This was in contrast to the above Danish 
study, which used an array of exosomal markers (CD9, CD63, and CD81) in order to specifically 
characterise smaller EVs. The study found that platelet-derived EVs were the most abundant in both 
male and female plasma. Platelet- and endothelial- EVs as well as P-selectin and phosphatidylserine-
expressing EVs were found to be higher in women compared to men.  However, when only 
premenopausal females were evaluated and compared to age-matched males, lower erythrocyte 
and stem/progenitor cell EV signals were observed.  Tissue factor (TF)-positive EVs were lower in 
postmenopausal women and erythrocyte derived ones were higher, with the latter marker 
correlating positively with age in females. Males showed a positive correlation of adipocyte-derived 
EVs with age [Gustaffson CM, 2015]. These findings contrast with my results where my analysis of 
percentage distribution showed the highest proportion of monocyte/macrophages EVs followed by 
platelets-, erythrocyte- and endothelial-derived EVs. This discrepancy may be due to the use of 
different methodology as measurements did not include small EVs (exosomes) in the Gustaffson 
study (which used flow cytometry alone). Both Gustafsson’s study and my data indicate, however, 
that FABP4-expressing EVs (potentially representing an adipocyte origin) were higher in males.  I also 
believe that some of the discrepancies between my results and the above cited studies are due to 
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the fact that my cohort was in fact very young (mean age 33, only 2 postmenopausal subjects 
included) and with no history of smoking. 
The EV differences in women merit further consideration and may have future practical implications. 
A recent study by Toth B et al aimed to evaluate if the increased risk of thromboembolic events in 
young women might relate to gender differences in plasma EV profile. They found (using 
flowcytometry) that annexin V –binding EVs, platelet-derived EVs, P -and E- selectin expressing EVs 
were higher in women and that the luteal phase of the menstrual cycle was associated with 
increased platelet- and endothelial-derived EVs [Toth B, 2007]. Further research evaluating 
differences between pre- and postmenopausal women as well as EV fluctuations in response to the 
menstrual cycle is required in order to establish accurate reference ranges. 
3.6.4 Exosomes as carriers of adipokines 
Finally, it is important to note that my study showed an association between CD9 (exosomal marker) 
and adipokines such as FABP4, interferon γ and adiponectin. This might suggest that CD9-expressing 
small EVs (<150nm in diameter) are the main carriers of these adipokines within the total EV 
population. This is a potentially important observation as exosomes have a distinct secretory 
pathway from other EVs (as discussed in chapter 1). Importantly, corresponding plasma adipokine 
markers did not correlate with that found in EV, again implying specific packaging. The recent efforts 
from various EV research centres in the last few years have been focused on developing 
reproducible methodology to isolate specific subpopulations of EVs from plasma/cell medium, which 
in the longer term could be used in novel pharmacological therapeutic and diagnostic approaches. 
Various functions have been so far described for exosomes, sometimes contraindicatory, which 
suggest that EVs of different intracellular origin may have different function and this should be 
reflected in their composition [Kowal J, 2014]. The obvious barrier at present is a lack of a gold 
standard approach to EV isolation in general, and even less so with specific EV subpopulations which 
is an area our group is also working on using magnetic beads and co-labelled antibodies [Connolly 
KD, 2018].  Recent work by Kowal et al on dendritic cell-derived EVs proposed a protocol combining 
differential centrifugation followed by immune-labelling or ioixanol gradient separation and 
extensive proteomic analysis, allowing EVs of different sizes and cellular compartmental origin to be 
distinguished [Kowal J, 2016]. This was a pilot study and given how labour intensive such an 
approach is, it appears that this approach might not easily translate to application on a larger scale. 
Secondly, as EVs are a hugely heterogeneous group we still have not understood the exact pathways 
controlling specific EV subpopulation secretion and packaging. Given how crucial EVs appear in 
intercellular signalling, potential methods allowing control of their content and uptake could have 
revolutional effects in driving novel pharmacotherapies. There are already some promising studies in 
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dermatology, vaccines and oncology [Fais S, 2016] but all are based on loading ’nanoparticles’ with a 
certain therapeutic exogenous agent rather than controlling endogenous EV secretion. These 
obstacles need to be overcome before EVs can be practically used as therapeutic agents.
My data showing that specific EVs subpopulations carry adipokines associated with
obesity and inflammation form a useful addition to what is already known. 
3.7 Summary 
3.7.1 Study limitations 
The main limitation of the study is that the cohort was relatively young and in my overweight/
obese subgroup I did not have many participants with class III obesity (BMI>40kg/m2). The study 
would benefit from a larger cohort size and a follow-up analysis after a 5 to 10-year period of 
observation. Moreover, since my study was performed, there is more interest in using 
precipitation assays or size exclusion for more precise  isolation of a purified EV fraction. 
3.7.2 Study strengths 
Most EV studies so far have focused on characterisation of the EV profile in various pathological 
states such as malignancy, autoimmune disease or cardiovascular disease and used the healthy 
cohorts for comparison purposes mainly. Data on “healthy EVs” is lacking and this study by its 
strict selection of healthy, non-smoking and relatively young individuals adds to our understanding 
of what a ‘healthy EV” profile consists of.  All samples were handled in a standardised reproducible 
manner, which limits any variation that might arise from different sample timing, processing or 
storage conditions.  
3.7.3 Conclusions 
The main findings from this study are outlined below: 
- The EV profile is similar in lean subjects and in people with obesity alone without any other
features of the metabolic syndrome. Therefore, EVs are not early markers of metabolic
dysfunction but should be regarded as important messengers in intercellular communication
maintaining the physiological milieu in the healthy state
- Healthy men have a more ‘proinflammatory’ EV profile, which may explain in part why they
are predisposed to cardiometabolic disease compared to women
- Plasma ‘free’ and EV-expressed adipokines do not correlate which suggests that different
secretory pathways may be involved in their release into the circulation.
- Plasma FABP4 correlates strongly with BMI and may be regarded as a marker of impending
metabolic dysfunction
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- Given that my study showed no differences in circulating EVs in individuals of varying BMI
who have not yet developed any metabolic consequences of increased adiposity,
longitudinal studies evaluating the change in EV profile over a prolonged period of time
would be of interest. Due to obvious time restrictions I was not able to perform such an
analysis.
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Perspective 
Following the work undertaken on EV characterisation in healthy volunteers, I intended to undertake 
similar analysis on a cohort of morbidly obese individuals and to evaluate the effects of weight loss 
on the EV profile. Whilst the study described in chapter 5 was being developed, an opportunity for a 
scientific collaboration with Professor Jeffrey Stephens from the local bariatric surgery research 
centre became available. This allowed me to add an interventional arm to my work with the 
additional advantage of accessing samples from a study that was already established, and hence 
immediate sample availability. However, a disadvantage was the limited volume of plasma available, 
since many other metabolic effects of bariatric surgery were being evaluated by other researchers in 
this study.  Following a period of discussions with my supervisors, I decided to perform the analysis 
of those samples despite some methodological limitations encountered which are discussed later.  
Parts of this chapter have been published in: 
Witczak JK, Min T, Prior S, Stephens JW, James PE, Rees DA. Bariatric surgery is 
accompanied by changes in extracellular vesicle-associated and plasma Fatty Acid Binding 
Protein 4. Obes Surg. 2018 Mar;28(3):767-774. doi: 10.1007/s11695-017-2879-z.  
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4.1 Introduction 
Bariatric surgery markedly reduces fat mass but the effects on circulating extracellular vesicles  are 
unclear. As EVs are secreted by a variety of cells, they may mediate some of the cardiometabolic 
benefits accompanying weight loss. However, it is unclear how EVs, particularly adipocyte-derived 
EVs, alter in response to bariatric surgery. 
As mentioned previously, adipose tissue is no longer regarded simply as a passive energy store but as 
an active endocrine organ that communicates with other tissues by secreting a variety of molecules 
including leptin, adiponectin, cytokines, growth factors and complement proteins. The obesity 
pandemic has led to a greater adoption of bariatric surgery as a treatment for morbid obesity and its 
secondary complications [Batterham RL, 2016]. Bariatric surgery exerts multiple effects on adipose 
tissue, including reducing adipocyte size, improving sensitivity to insulin and catecholamine-mediated 
lipolysis, increasing levels of adiponectin and decreasing levels of leptin, CRP, IL-6, TNFα and Monocyte 
Chemoattractant Protein-1 (MCP-1)[Frikke-Schmidt H, 2016]. However, the pathways regulating these 
changes are not fully understood.  
Adipocyte-derived EVs (AD-EVs) are likely to play important roles in paracrine and endocrine 
communication within adipose tissue and possibly the circulation but comparatively little is known 
about their function. They probably represent only a small percentage of the total population of EVs 
present in the circulation [Ertunc ME, 2015], at least in the healthy state, but are known to affect 
target cell activity [Ogawa R, 2010, Aoki N,2010] such as increasing lipid storage in small adipocytes 
[Muller G, 2011]. 
Fatty Acid Binding Protein 4 (FABP4) is one of the most abundant cytoplasmic proteins within 
adipocytes, whose function extends beyond lipid transport to include regulation of glucose 
metabolism and inflammatory responses [Hotamisligil GS, 2015, Furuhashi M, 2015]. Indeed, its 
circulating concentration correlates strongly with the risk of metabolic disease [Furuhashi M, 2015]. 
Recent data in 3T3-L1 adipocytes and mouse adipose tissue demonstrate that lipolytic stimuli trigger 
accumulation of FABP4 within intracellular multivesicular bodies (MVB), and its subsequent secretion 
via the non-classical pathway in vesicles expressing exosomal markers (CD63 and ALG-2 interacting 
protein X(ALIX)) [Ertunc ME, 2015].  It appears, however, that only a small proportion of total FABP4 
is transported this way [Hotamisligil GS,2015, Ertunc ME, 2015]. Although it is currently not clear what 
the precise biological function of such EVs is, they are likely to play an important role in intercellular 
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communication at both a paracrine and systemic level and may influence how adiposity contributes 
to the development of obesity-associated comorbidities.  
Since lipolysis triggers EV secretion from adipocytes, conditions associated with substantial weight 
loss might result in increased secretion of adipocyte-derived EVs into the circulation. I therefore 
hypothesised that bariatric surgery would result in increased expression of adipocyte-derived 
proteins, including FABP4, not only in a free form but also in association with EVs.  
4.2 Aims 
The aim of this study was to characterise a cohort of patients undergoing bariatric surgery at 
baseline and 2 follow-up time points (1 and 6 months) with regard to the following variables: 
• Anthropometric measurements (weight, BMI, % weight loss)
• Plasma-derived EV concentration, cellular origin and adipocytokine content
• Plasma concentration of FABP4, IL-6, fasting glucose, insulin, HOMA-IR
4.3 Methods 
4.3.1 Study population 
Study participants were recruited from patients undergoing planned bariatric surgery at the Welsh 
Institute of Metabolic and Obesity Surgery (WIMOS).  At the time of recruitment for this study, 
individual suitability for receiving bariatric surgery in Wales was evaluated using  the Swansea 
modified Dudley Bariatric Surgery Comorbidity Score (DUBASCO) (Table 4.1) and funding was 
approved for those scoring >=12. This scoring system takes into account BMI, age and comorbidities 
but negative scores are also allocated if any of the following is present: failed weight loss following 
gastric balloon insertion (-1 point), established chronic cardiovascular disease/ejection fraction<40% 
(-2 points), chronic illness with a prognosis of less than 5 years (-3 points), inability to mobilise more 
than 10 metres (-4 points) and estimated glomerular filtration rate (eGFR) <40 ml/min/m2 (-4 points). 
People with previous complex gastrointestinal surgery, ongoing psychiatric illness or untreated eating 
disorders were deemed unsuitable to receive this treatment. 
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Score 1 2 3 4 
BMI (kg/m2) ≥ 35.0-40.0 ≥ 40.0-50.0 > 50.0-60.0 ≥ 60.0 
Age (years) ≥ 60 51-60 41-50 ≤ 40 
Co morbidities 
Type 2 diabetes 
(duration <15 
years) 
IGT/IFG 
Optimal 
glycaemic 
control 
(HbA1c ≤7.5%) 
Suboptimal 
glycaemic 
control 
(HbA1c 7.6-10%) 
Poor glycaemic 
control 
(HbA1c >9%) or 
on insulin 
Hypertension 
Well controlled 
on 1 medication 
(BP <140/90 
mmHg) 
Well controlled 
on 2 medications 
(BP <140/90 
mmHg) 
Poorly controlled 
on 2 medications 
(BP ≥ 140/90 
mmHg) 
Poorly controlled 
on  more than 2 
medications 
(BP ≥ 140/90 
mmHg) 
Dyslipidaemia 
Requiring no 
treatment 
Well controlled 
on 1 medication 
(TC ≤5 mmol/l, 
TG ≤1.7 mmol/l) 
Well controlled 
on 2 medications 
(TC ≤5 mmol/l,  
TG ≤1.7 mmol/l) 
Poorly controlled 
on 2 medications 
(TC >5 mmol/l,  
TG >1.7 mmol/l) 
Sleep Apnoea 
Neck 
circumference 
>43 cm or snorer
OSA, no CPAP 
OSA, Epworth 
<15 on CPAP 
OSA, Epworth 
>15 on CPAP
Total 
Gross Score 
Negative score a Reason for negative score: 
Net Score 
BP: blood pressure; TC: total cholesterol; TG: triglyceride; OSA: obstructive sleep apnoea; CPAP: 
continuous positive airway pressure; Epworth: Epworth sleepiness scale 
Tab.4.1: The Swansea modified DUBASCO score.
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The study eligibility criteria in those who were suitable for bariatric surgery were: 
• Age 20-60 years
• BMI >40kg/m2
• Physical fitness for surgery
• Type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT) diagnosed previously or
prior to the study by the 75g oral glucose tolerance test (OGTT) according to the American
Diabetes Association (ADA) criteria [ADA 2015].
4.3.2 Types of intervention 
Study participants received one of the following treatment modalities: adjustable laparoscopic 
gastric banding (GB), laparoscopic sleeve gastrectomy (SG) or biliopancreatic diversion (BPD).  
Gastric banding (GB) is a comparatively straightforward and lower risk procedure which involves 
placement of a tight adjustable band distal to the stomach entrance in order to create a pouch. The 
silicon ring within the band is connected to an infusion port placed within the subcutaneous tissue. 
This allows the degree of gastric restriction to be increased by infusion of 0.9% saline through the 
port which will lead to decreased band diameter. 
Sleeve gastrectomy (SG) is also a laparoscopic procedure which converts the stomach into a tube-
like structure by removing approximately 80% of it using endoscopic stapling devices.  In contrast to 
GB, it is not reversible. Both GB and SG were traditionally considered as ‘restrictive’ types of bariatric 
surgery i.e. only affecting the amount of food that can be ingested. However, in recent years there 
has been some data emerging which indicates these procedures may also lead to weight loss by 
other mechanisms such as induction of satiety by gastric cardia compression from the gastric band 
[Burton, 2011] or changes in gut hormone profile in subjects undergoing sleeve gastrectomy 
[Colomb, 2015]. For the purpose of this study, subjects undergoing these procedures were, however, 
grouped together as those undergoing ‘restrictive’ surgery. 
Finally, biliopancreatic diversion (BPD) is a malabsorptive procedure whereby subtotal gastrectomy 
and bypass of most of the small bowel (except for the distal 100cm) is performed. It therefore leads 
to significant weight loss but is also associated with a risk of malnutrition [Topart P, 2017]. 
The choice of operation for an individual was decided by the multidisciplinary specialist team and 
was not affected by participation in this study. 
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4.3.3. Study design 
As mentioned above, participants were reviewed at 3 time-points: 1 week prior to planned bariatric 
surgery, and at 1 and 6 months postoperatively. During those visits demographic information (age, 
gender), clinical measurements (weight, BMI) and fasting blood samples were obtained. All 
participants were given a unique study number. 
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4.3.4  Ethical approval 
The study was approved by the Local Research Ethics Committee, Research and Development Office 
and Cardiff Metropolitan University (LREC No: 06/WMW02/7, R&D: S06GenMed569). All participants 
provided written informed consent. A material transfer agreement between Swansea University and 
Cardiff Metropolitan University was established in order to perform the EV analysis. 
4.3.5 Clinical measurements 
Clinical measurements (weight, BMI) were performed as described in the Methods chapter (section 
2.4.). 
 4.3.6 Sample collection 
Fasting venous blood was collected from a large peripheral vein into EDTA vacutainers. Samples 
were immediately spun twice at 3000g for 10mins to render plasma acellular, then frozen and stored 
at -80ºC until further analysis. 
 4.3.7 EV isolation and characterisation 
EVs were isolated by differential centrifugation at the Department of Biomedical Sciences at Cardiff 
Metropolitan University and measured by Nanoparticles Tracking Analysis (Nanosight, Malvern, UK) 
as previously described (Methods chapter, section 2.5). Since only 2mLs of plasma were available 
from each participant at each time-point, only 5x109 EVs /well were available to perform the TRF 
immunoassay using the markers described in the previous chapter for EV cellular origin and content 
(CD41: platelets, CD11b: monocytes/macrophages, CD235a: erythrocytes, CD144: endothelial cells, 
CD9: exosomes, IL-6, TNFα, Interferon-γ, adiponectin, FABP4 and PPARγ). The primary antibodies 
used in this assay were obtained from the same supplier and used in the same concentration as 
described in the Methods chapter (Table 2.2). However, since I used a different EV loading number 
in the TRF immunoassay, no direct comparison between this cohort and subjects described in 
chapter 3 was performed.  
4.3.8 Plasma measurements 
Plasma FABP4 concentration was established using a human FABP4 Quantikine ELISA kit (R&D 
Systems, Minneapolis, MN, USA), and  plasma free fatty acids were measured by a Colorimetric 
Quantification Assay Kit (ab65341, Abcam, Cambridge, UK) in the Biomedical Sciences Laboratories 
at the Cardiff Metropolitan University. Measurements of fasting glucose were undertaken on the day 
of sample collection at the Department of Medical Biochemistry, Morriston Hospital using a Roche 
Modular P800 Analyser. A Roche Modular E170 analyser was used to measure fasting insulin. 
HOMA-IR was calculated as described in Methods chapter (section 2.6.5). Plasma IL-6 concentration 
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was evaluated by a Quantikine ELISA human IL-6 kit (R&D Systems, Minneapolis, MN, USA) at the 
Diabetes Research Group at the Institute of Life Science, Swansea University Medical School.  All 
samples were assayed in duplicate.  
4.3.9 Statistical analysis 
4.3.9.1 Sample size 
This was a proof of concept study that had the primary aim of determining the change in plasma and 
EV-expressed FABP4. There are very limited data available in relation to FABP4 in plasma following 
bariatric surgery and, to my knowledge, no studies investigating EV FABP4 in this context. As I 
expected a substantial 20% change in plasma FABP4 over the three sampling points and a range of 
10-15% (based on previous variation measured from plasma) [Stejskal D, 2008], a power calculation 
suggested that I would need at least 15 subjects to detect this difference (one-way ANOVA at 3 
levels; p=0.05; alpha=0.8). As this study was limited to a previous sample size of 20, my study was 
adequately powered. 
4.3.9.2 Statistical tests 
Normally distributed variables were reported as mean ± SD whereas non-normally distributed 
variables were summarised as medians with interquartile ranges (IQR). For normally distributed 
variables the differences at different time points were analysed using repeated measures ANOVA 
with Bonferroni’s multiple comparisons post-test analysis. For changes in variables with non-
Gaussian distribution, the Kruskall-Wallis test was applied with post-test Dunn’s comparison. 
Spearman’s correlation analysis was applied to detect significant correlations between evaluated 
parameters. Statistical significance was accepted at p<0.05 and Graph Pad version 6.0 was used.  
4.3.10 My involvement 
Participant recruitment, clinical measurements, sample collection, analysis of glucose homeostasis 
and plasma IL-6 measurement were performed by Prof J. Stephens, Dr SL Prior and Dr T Min from 
the Diabetes Research Group, Swansea University. My role included undertaking EV isolation and 
analysis and measurement of plasma FABP4 and FFA at Cardiff Metropolitan University. I remained 
blind to surgical therapy group and all other measurements until all experiments were completed. 
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4.4 Results 
4.4.1 Population characteristics 
In total, 20 participants completed the study. There were thirteen female and seven male patients, 
with a mean age of 50.7 ± 8 years and a baseline mean body weight and BMI of 151.3 ± 31 kg and 54 
± 12.6 kg/m2, respectively. The anthropometric and metabolic characteristics are summarised in 
Table 4.2. As anticipated, all patients undergoing bariatric surgery achieved significant % total weight 
loss (%TWL) ( -8.3% at 1 month and -20% at 6 months to mean values of 138.8±28 kg and 121.6±26 
kg, respectively; p<0.001) and BMI reduction of -10% and -18.5% (to mean values of 48.9 ± 11 and 44 
± 10.2 kg/m2, respectively; p<0.001). Thirteen of the patients underwent restrictive laparoscopic 
surgery (sleeve gastrectomy (SG) n=10, gastric banding (GB) n=3) and seven an open malabsorptive 
procedure (biliopancreatic diversion (BPD)).  
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Tab.4.2: Anthropometric and metabolic characteristics of patients undergoing bariatric 
surgery at baseline, 1- and 6-months’ follow-up. ns=non-significant. 
Baseline 
(n=20) 
1 month 
post-surgery 
P 
(vs. 
baseline) 
6 months 
post-
surgery 
P 
(vs. baseline) 
Age (years) 50.7 (8) 
Gender (M/F) M=7, F=13 
Weight (kg) 151.3 (31) 138.8 (28) <0.001 121.6 (26) <0.001 
BMI (kg/m2) 54 (12.6) 48.9 (11) <0.001 44 (10.2) <0.001 
Glucose (mmol/L) 
IGT subgroup 
T2DM subgroup 
7.9 (3.2) 
5.8 (0.7) 
9.9 (3.4) 
6.2 (1.5) 
5.5 (1.2) 
6.9 (1.6) 
<0.05 
ns 
<0.05 
6.1 (3.0) 
6.1 (4.2) 
6.2 (1.2) 
0.092 
<0.05 
<0.001 
Insulin (mIU/L) 
IGT subgroup 
T2DM subgroup 
111.7 (74.7) 
104.4 (52.5) 
119 (95) 
103.3 (76.5) 
106.2 (72.9) 
100.5 (84.1) 
ns 
ns 
ns 
74.7 (57.5) 
79.3 (67.6) 
69.7 (47.4) 
0.054 
ns 
0.054 
HOMA-IR 
IGT subgroup 
T2DM subgroup 
2.40 (1.37) 
2.25 (0.7) 
2.5 (1.8) 
1.97 (1.36) 
2 (1.4) 
1.9 (1.3) 
ns 
ns 
ns 
1.60 (1.68) 
1.8 (2.1) 
1.37 (0.9) 
<0.001 
ns 
<0.05 
IL-6 (ng/mL) 9.5 (8.3) 11.1 (11.3) ns 14.7 (24.6) ns 
FABP4 (ng/mL) 67.8 (18.5) 82.7 (17.7) <0.05 62.7 (19.9) ns 
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4.4.2 EV concentration, cellular origin and content 
There were no significant differences in mean EV concentration/mL of plasma between baseline 
(1.44 ± 0.9x1011 nanoparticles/mL), 1 month (1.3 ± 0.7 x1011) and 6 months postoperatively (1 ± 
0.4x1011) (Figure 4.1a). However, detailed analysis of EV concentration within different size ranges 
(measured using a 100nm band width) revealed a significant reduction in EVs measuring between 
100 and 200nm in diameter at 6 months compared to baseline (p<0.01, Fig 4.1b). 
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Fig.4.1: EV concentration/mL plasma and size distribution at 3 timepoints : a) EV 
concentration/mL of plasma at baseline, 1 month and 6 months’ follow-up (mean±SEM) b) 
Two-way ANOVA with Bonferroni post-test revealed significant decrease in EVs sized 
100.5-199.6nm in diameter at 6 months’ follow-up compared to baseline (mean±SD), 
p<0.01(**).
134 
The relative distribution of the main EV cell-of-origin markers (CD41 (platelets), CD11b 
(monocytes/macrophages), CD235a (erythrocytes), CD144 (endothelial cells)) did not change in 
response to surgery (Fig.4.2).  
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Fig.4.2: Bariatric surgery did not alter EV cellular origin. Relative expression at baseline, 1 
and 6 months postoperatively: CD41 (platelets): 25±13% vs 27±20% and 27±17%; CD11b 
(macrophages/monocytes): 51± 25% vs 51±26% and 54±24%; CD235a (erythrocytes): 
10±6% vs 11±10% and 9±5%; CD144 (endothelial cells):  15±10% vs 16±12% and 15±13%, 
respectively,  all p=non-significant.  
Following surgery, there were no differences in median TRF signal for the exosomal marker CD9, 
EV-
expressed adiponectin, IL-6, TNFα, interferon ϒ or PPARγ (Fig 4.3).   
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Fig.4.3: Median EV expression of CD9,  adiponectin, TNFα, interferon-γ, IL-6 and 
PPARγ), p=ns. 
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However, the FABP4 EV signal increased (non-significantly) at 1 month before falling significantly by 
6 months (p<0.01) (Fig. 4.4a, 4.4b). The  median FABP4 EV signal at 6 months’ follow-up was 
significantly lower in the group who underwent biliopancreatic diversion surgery (n=7) compared to 
those who had sleeve gastrectomy or gastric banding (n=13) (19775 (6565-24094) vs 28057 (14683-
45459) a.TRF, p<0.05) (Fig. 4c), with no differences in EV FABP4 expression between those groups at 
baseline or 1 month (26302 (21641-55806) vs 38483 (285-100213) a.TRF, p=0.51 and 40571 (23923-
96781) vs 45422 (13383-81841) a.TRF, p=0.6, respectively). 
A significant correlation was observed between the EV signal for CD9 and each of FABP4 (r=0.5, 
p<0.0005), adiponectin (r=0.59, p<0.0001), TNF-α (r=0.53, p<0.0001) and interferon ɣ (r=0.41, 
p<0.005) (Figures 4.4 d-g), suggesting that these adipocytokines are transported by an EV population 
which is specifically of exosomal origin. 
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Fig. 4.4: a) Changes in EV FABP4 (median with IQR) reveal significantly lower TRF signal at 
6 months’ follow-up compared to 1-month (p<0.05) b) Individual pattern of changes in EV 
FABP4 TRF signal for all study participants at 3 timepoints c) Median EV FABP4 signal was 
significantly lower in the cohort that underwent biliopancreatic bypass diversion surgery 
at 6 months’ follow-up (p<0.05). Spearman’s correlation analysis across the whole cohort 
revealed significant correlation between the exosomal marker CD9 and EV-derived: FABP4 
(d), adiponectin (e), TNFα (f) and interferon ϒ (g). *=p<0.05, **= p<0.01 
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4.4.3 Plasma FABP4 
A similar pattern of change to that observed for EV FABP4 was observed with free plasma FABP4, 
with a significant rise at 1 month (p<0.001 vs baseline) before a significant decrease by month 6 
(p<0.001 vs month 1) (Fig. 4.5a, 4.5b).  Furthermore, we observed that plasma FABP4 concentration 
correlated with plasma free fatty acid concentration at 1 month follow-up (r=0.48, p<0.05, Fig.4.5 e) 
but not at baseline or 6 months. Neither BMI nor plasma FABP4 correlated with EV FABP4 (Fig. 4.5c, 
4.5d).  
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Fig.4.5: a) Plasma free FABP4 levels (means) were significantly higher at 1 month follow-
up compared to baseline and 6 months’ follow-up b) Plasma FABP4 concentration at 3 
time points for all study participants (n=20) c) Spearman’s correlation analysis revealed 
significant correlation between plasma FABP4 and BMI (r=0.6, p<0.0001) d) No correlation 
between EV-contained and plasma free FABP4 was observed (r=0.05, p=ns) e) Significant 
correlation was observed between plasma FABP4 and plasma free fatty acids at 1 month 
follow up (r=0.48, p<0.05).  *=p<0.05, **= p<0.01, ***=p<0.001 
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4.4.5 Additional analysis 
 In order to explore any relationship between EVs and weight loss, I subsequently subdivided this 
sample into two similar-sized groups: those who achieved more than 18% TWL at 6 months (n=9) 
and those who did not (n=11). Two significant differences were observed: significantly lower EV 
PPARϒ in the group that achieved greater weight loss at 6 months’ follow-up (5015 (2979-12973) vs 
20133 (7066-27583) a.TRF, p<0.05), and significantly higher EV TNFα at 1 month follow-up in the 
group that failed to achieve weight loss of >18% (3629 (8053-90438) vs 14650 (4177-44817) a.TRF, 
p<0.05)). In contrast, no relationships between any EV changes and improvements in glucose 
metabolism (defined as achievement of FPG less than 6mmol/L and/or HOMA-IR <1.4) were 
observed between the 12 subjects who achieved it and the 8 that did not (all p=ns). 
Since differences in fat distribution and lipolysis between men and women have been described 
[Frühbeck G , 2014] and I observed gender differences in the healthy volunteer EV profile in chapter 
3, I then analysed my data split by gender. There were no gender differences in FFA concentrations 
at any time-point. Plasma FABP4 concentration at 6 months’ follow-up was higher in females 
(78.47±14.9 vs 48.27±21 ng/mL, p<0.05) despite no significant EV FABP4 or BMI differences between 
genders at this time-point (21354 (6565-44491) vs 24671 (14683-45459) a.TRF, p=0.54, 45.3±10.8 vs  
41.5±9 kg/m2, p=0.43, respectively). EV CD11b (monocyte/macrophages marker) was higher in 
females at all time-points (preoperatively: 56507 (26078-208501) vs 10729 (6400-74280) a.TRF, p< 
0.005); at 1 month: 65244 (15779-177945) vs 15362 (7669-85205) a.TRF, p=0.05 and at  6 months: 
66257 (6361-164498) vs 23398 (10124-86499) a.TRF).  Baseline EV PPARϒ was also higher in females 
(10400 (5268-37321) vs 4185 (616-7605) a.TRF, p<0.05); however, no differences were observed 
post-surgery (p=ns). No other gender differences were observed in other EV markers
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4.5 Discussion 
This study shows that bariatric surgery is followed by dynamic changes in the expression of EV-
associated as well as free plasma FABP4. Since FABP4 is predominantly expressed in adipocytes, our 
finding of altered EV-expressed FABP4 after surgery is likely to reflect changes in adipocyte EV 
secretion.  As demonstrated by Ertunc et al, lipolysis triggers a non-classical pathway of FABP4 
secretion within EVs, and these EVs may be intended to play a different role in intercellular 
communication compared to their free circulating form [Ertunc ME, 2015]. Bariatric surgery is known 
to rapidly reduce visceral and subcutaneous lipid depots, accompanied by an increase in plasma free 
fatty acids and beta-hydroxybutyrate levels, reflecting increased lipolysis [Johansson L, 2008]. 
Previously, increased expression of lipolytic genes within adipose tissue following bariatric 
intervention was demonstrated, including triglyceride lipase (ATGL), hormone-sensitive lipase (HSL) 
and perilipin [Karki S, 2015]. ATGL, HSL and free fatty acids have been found to affect FABP4 
secretion [Ertunc ME, 2015].  
In this study, EVs expressing FABP4 and plasma free FABP4 showed a similar pattern of change with 
a transient peak in the early postoperative period followed by significant reduction at 6 months’ 
follow-up compared to 1 month. Furthermore, plasma FABP4 levels at 1 month correlated with 
plasma free fatty acid levels. I therefore believe that the transient postoperative rise in EV and 
plasma FABP4 may reflect the dynamic changes occurring in adipose tissue following surgery, 
including reduced total fat mass and adipocyte size, and increased lipolysis, albeit that a limitation of 
my work is that I did not measure plasma glycerol due to limited volume of plasma available as 
discussed earlier. Previous studies have shown similar changes in circulating FABP4 levels following 
weight loss [Furuhasi M, 2016, Comerford KB, 2014]. Stejskal et al indicated that this pattern of an 
initial rise in plasma FABP4 with subsequent normalisation to baseline levels was observed 
particularly in individuals who achieved sustained weight loss [Stejskal D, 2008]. However, I am 
unaware of any previous study evaluating EV-expressed and plasma free FABP4 simultaneously in 
the context of bariatric surgery.   
Open bariatric surgery might involve more adipose tissue damage compared to a laparoscopic 
approach. However, at 1 month follow-up I did not observe differences in plasma and EV FABP4 in 
the BPD group compared to the SG/GB group. Nevertheless, it is entirely possible that differences in 
plasma- and EV-FABP4 between open and laparoscopic surgery might be apparent at very early 
time-points post-surgery and this would be an interesting area to explore in future studies.   
143 
I did not find a correlation between plasma FABP4 and the EV FABP4 TRF signal, nor between EV 
FABP4 and BMI. This might relate to the fact that adipocyte-derived FABP4-containing EVs probably 
carry only a small proportion of the total FABP4 secreted by adipocytes [Hotamisigli GS 2015, Ertunc 
ME, 2015]. Moreover, adipocyte-derived EVs containing FABP4 could also be taken up by 
neighbouring cells in adipose tissue in a paracrine manner, as shown in previous studies [Aoki N, 
2010]. Therefore, establishing a correlation between BMI and both plasma soluble FABP4 and EV-
contained FABP4 is difficult, at least using current methodology used for plasma EV isolation. In 
contrast, EV-expressed TNFα was greatest at 1 month in subjects showing less weight loss. Whilst 
mechanisms other than weight loss may contribute to the changes in EV FABP4, it is tempting to 
speculate that EVs in patients showing the greatest weight loss exhibit a reduced inflammatory 
profile. However, this remains to be fully elucidated.  
Previous studies examining the effects of bariatric surgery on circulating EVs have largely focused on 
changes in EV concentration and cell-of-origin expression, such as platelets, monocytes or 
endothelial cells. Campello et al  evaluated changes in a range of EV subtypes in 20 patients 
undergoing sleeve gastrectomy and found a significant decline in endothelial-, platelet-, and 
leukocyte-derived EVs and in annexin V, tissue factor and CD36-expressing EVs at 12 months’ follow-
up [Campello E, 2016]. The percentage reduction in EV subtypes correlated with the reduction in 
BMI. Similarly, Cheng et al found a reduction in platelet-, endothelial-, monocyte- and tissue factor-
expressing EVs in patients following Roux-en-Y gastric bypass surgery, with the monocyte EVs 
showing an association with HbA1c and BMI reductions [Cheng V, 2013].  In contrast, Stepanian et al 
found no effect of significant weight loss (mean BMI decrease of 24%, n=32, including 27 patients 
who had gastric bypass or sleeve gastrectomy) on total-, platelet- or endothelial-derived EVs, despite 
improvements in HOMA-IR, lipid profile and CRP [Stepanian A, 2013]. This is in keeping with my 
findings, since I found no effect on platelet, leukocyte, erythrocyte or endothelial EVs nor overall EV 
concentration irrespective of the type of bariatric surgery performed and despite improvements in 
weight and glycaemic control. However, it should be noted that all of these referenced studies used 
flow cytometry to evaluate EV concentration and origin/protein expression. This approach is not 
sensitive enough to distinguish between different populations of EVs and to detect very small EVs 
(<200nm), as the analysis gate in standard flow cytometers is usually determined using 1µm beads. 
Therefore, the exosomal EV range which showed very interesting biological correlation in my data 
cannot be fully evaluated using flow cytometry alone.  Identification of more precise changes 
pertaining to adipobiology that take place following the surgical approach are in line with the 
usefulness of new criteria to define success of bariatric and metabolic surgery that are being put 
forward [Frühbeck G, 2015]. Despite the significant weight loss achieved by all study participants, 
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the average 6 months’ follow-up BMI remained within the class III obesity range (Table 4.2) which 
may partially explain why no significant differences in more of the EV markers were observed and 
why the baseline and 6 months' follow-up plasma and EV-FABP4 results did not differ.  Individuals 
who were selected to undergo BPD surgery had a higher average BMI at all 3 time-points compared 
to the SG/GB cohort (baseline 66.2±12.7 vs 47.6 ±6.3kg/m2; at 1 month 59.7±10 vs 43±6.2 kg/m2; at 
6 months 54.2 ±8.1 vs 38.5 ±6.1 kg/m2, all p<0.001), which corresponded with equally higher 
concentration of plasma FABP4 in BPD group (baseline 83.2±10.7 vs 59.5 ±16.3 ng/mL, at 1month 
99.4 ±8.4 vs 73.6±14.4 ng/mL; at 6 months 78.3 ±15.1 vs 54.2 ±17.2 ng/mL, all p<0.001). 
Interestingly, however, the 6 months’ follow-up EV FABP4 signal was significantly lower in the BPD 
arm compared to the SG/GB one (Fig 4.4c), despite no differences at baseline or 1 month follow-up 
between these groups. Given that FABP4-expressing EVs are likely to derive from adipocytes, this 
may suggest that BPD has a greater effect on postoperative processes within adipose tissue 
regulating the secretion of this group of EVs. Although the mechanism behind this and the biological 
relevance of this phenomenon is not clear at present, this finding may be in keeping with previous 
reports indicating that this form of metabolic surgery might be more effective in reversing obesity-
driven comorbidities such as type 2 diabetes, hypertension and dyslipidaemia [Celio AC, 2016, Lee 
SK, 2016]. Finally, it should be noted that although increased circulating adipocyte-derived EVs 
suggest disturbed adipose tissue homeostasis, their full biological role has not been fully 
investigated and they may, depending on clinical circumstances, play a deleterious as well as 
protective role, as has been recently shown for circulating endothelial EVs in the context of vascular 
disease [Dignat-George F , 2011]. 
4.6 Study limitations 
Similar to previous research evaluating EV changes post-bariatric surgery, the main limitation of this 
study includes the relatively small sample size (n=20). The study may therefore be underpowered to 
show significant differences in other EV cytokines. Secondly, many of the participating patients were 
taking concomitant medications at the time of study enrolment, including diabetes medication as, in 
contrast to most previous studies, I did not exclude patients with chronic illnesses such as 
hypertension or dyslipidaemia, which could have interfered with the EV readings (as only patients  
with obesity accompanied by comorbidities as per the DUBASCO scoring system qualify for bariatric 
surgery in Wales). Thirdly, this study had a relatively short follow-up; studies with a longer follow-up 
period are needed in the future to fully describe the chronic changes in EVs post-bariatric surgery. 
Fourthly, it would have been helpful to have included a control group of patients undergoing non-
bariatric surgery for comparison. Lastly, direct comparisons between clinical studies evaluating 
changes in circulating EVs are limited by the fact that establishing a gold standard method for EV 
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isolation to be adopted across laboratories has only recently been a focus of the International 
Society of Extracellular Vesicles (ISEV) [Witwer K, 2013], although my adopted approach is one of the 
most commonly accepted protocols that I have followed to yield consistent samples and results. This 
approach was not used in the studies by other authors [Campello E, 2016, Cheng V, 2013, Stepanian 
A, 2013] and similarly the EV analysis in the studies I cited above was performed by flow cytometry 
which is typically not sensitive enough to detect EVs of exosomal origin and differs from the 
immunophenotyping method which was adapted for EV analysis specifically [Webber J, 2014, 
Connolly K, 2015]. 
Due to the limited amount of plasma volume available, I was also limited by the number of EVs 
generated which led to alteration in my TRF immunoassay protocol and made it impossible to 
compare the EVs characteristics to those from the healthy volunteer cohort.  I was also unable to 
undertake additional plasma measurements such as glycerol concentration which could have added 
more useful information to this study. 
4.7 Conclusions 
To my knowledge, this study is the first to report concomitant fluctuations in plasma free FABP4 in 
addition to exosome-associated FABP4 secretion in the follow-up period after bariatric surgery 
which may relate, at least in part, to increased lipolysis. These changes are likely to play an 
important role both in paracrine communication within adipose tissue and endocrine 
communication with other target tissues, since EVs are able to affect recipient cells’ function and 
gene expression. However, further research is required to understand the precise mechanisms 
regulating secretion and content of adipocyte-derived EVs.
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Chapter 5 
The effects of a multidisciplinary weight 
loss programme on circulating 
extracellular vesicles 
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Perspective 
Following the work undertaken on characterisation of EVs derived from healthy volunteers and 
people undergoing bariatric surgery, I wanted to complement my work by adding a third 
volunteer/patient group undertaking a lifestyle or dietary intervention to induce weight loss. During 
this time, a new multidisciplinary tier 3 weight loss management service was being established by Dr 
Dev Datta at University Hospital Llandough (UHL). Engagement in such multidisciplinary intervention 
is now mandatory for all patients who wish to be considered for bariatric surgery in Wales, with the 
aim of helping patients achieve weight loss and potentially avoiding surgical intervention.  
The development of this service fitted well with the aims of the study I wanted to perform and did 
not require any additional resources. It also allowed me to run the EV analysis on ‘fresh’ samples 
which were processed and stored in the same way as the samples from results chapter 3. This would 
facilitate direct comparison of the results from the morbidly obese individuals with the healthy 
volunteer cohort. 
As there was almost a 2-year time gap between recruitment and analysis of study participants from 
chapters 3 and 5, new methods had been advocated for EV processing, such as size exclusion 
chromatography columns for sample purification. Therefore, for the analysis of the samples in this 
chapter, I decided to employ both methods: differential ultracentrifugation alone as described in 
chapter 3 and 4 and column-based size exclusion chromatography.  
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5.1 Introduction 
As discussed in previous chapters, EVs are being increasingly recognised as disease biomarkers and 
vectors of paracrine communication.  They appear to be involved not only in intercellular 
communication but also in maintaining tissue homeostasis. 
The growing pandemic of obesity puts increased burden on the health services due to associated 
comorbidities such as cardiovascular disease, type 2 diabetes mellitus, several malignancies, mobility 
problems and also social stigma and isolation, which may lead to further deterioration in health and 
quality of life. In the UK, the economic cost of people being overweight or obese was estimated at 
£16 billion in 2007, a figure which is expected to rise further by 2050. [NICE, 2014] Interventions to 
reduce this burden are therefore critical.  
The current management of obesity is very complex and challenging. Approaches vary from lifestyle 
interventions incorporating dietary changes and/or increased physical activity, pharmacological 
therapies (which have not been very promising to date due to low efficacy or side-effects), to 
invasive management in the form of bariatric surgery (which carries risks involved with the 
procedure itself and postoperative complications and comorbidities).  
Typically, an initial weight loss target of between 5 and 10% of initial body weight is recommended 
[Rossner S, 1997]. For the intervention to be regarded as successful, the results should be 
maintained for at least a year [Wing R, 2001].  Maintenance of the weight lost post-intervention is 
crucial to achieve long-term health benefits such as a decreased incidence of type 2 diabetes 
mellitus. This was evident in landmark trials such as the Diabetes Prevention Program (DPP) and its 
10-year follow-up data [Knowler WC, 2009].  Lifestyle interventions (diet and exercise) have also 
been shown to reduce ectopic fat accumulation in overweight and obese individuals and thus 
prevent the development of insulin resistance [Hens W, 2015]. 
It is now accepted that a multidisciplinary team approach to weight loss management is preferable 
in order to address the breadth of treatment approaches that are required, such as psychological 
counselling, dietary support and advice, individually tailored physical exercise regimens and/or 
pharmacotherapy and management of coexisting comorbidities [Montesi L, 2016]. 
This is in keeping with the recent NICE (National Institute for Health and Care Excellence) guideline 
recommendations which give specific directions on the establishment and composition of such 
multidisciplinary services. The Department of Health has been recommended to commission local 
weight management programmes which are completed by at least 60% of participants with a target 
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average weight loss of 3% total body weight, with at least 30% of participants losing 5% or more of 
their initial body weight [NICE, 2014]. 
Although more long-term studies are required to evaluate the long-lasting effects of participating in 
such programmes, the obvious advantage of these interventions is that they are believed to be safe 
and unlikely to cause any harm to patients. For this reason, and in view of increasing demand on 
bariatric surgery services, the Welsh Institute of Metabolic and Obesity Surgery (WIMOS) requires all 
patients in Wales to complete a 2-year lifestyle intervention before they are considered for bariatric 
surgery referral.  
In the context of my work, current data on the effects of a structured weight loss programme on 
circulating extracellular vesicles are very limited with only one previous manuscript evaluating 
changes in adipocyte-derived EVs in this context [Eguchi A, 2016]. Evaluating the changes in EV 
concentration and characteristics along with the associated changes in the metabolic and 
anthropometric measurements would contribute to our understanding of the role of circulating EVs 
in adiposity-driven metabolic derangements and would help to establish whether they could be used 
as future early disease biomarkers in this clinical context.   
Due to time restrictions, my study specifically focused on changes in EV characteristics following 6 
months’ participation in the 2-year programme offered to patients in Cardiff and the Vale of 
Glamorgan. 
5.2 Aims 
The aims of this chapter were to characterise a cohort of individuals undergoing a tier 3 weight loss 
management programme with respect to: 
1. Anthropometric measurements: weight, BMI, age, gender
2. Baseline and follow-up metabolic profile: HbA1c, lipid profile, thyroid function, circulating
plasma adipocytokines: IL6, TNFα, adiponectin, FABP4
3. Evaluation of psychological wellbeing/health (by a questionnaire)
4. Plasma-derived EV concentration, cellular origin and adipocytokine content (as described in
previous chapters) pre- and post-intervention using 2 different isolation methods:
differential ultracentrifugation and size exclusion chromatography columns
5. Comparison of circulating plasma EV concentration between severely obese individuals and
healthy volunteers
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5.3 Methods 
5.3.1 Study design 
This study was designed as a 24-week non-randomised observational study evaluating the effects of 
a multidisciplinary weight loss management plan on circulating EVs in patients with morbid obesity. 
Participants were recruited from patients who were referred to the newly established level 2/ 3 
weight management service at Cardiff and Vale University Health Board. The structure of this service 
and the care delivery pathways remained unchanged and were not affected by an individual’s 
participation in the study.  As per established practice, referrals to the obesity management clinic 
were reviewed by the lead physician, Dr Dev Datta, and/or discussed at the Multidisciplinary Team 
Meeting consisting of Dieticians, a Specialist Nurse, Physiotherapist/ Occupational Therapist and a 
Psychologist at the University Hospital Llandough. Only patients qualifying for tier 3 weight loss 
management support were included in this study as those attending tier 2 dietician and specialist 
nurse-led services were seen at community-based GP surgeries, hence it would not be logistically 
possible to obtain and process the blood samples for EV isolation in such a setting.  
Patients were evaluated at the point of first contact with the service (baseline) and around 22-24 
weeks (6 months) after intervention commencement. Participation in the study only required the 
patients to donate additional blood samples for EV isolation during already scheduled routine 
appointments with the lead physician, and was usually coordinated with the timing of their routine 
baseline and follow-up blood samples that constituted part of their general clinical care. 
The CAV Adult Weight Management Services Patient Pathway is attached in the Appendix section.  
Flow chart/visit summary 
Visit 1 (Cardiff and Vale UHB, Llandough Hospital, Out-patient Department) 
- Eligibility check and informed consent
- Standard clinical consultation (incl. weight, BMI, BP measurement)
- Blood sampling
Visit 2 at ~24 weeks (Cardiff and Vale UHB, Llandough Hospital, Out-patient Department) 
- Standard clinical consultation (incl. weight, BMI, BP measurement)
- Blood sampling
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Between visits, participants underwent a multidisciplinary weight loss management programme as 
per the usual clinical care plan already in place. Briefly, this consists of frequent 
appointments/telephone encounters with the dietician and a specialist nurse, and when required, 
separate sessions with a psychologist with the expertise in management of eating disorders.  In 
addition to that, regular visits to the Consultant Led clinic are scheduled at 2-3 monthly intervals.  
5.3.2 Study population 
Participants were recruited from a cohort of patients undergoing the tier 3 weight loss management 
programme at UHL. The referral criteria to attend this programme were: 
• Individuals with BMI >40kg/m2 or
• Individuals with BMI >35kg/m2 and comorbidities such as obstructive sleep apnoea (OSA),
type 2 diabetes mellitus or impaired glucose tolerance (IGT), dyslipidaemia, hypertension,
non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS),
orthopaedic/mobility problems.
The exclusion criteria were: 
- current acute illness
- pregnancy
- active malignancy
- inability to provide full written consent
- recent acute illness or surgery
- previous bariatric surgery
152 
5.3.3 Ethical approval 
The study received full ethical approval (REC approval number 16/EE/0342; East of England, 
Cambridge South Research Ethics Committee), local R&D (approval no: 16/JUL/6572) as well as 
Cardiff Metropolitan University ethical approval (CHS ethics no 8371). A 3-way material transfer 
agreement was prepared for samples to be stored and analysed at Cardiff Metropolitan University.  
All participants provided informed written consent. 
5.3.4 Anthropometric measurements 
Weight, height and BMI were measured as described in Methods chapter section 2.4 and were 
performed as part of patients’ routine clinical care. 
5.3.4 Sample collection, processing and storage 
Venous blood was drawn from a large peripheral vein as described in the Methods chapter (section 
2.5.1.2). Blood was then immediately centrifuged for 10mins at 3000g using a Heraeus Labofuge 400 
(DJB Labcare) centrifuge at the UHL Biochemistry Department. The supernatant was collected and 
centrifuged again at 3000g for 10mins to render plasma acellular. Plasma was then aliquoted and 
transported to Cardiff Metropolitan University where it was stored at -80ºC until further analysis.   
5.3.5 EV isolation, measurement and analysis. 
EVs were isolated from thawed plasma by ultracentrifugation at 100,000g using a Sorvall centrifuge 
and Surespin 360 rotor. EV concentration, size, cellular origin and content were measured as 
described in the Methods chapter (sections 2.5.4. and 2.5.5). For the analysis of this cohort, an 
additional exosomal marker antibody (anti-CD63, rabbit polyclonal, 200 µcg/mL)(sc-15353, Santa 
Cruz Biotechnology) was used alongside anti-CD9. Otherwise, all primary antibodies used were from 
the same supplier and the same concentration as described previously (Methods chapter, section 
2.5.5.2), except for anti-IL6 antibody used for size exclusion chromatography EV samples which was 
purchased from Thermo Fisher Scientific (IL-6 Antibody (4H16L21), ABfinity™ Rabbit Monoclonal, 
701028) due to a supply problem from Abcam. 
5.3.5.1 Size exclusion chromatography columns 
Exo Spin Midi Columns (Cell Guidance Systems) were used to obtain EVs, with no ultracentrifugation 
performed in this method. These columns were pre-equilibrated with ultra- pure water and 20% 
ethanol, and were then equilibrated with sterile PBS prior to EV isolation (2x10mL).  One millilitre of 
thawed double-spun plasma was applied when there was no remnant buffer on the top surface of 
the column and 500µL fractions were then collected (n=24) (Fig 5.1 a-c). Based on the product 
information sheet and our local laboratory experience, it was established that exosome/EV rich 
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fractions accumulate in fractions 5-10.  These 6 fractions were then pooled together giving a total
sample volume of 3 mL; EV concentration was then measured by NTA as previously described. 
Unfortunately, the overall EV/mL plasma concentration was lower than in the samples which were 
obtained by ultracentrifugation and from a larger volume of plasma. Therefore, for the EV origin and 
adipocytokine content analysis by TRF immunoassay, only 3x109EVs/well were loaded. It was thus 
unfortunately not possible to directly compare ‘columned’ and ‘non-columned’ EVs since the TRF 
signal does not have a linear relationship with the number of EVs loaded in the well in our 
experience. 
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a)  b) 
     c) 
Fig.5.1: Isolation of EV fractions using Exo-Spin Midi Columns (Cell Guidance Systems) a) 
Loading of 1mL of plasma b) Collection of early fractions c) Collection of EV-rich fractions.
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5.3.6 Plasma adipokine and cytokine concentration 
Plasma IL-6, TNFα, adiponectin and FABP4 were measured using the same assays and protocols as 
described in the Methods chapter (section 2.6). 
5.3.7. Other plasma measurements 
As part of routine clinical care, individuals also underwent measurement of various markers of 
metabolic health such as plasma lipids, HbA1c and Thyroid-Stimulating Hormone (TSH) which were 
performed at the medical biochemistry laboratories at Cardiff and Vale UHB. 
Total cholesterol was measured by an enzymatic method, as were triglycerides (glycerol phosphate 
oxidase). HDL cholesterol concentration was evaluated by a colorimetric method with a selective 
detergent step to remove the non-HDL cholesterol. The Abbott Architect (Abbott Diagnostics) 
system was used to perform these analyses. The Friedwald formula was then applied to estimate the 
LDL cholesterol concentration ([LDL-chol] = [Total chol] - [HDL-chol] - ([TG]/2.2)) [Roberts WC, 1988]. 
HbA1c was measured by ion-exchange chromatography (Tosoh Bioscience G8 Analyser). 
5.3.7 Evaluation of overall wellbeing/health 
The EQ-5D-5L tool was used as a standardised measure of health status. This addresses 5 different 
health aspects: mobility, self-care, usual activities, pain/discomfort and anxiety/depression that can 
be scored on a 5 level scale or severity [Whynes DK, 2008]. The EQ-5D-5L index values were 
presented as mean (SD/standard error) for the cohort pre- and post- intervention. 
5.3.8 Statistical analysis 
Normally distributed data were presented as mean (SD) values, whilst non-normally distributed data 
were presented as median (range); Normality was tested by the Shapiro-Wilk test. Pre- and post-
intervention changes were evaluated using the Student t test for normally distributed variables, and 
the Wilcoxon matched pairs signed rank test for non-normally distributed ones. A p value <0.05 was 
accepted as statistically significant and GraphPad software version 6.0 was used. 
5.3.9. Sample size and power calculations 
The primary outcome of this study was to evaluate the effects of a multidisciplinary weight loss 
programme on circulating EVs. As there were no data available on the effects on circulating EVs of 
such a programme, power calculations were initially based on the recent paper evaluating changes 
in EVs following bariatric surgery by Campello et al [Campello E, 2016]. 
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In this publication, twenty patients with grade III obesity undergoing bariatric surgery had EV 
measurements taken at time 0, 3 and 12 months’ post-bariatric surgery. This study showed a 
significant decrease of all EV types at 12 months (Annexin V-EVs, endothelial–derived EVs, platelet-
derived EVs, leukocyte–derived-EVs, with percentage reductions of  -16 ± 10%, -30 ± 23%, -27 ± 16% 
and  -35 ± 18%, respectively) with corresponding 41% loss of body weight [Campello E, 2016]. 
Allowing for up to 10% dropout, it was estimated that recruiting 50 subjects into my study would 
provide over 80% power to detect a shift of 0.3 times the standard deviation of within-group 
changes in EV subtypes and concentration at the 5% alpha level using 3-way ANOVA.  
However, due to time constraints and insufficient numbers of new patients meeting the inclusion 
criteria being referred to the service, I was unable to recruit this number of participants within the 6 
months’ time period. 
Disclosure 
Most patient recruitment, sample collection, initial processing, storage and analysis was performed 
by myself, hence I was not blinded whilst performing the analyses. 
Dr Katherine Connolly and Mr Cass Whelan assisted in the EV isolation by SEC and the 
immunophenotyping of that sub-cohort.  
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5.4  Results 
Twenty-one patients were recruited to take part in the study but only 15 completed it due to loss of 
engagement with the service or failure to attend follow-up appointments. Therefore, for the analysis 
of the effects of the multidisciplinary weight loss programme on circulating EVs, only 15 paired data 
sets were analysed. Since there were only 5 male patients recruited and only 2 of them completed 
the programme, no analysis of gender-driven differences was performed with regard to plasma EVs 
and adipocytokines in this cohort. 
The mean baseline BMI amongst all 21 recruited patients (F=16, M=5), age 49.7(11.2) years  was 
55.1 ± 7.19 kg/m2 and mean weight 152.6 ± 26.2kg. 
5.4.1 Baseline and follow-up anthropometric characteristics, glucose, HbA1c and lipids 
The baseline and follow-up measurements (n=15) are presented in the table below. There were no 
significant differences between baseline and 6 months’ follow-up in any of the clinical measures 
studied (Tab. 5.1). 
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Variable (mean (SD)) Baseline 6 months follow up P value 
Weight (kg) 152.8(23.2) 150.32(23) 0.77 
BMI (kg/m2) 54.92(6.6) 53.7(6.8) 0.62 
TSH (mIU/ml) 1.56(1.06) 1.71(0.93) 0.68 
HbA1c (mmol/mol) 46.5(18.1) 43.7(13.8) 0.63 
Total cholesterol 
(mmol/L) 
4.66(0.92) 4.77(0.97) 0.75 
Triglycerides 
(mmol/mL) 
1.95(0.77) 2.04(0.95) 0.77 
HDL (mmol/mL) 1.13(0.26) 1.22(0.34) 0.42 
LDL (mmol/mL) 2.67(0.81) 2.7(0.98) 0.92 
Tab. 5.1: Summary of anthropometric and metabolic variables pre-and post-intervention 
of the sub-cohort that completed the study (n=15, M=2, F=13, age 48.2 ± 11.4 years). 
5.4.2 Measurement of psychological well being 
The mean EQ-5D-5L score pre-intervention was 0.255 ±0.41 and post-intervention 0.3±0.221, 
p=0.71. 
5.4.3 Plasma adipocytokines 
5.4.3.1. Plasma IL-6  
There was no difference between baseline and follow-up plasma IL-6, with mean concentrations of 
2.39 ±0.66 pg/mL vs 2.22 ±0.98 pg/mL; p=0.49. The median IL-6 concentration in the healthy cohort 
from chapter 3 was significantly lower compared to baseline IL-6 in the morbidly obese cohort from 
this study (1.49(0.42-7.4) vs 2.24(1.17- 3.83), p<0.01). (Fig.5.2) 
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Fig.5.2: Differences in plasma IL-6 concentrations: a) in the morbidly obese cohort at 
baseline and 6 months’ follow-up (n=15) b) between healthy volunteers (HV)(n=40) and 
morbidly obese (MO) patients (n=21), **=p<0.01. 
5.4.3.2 Plasma adiponectin 
Plasma adiponectin did not differ between baseline and 6 months (median baseline concentrations 
47.4 (16.2-99.15) vs 52.05 (17.85 vs 164) µg/mL, respectively; p=0.38). As expected, the median 
plasma adiponectin in the healthy cohort was significantly higher compared to the morbidly obese 
one (203.4 (42.75-822.9) vs 47.4 (16.2-103.5) µg/mL, p<0.0001. (Fig.5.3) 
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Fig.5.3: Differences in plasma adiponectin concentrations: a) in the morbidly obese cohort 
at baseline and 6 months’ follow-up (n=15) b) between healthy volunteers (n=40) and 
morbidly obese patients (n=21), ***=p<0.005. 
5.4.3.3. Plasma TNFα 
The median plasma TNFα concentration was not different pre-and post-intervention (58.13 (29.27-
374) vs 45.93 (19/51-314.6) pg/mL, p=0.168). There were also no significant differences between HV
and MO cohorts: 47.67 (2-833) vs 53.25 (29.27-374) pg/mL, p=0.45 (Fig.5.4) which was unexpected 
but is likely due to wide error bars in the measurements. 
161 
0 6
0
1 0 0
2 0 0
3 0 0
4 0 0
T im e p o in t
T
N
F

 (
p
g
/
m
L
)
H
V
M
O
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
T
N
F

 (
p
g
/
m
L
)
a )
b )
Fig.5.4: Differences in plasma TNFα concentrations: a) in the morbidly obese cohort at 
baseline and 6 months’ follow-up (n=15) b) between healthy volunteers (n=40) and 
morbidly obese patients (n=21). 
5.4.3.4 Plasma FABP4 
There were no significant differences in mean plasma FABP4 concentrations at the beginning of the 
enrolment to the weight management programme and 6 months later (56.74±10.44 vs 51±22.55 
ng/mL, p=0.38). 
The morbidly obese patients had significantly higher mean plasma FABP4 concentrations compared 
to healthy volunteers (55.44±9.5 vs 19.9±9 ng/mL, p<0.0001). 
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Fig.5.5: Differences in plasma FABP4 concentrations: a) in the morbidly obese cohort at 
baseline and 6 months’ follow-up (n=15) b) between healthy volunteers (n=40) and 
morbidly obese patients (n=21), ****=p<0.0001. 
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5.4.4 The effects of lifestyle intervention on circulating plasma EVs concentration, 
cellular origin and profile. 
Participation in the weight loss management programme did not affect total EV concentration in 
plasma (1.24±0.72 vs 1.1±0.52x1012/mL, p=0.6) (Fig. 5.6 a) and the size distribution analysis revealed 
no differences either in concentration of smaller versus larger EVs subpopulations (p>0.99). (Fig. 5.6 
b-c)
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Fig.5.6: a) Mean EV concentration/mL of plasma pre-and post-lifestyle intervention did 
not differ (p=0.6); b) and c) The size distribution analysis by two-way ANOVA did not 
reveal any differences in EV concentration/mL between the timepoints when analysed 
‘bin by bin’ (b) or grouped in 100nm intervals (c), both p>0.99.
165 
Following the lifestyle intervention, there was a significant reduction in the mean platelet-derived 
(CD41) EV TRF signal 33310(19692) vs 15559 (13803) arbitrary units (a.u), p=0.01,  but the other 
cellular origin markers as well as exosomal markers did not differ (median  CD11b: 14903(5417- 
174226) vs 56810(12460- 118259) a.u, p=0.83, median CD235a: 6263 (2668-19603) vs 7134 (92-
11977) a.u, p=0.91,median CD235a 6263(2668-19603) vs 7134 (82-11977), median CD144: 
11405(5905- 36748) vs 11547(2593- 34280) a.u, p=0.55, median CD63: 40172(17941- 115798) vs 
41319(9135- 78858) a.u, p=0.73 and median CD9: 49565(17393- 117688) vs 27449(5183- 203980) 
a.u , p=0.233. (Fig. 5.7)
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Fig.5.7: Expression of EV cellular origin markers (CD41:platelets, 
CD11b:monocytes/macrophages, CD235a: erythrocytes, CD144: endothelial cells) and 
exosomal markers (CD9 and CD63) at baseline and 6 months after lifestyle intervention. 
(**p<0.01) 
With regard to EV adipocytokine content, significant changes were observed in EV-contained FABP4, 
with median EV FABP4 pre-and post-intervention being 45455 (11637- 77248) vs 20099(6218- 
137144) a.u respectively, p=0.0033. (Fig 5.8) 
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Fig.5.8: Changes in EV-expressed FABP4 at baseline and 6 months following lifestyle 
intervention. (**=p<0.05) 
There were no statistically significant changes observed in other adipocytokines between the 
baseline and follow-up visits, with median EV TNFα values of 30161(17651- 107710) vs 16218(1346- 
40973) a.u, p=0.052; median EV interferon ϒ  59583(4558- 157275) vs 20149(4529- 142380) a.u, 
p=0.068; median EV adiponectin 119103(73825- 433938) vs 82753(48390- 276872) a.u, p=0.067 and 
median PPARϒ 12921(2373- 50183) vs 9278(1855- 87145) a.u, p=0.55. (Fig.5.9) 
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Fig. 5.9. EV expressed TNFα, interferon γ, adiponectin and PPARγ at baseline and 6 
months following lifestyle intervention. 
Unfortunately, the assay did not appear to detect signals from EV-contained IL6, with detectable 
signals above the baseline in only  10 samples overall, hence paired analysis was not possible.  
I subsequently undertook an analysis of my data split according to whether patients had type 2 
diabetes or not. There were no differences observed in EV concentration or adipokine profile 
between participants with (n=8) or without T2DM (Tab 5.2) (n=13) which is likely due to the fact 
there were no BMI/age differences between those cohorts (53.4±5.6 vs 54.3±7.3 kg/m2 p= 0.82; 
48.6±8 vs 49.2±14 years, p=0.9). This could be explained by the lack of power due to low 
numbers in each subgroup. 
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Measurement 
(median with range) 
T2DM (n=8) Non-diabetic (n=13) P value 
EV 
concentration/mL 
1.08 (0.23-1.66) 0.845 (0.22-7.05) 0.8 
CD41 27836 (21203- 
65046) 
22694 (10402- 
72078) 
0.58 
CD11b 14729 (7077- 
174226) 
14948 (2111- 
482013) 
>0.99
CD235a 7421 (4652- 19606) 9630 (2668- 24785) >0.99
CD144 13762(7461-24991) 10771 (3941-58123) 0.599 
CD9 49663 (23277-
78883) 
48348 (17393-
79133) 
0.77 
CD63 41054 (27108-
101295) 
36459 (17941-
115798) 
0.38 
EV TNFα 29047 (18682-
60883) 
23973 (15835-
107710) 
0.57 
EV Interferonγ 59824 (50674-
81591) 
51509 (4558-
157275) 
0.24 
EV adiponectin 128738 (99576-
167990) 
118413 (73825-
433938) 
0.57 
EV FABP4 37733 (11637-
58466) 
37764 (19450-
76448) 
0.9 
EV PPARγ 22895 (4220-26587) 9174 (2373-69268) 0.53 
Tab.5.2: Comparison of EV concentration, cellular origin and adipokine content at baseline 
between participants with T2DM and those with no diabetes. 
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5.4.5. Differences in EV profile between morbidly obese subjects and healthy 
volunteers 
The median EV concentration at baseline in the morbidly obese (MO) cohort was significantly higher 
compared to the healthy volunteers (HV) from chapter 3: 9.4 (2.200- 70.50) vs 4.13 (2.200- 
12.15)x1012/mL, p<0.0001. (Fig. 5.10) 
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Fig.5.10: Differences in EV concentration/mL of plasma between healthy volunteers (n=49) 
and morbidly obese individuals (n=21), ***=p<0.005. 
The EVs from the MO cohort also had significantly higher median expression of CD41 (platelets), 
CD235a (erythrocytes) and CD144 (endothelial cells) markers (22926 (10402-72078) vs 12962 (2568-
34360) a.u, p<0.0001; 12080 (3941-58123) vs 6076 (320.0-36106) a.u, p<0.01; 9585 (2668-24785) vs 
5232 (416.0-25128) a.u, p<0.01).  No differences were observed for CD9 (exosomes) or CD11b 
(monocytes/macrophages) (50874 (17393-117688) vs 33222 (5536-104080) a.u, p=0.054; 14903 
(2111-482013) vs 2756 2(404.0-112260) a.u, p=0.96. (Fig.5.11)
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Fig. 5.11: Comparison of median (ranges) expression of markers of EV cellular origin 
between healthy volunteers (HV, n=49) and morbidly obese subjects (MO, n=21), 
**=p<0.01, ***=p<0.005. 
MO subjects showed significantly higher EV expression of TNFα, interferon ϒ, adiponectin  and 
FABP4 (27769 (15835-107710) vs 5425 (42.00-35230)a.u; 57028 (4558-157275) vs 37982(1240-
103628)a.u; 47214(5264-114310) vs 121859(73825-433938); 38849 (11637-77248) vs 14445 (258.0-
57026) a.u, all p<0.001) with no differences for PPARϒ expression (11392(328.0- 33394) vs 
18455(2373- 69268)a.u, p=0.105). (Fig.5.12)
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Fig.5.12: Differences (median(range)) in EV-expressed adipocytokines (TNFα, interferon-γ, 
FABP4 and PPARγ) between healthy volunteers (n=49) and morbidly obese subjects 
(n=15), ***p<0.005).
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5.4.6 Changes in pre- and post-lifestyle intervention in plasma EV profile isolated by 
size exclusion chromatography 
There were 10 paired surplus plasma samples available to analyse the changes in circulating EV 
profile pre-and post-intervention using Exospin midi columns for EV isolation. Unfortunately, the 
yield of EVs was very low in fractions obtained from 2 of these subjects by this method and the TRF 
signals obtained were thus below the detection threshold of the assay and had to be excluded. 
Hence only 8 paired samples were included in the final analysis. As the overall EV concentration and 
number were much lower (sample dilutions required to obtain EV concentration readings on 
Nanosight were 1:200 rather than 1:10000 for the differential centrifugation method from higher 
plasma volume), from the total available volume of 6 pooled fractions (3mLs) I was only able to load 
3x109EVs/well for the TRF immunoassay. The same antibodies were used in the same concentration 
as in previous experiments, as described in the Methods chapter. However, given that the 
relationship between the TRF signal and the EV load is not linear based on our experience, no direct 
comparison was performed between TRF signals from EVs isolated by differential ultracentrifugation 
vs those obtained by size exclusion chromatography. 
I was however able to compare the profile of main cellular origin of EV families for samples obtained 
by UC vs SEC (Fig.5.13) which demonstrated that the profile of EV cellular markers distribution was 
very similar pre and post intervention (with the consistently dominant signal from CD11b) with only 
subtle differences observed between UC and SEC sample profiles. 
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Fig.5.13: Distribution of TRF signal for main EV cellular origin markers (CD41-platelets, 
CD11b-monocytes/macrophages, CD235a-erythrocytes, Cd144-endothelial cells) in 
baseline and 6 months follow up EV samples isolated by differential ultracentrifugation 
(UC) (a) and size exclusion chromatography columns (SEC) (b).
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There were no significant differences observed in the EV cellular markers pre- and post-lifestyle 
intervention with median CD41: 18053 (8817-33688) vs 14150 (9618-27727)a.u, p=0.62; median 
CD11b:  76187(1489- 143564) vs84320(5704- 137881)a.u, p=0.87; median CD235a: 9380(4810- 
62707) vs 11389(3853- 44727)a.u, p=0.93; median CD144: 9003 (5180-16768) vs 8234 (5934-
13175)a.u, p=0.56 and the exosomal markers: median CD9: 20086 (3894-44034) vs 21946 (9368-
36799)a.u, p=0.99 and median CD63 56822 (19773-126063) vs 54329 (37965-66993)a.u , p=0.507. 
(Fig.5.14) 
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Fig.5.14: Differences in EV cell of origin and exosomal markers pre-and post- lifestyle 
intervention using Exo Spin columns for EV isolation (n=8). 
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With regard to EV-expressed adipocytokines there was a difference, of borderline significance, in 
median EV  FABP4 signal [59459(14885- 133456) vs 16344(7231- 32112)a.u, p=0.054] but the other 
EV adipokines were not different, with median IL6 [11050 (6299-15394) vs 9387(1892-26957) a.u , 
p=0.11], median TNFα [35006 (17494-59768) vs 19708 (13408-45654) a.u, p=0.13], median 
Interferonϒ [43360 (25860-97858) vs 30567 (16615-65262)a.u , p=0.26], median adiponectin 
[54147(29578- 181324) vs 40281(14484- 114247)a.u , p=0.46] and median PPARϒ [13990(186.0- 
24594) vs 5711(2604- 27923)a.u, p=0.81]. (Fig.5.15) 
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Fig.5.15: Expression of EV adipocytokines pre- and post-lifestyle intervention 
using Exo Spin columns for EV isolation (n=8). 
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5.5 Discussion 
5.5.1 Lifestyle intervention and circulating EVs 
This study showed that even a brief period of lifestyle intervention may have an effect on the 
circulating EV profile despite no significant effect on weight/BMI, plasma ‘free’ adipocytokines or 
traditional markers of metabolic health such as lipids or HbA1c. Similar to the bariatric cohort 
described in chapter 4, EV-FABP4 appears to be the most responsive EV marker. EV-contained TNFα 
also decreased at 6 months’ follow-up, albeit of borderline statistical significance. Interestingly, I also 
found a significant decline in TRF signal from platelet-derived EVs following the lifestyle intervention. 
This was not observed in the sub study using columns for EV isolation but the potential reasons for 
that will be discussed later in this chapter. Overall, however, there is evidence in my study of 
lifestyle-induced changes in the circulating EV profile before any other measurable health benefits 
are seen. 
There are only a few studies in the literature that have evaluated the effects of a lifestyle 
intervention on circulating EVs. One of the reasons for this may be that EV research in the clinical 
setting is still quite novel.  Given the logistics and costs of properly designed lifestyle intervention 
studies, more traditionally established metabolic markers and health outcomes are of greater 
interest at present as they can be more easily translated into clinical practice.  As discussed in 
previous chapters, the EV field still suffers from large variations in EV isolation and characterisation 
techniques. Furthermore, the significant amount of time required for EV isolation would not support 
their widespread use in large populations. Nonetheless, the small ‘lifestyle modification’ studies that 
have been conducted to date provide quite a useful insight into the possible role of EVs and add 
value to the results of my project.  
In the most recent paper by Eitan et al evaluating the effects of lifestyle intervention, an 
experimental approach was undertaken aiming to attenuate tumour growth in overweight prostate 
cancer patients awaiting prostatectomy by limiting daily protein intake, thus decreasing the amount 
of circulating amino acids [Eithan E, 2017]. Although the trial duration was only 1 month, the authors 
showed that plasma EVs had increased expression of leptin receptors in the cohort as a whole, as 
well as L1CAM- (L1 cell adhesion molecule) expressing EVs in the intervention arm compared to the 
control group. Moreover, there were changes in phosphorylation status of insulin receptor signal 
transducer protein-1 (IRS1) in L1CAM-expressing EVs in keeping with increased insulin sensitivity. 
Similar to my study, NTA was used to determine EV concentration and size distribution, with no 
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changes observed in these parameters post- intervention. The authors also used CD9 as their 
exosomal marker, again in keeping with my study. They focused mainly on EV content with regard to 
leptin receptor and insulin signalling protein 1 (IRS1), and suggested that although leptin and insulin 
levels have been extensively researched in the context of obesity, more focus is needed on receptors 
and mediators of their action. They proposed that EVs reflect biological processes within their cell of 
origin and are therefore likely to be very ‘plastic’ and reflect cellular processes in response to diet 
quite rapidly. This could open a new avenue of research in evaluating the molecular processes in 
response to food intake in human subjects. Of interest, the authors also proposed that evaluating EV 
adipokine expression may be better than evaluating their total soluble plasma concentration, as the 
plasma-derived proteins represent a ‘mixture’ derived from different cells; since EVs carry their cell 
of origin markers, this can help us establish the effects of diet on specific cell populations [Eithan E, 
2017]. The observations in this paper support my hypothesis that the dietary intervention in my 
study possibly led to a decrease in adipocyte-derived EVs in the plasma, as seen by decreased 
FABP4- and TNFα-expressing EVs. 
With regard to other dietary interventions, there are 2 recent studies on the benefits of 
consumption of natural cocoa on vascular health and the EV profile.  Horn et al showed that in 
response to a 30-day period of high dose cocoa flavanol drink ingestion in patients with coronary 
artery disease, the levels of EVs expressing the endothelial markers CD31⁺/41⁻ and CD144⁺ 
decreased (by 25 and 23%, respectively), with no such effect seen in the group that consumed low 
doses [Horn P, 2013]. Since EVs correlated inversely with flow mediated vasodilatation in this study, 
it was postulated that this reduction in EVs may be important in the associated improvement in 
endothelial function. A further functional study was also performed evaluating the procoagulant 
activity of EVs (measured as the formation of activated factor X per time) but this was not affected in 
response to either low or high flavanol diet [Horn P, 2015]. 
McFarlin et al also showed similar beneficial results of natural cocoa consumption on vascular 
health. In their cross-over study, young healthy females of various BMIs (normal, overweight, obese) 
were evaluated, and asked to consume daily either a cocoa-rich product or a placebo for 4 weeks 
with a 2-week wash-out period. In obese subjects, natural cocoa consumption led to a significant 
decrease in endothelial-derived EVs (CD42a-/45-/144+) and monocyte-derived ones (CD62L) as 
evaluated by flow cytometry. Regardless of BMI, there was an 18% increase in plasma HDL 
concentration and a 60% decrease in endothelial-derived EVs [McFarlin BK, 2015]. 
Zhang et al, in their study on dietary intervention in newly diagnosed type 2 diabetes mellitus 
patients, compared the effects of 8 week standard dietary advice versus an oat-rich diet on the EV 
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profile. Interestingly, the oat-rich diet led to a reduction in concentration and proportion of tissue 
factor- and fibrinogen-expressing platelet-derived EVs and CD 11b (monocyte/macrophage) 
expressing EVs. In contrast, standard dietary advice only led to a decrease in the fibrinogen-
expressing platelet-derived EVs [Zhang X, 2014]. 
Finally, an Italian study recruited 100 patients from a lipid clinic with CRP >2mg/dL and LDL 100-
160mg/dL with no history of cardiovascular disease,  and randomised them to receive either a 
nutraceutical preparation containing red yeast rice, berberine, policosanol, astaxanthin, folic acid 
and coenzyme Q10 for 3 months or not. They evaluated the effects of such an intervention on 
endothelial-derived EVs as well as lipid profile and CRP. As in my study, there were no changes 
observed in BMI, but the group receiving the nutraceutical preparation displayed a significant 
reduction in endothelial-derived EVs. This reduction was greatest in the subgroup that achieved the 
biggest decrease in LDL cholesterol and CRP [Pirro M, 2016]. 
As opposed to dietary supplementation with ‘healthy’ food products, a study by Eguchi et al 
reported that calorie restriction to 1500kcal/day over a 12 week period in subjects with metabolic 
syndrome (n=14) led to decrease in BMI, fat mass and overall plasma EV concentration as well as 
perilipin A-expressing EVs (by Western blotting). They also confirmed an increased plasma EV 
concentration in obese vs lean individuals and a significant correlation of EV concentration with 
HOMA-IR (as I noted in chapter 3) [Eguchi A, 2016]. The authors suggested that ‘stressed’ adipocytes 
might release a higher EV load into the circulation and that EVs might thus be viewed as markers of 
adipose tissue stress and hypertrophy, which is linked with the risk of developing insulin resistance 
and T2DM [Eguchi A, 2016]. In contrast to my study, perilipin A rather than FABP4 was used as the 
marker of adipocyte-derived EVs. Perilipin A is a protein that is involved in coating of lipid droplets 
and regulation of lipolysis and is considered to be adipocyte-specific [Brasaemle DL, 2007]. However, 
in the lean control group evaluated by Eguchi et al, this adipokine was only detectable in one 
subject, limiting its usefulness as a sole marker to distinguish adipose tissue health between lean and 
obese subjects. Studies evaluating the effects of weight loss on more than one adipocyte EV marker, 
such as perilipin A and FABP4, are therefore needed. During the conduct of this study I attempted to 
use perilipin antibody as an additional adipocyte marker for the TRF immunoassay (Perilipin-1 
(D1D8) XP, Rabbit mAb~9349, Cell Signalling). However, in contrast to my colleagues who used it for 
Western Blotting, I was only able to detect EV perilipin signals in 5 out 21 baseline non-columned EV 
samples and in view of these unsatisfactory results and the fact I did not have enough EV material to 
evaluate anti-perilipin antibody from an alternative supplier, further measurements were 
abandoned.  
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The above studies suggest that brief dietary changes may lead to acute changes in the EV profile that 
could potentially be beneficial to vascular and/or overall health, but data are currently lacking on the 
long-term effects of such interventions. My study may therefore add particular value in view of the 
longer participation period (6 months). It should be noted, however, that the dietary intervention in 
the weight loss management programme offered to patients participating in my study focused on 
healthy eating in general rather than dietary supplementation with certain products or ‘superfoods’. 
Furthermore, a limitation of my study is that it was embedded within routine clinical care, without a 
careful assessment of adherence to dietary change that a clinical trial might have ensured, although 
this offers the advantage of closer representation of the changes that might be seen in ‘real life’.  
Other studies have examined the effects of unhealthy dietary interventions on the circulating EV 
profile. This was recently reviewed by Vefaiadou et al. Although only a handful of studies have 
examined the effects of a high fat diet on EVs in healthy and diseased subjects, all have shown that 
consumption of high fat meals (50-100g fat daily) increased circulating EV concentration in both 
healthy and metabolically-compromised subjects, suggesting that EVs may mediate in part the 
adverse effects of a high fat meal on the endothelium [Vefaiadou K, 2012]. This is further supported 
by a rodent study undertaken by Heinrich et al which showed that high fat diet-fed obese rats had 
increased total as well as endothelial-, leukocyte- and platelet-derived EVs. These EVs also had the 
ability to activate reactive oxygen species formation, and vascular cell adhesion molecule (VCAM)-1 
expression in primary rat cardiac endothelial cells [Heinrich F, 2015]. These findings support the view 
that dietary factors can influence EV release and that EVs may in part mediate the effects of diet on 
cardiometabolic health.   
As previously discussed, the multidisciplinary programme offered to study participants in my project 
also comprised individually tailored psychological support. Although there were no differences in the 
health questionnaire scores post-intervention in the group that completed the programme, it should 
be noted that there is some interest developing into the role of EVs in psychological wellbeing. A 
study by Williams et al considered the relationship between platelet-derived EVs and depressive 
symptoms in patients hospitalised for the management of acute coronary syndrome (ACS). They 
found that those with ACS and moderate depressive symptoms had increased plasma TNFα, IL-6, 
and CRP as well as higher levels of platelet microparticles and higher platelet aggregation [Williams 
MS, 2014]. 
182 
5.5.2 Differences in EV profile between healthy volunteers and morbidly obese 
subjects 
The ability to compare the EV profile between the healthy volunteers and the morbidly obese 
individuals was one of my main study goals whilst performing this work. The results showing a higher 
total EV concentration and higher platelet- and endothelial-derived EVs in morbidly obese subjects 
compared to healthy volunteers supported my initial hypothesis. As I found in my chapter 3 study, 
there was no correlation between EV concentration or EV cellular origin markers and weight/BMI; 
this suggests that changes in the EV profile are likely driven by other mechanisms within adipose 
tissue itself rather than weight alone. Although I acknowledge that the healthy volunteers in my 
chapter 3 study were significantly younger than my morbidly obese population, I did not observe any 
correlation between age and the analysed EV markers in any of the groups, hence I do not believe 
that the lack of age-matching significantly affects interpretation of my data.  
A number of recent studies have confirmed changes in the EV profile in subjects with obesity or 
obesity-driven comorbidities such as T2DM, cardiovascular disease and hypertension. This suggests 
that EVs are not only biomarkers but may also contribute to development of metabolic and 
cardiovascular complications [Lakhter AJ, 2014]. For instance, endothelial EVs were found to affect 
the development of arterial stiffness in patients with diabetes[Chen Y, 2012]; in my study the MO 
cohort had significantly higher CD144 TRF signals compared to HV. (Fig.5.11) 
Interestingly, increased total circulating EVs levels have been described in the presence of obesity, 
irrespective of the presence of metabolic syndrome [Stepanian A, 2013].  
The MO cohort in my study also had higher TRF signals from FABP4, TNFα and interferon γ. As I 
showed previously, these EV-expressed adipocytokines correlate with the exosomal marker CD9  and 
with one another, which suggests they are co-secreted by adipocytes into EVs in the exosomal range 
as discussed in chapter 4.  Although these EV adipocytokines did not correlate with weight, I believe 
the significant differences in their expression between healthy and morbidly obese individuals 
suggest they may be markers of adipose tissue hypertrophy and inflammation.  
As shown in many other studies, plasma free adipokines such as FABP4 and IL-6 were also higher in 
my study in the MO group.  
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5.5.3. Effects of methodology on EV analysis – quality vs quantity? 
Given the growing need within the EV research community to streamline EV isolation in order to 
facilitate easier application in the clinical setting, I decided to isolate EVs using ExoSpin columns from 
the surplus plasma in my study. Although differential ultracentrifugation is considered the ‘gold 
standard’ isolation method, and one which is still most widely used worldwide [Gardiner C, 2016], it 
has its limitations. Firstly, it is very time- consuming and costly, and the results may vary depending 
on the equipment, rotor, speed and time used in the protocol. Some authors postulate that the high 
centrifugation forces used may lead to damage of some EVs and loss of material. Secondly, the 
question of sample purity and co-isolation of protein aggregates is often raised. Therefore, a great 
deal of effort is being put in to establish quicker, more reproducible methods of EV isolation such as 
ultrafiltration, size exclusion chromatography or precipitation methods. Hence, for my additional 
sub-study, I decided to use the ready-made commercial columns by Life Biosciences using a protocol 
that was developed previously by a colleague in a local EV research group and which was shown to 
deliver reproducible results [Welton J, JEV 2015]. The postulated advantage of this approach was to 
obtain ‘purer’  EV samples. My preliminary data, akin to those by Welton et al [Welton J, 2015], 
suggested that the EV-rich fraction comes before the large peak of protein-rich fractions as shown in 
the Methods chapter (section 2.5.2.2). The hypothesis was that by undertaking EV isolation by 2 
different methods this would allow me to understand whether the changes I observed were truly 
within EVs or possibly due to some free protein contaminants. The additional advantage of this 
approach was that, hypothetically, it only required a small sample volume (1mL) in contrast to the 
larger volume of plasma required for ultracentrifugation (5-7mLs). Although my experiments 
produced reproducible results, I was finding the particle peaks using NTA as expected [Welton J, 
2015] and all samples tested positive for CD63 and CD9 on the TRF immunoassay, it became 
apparent early in the study that EV yield was considerably compromised. As ultracentrifugation is 
also believed to lead to significant loss of material, I was hoping that the SEC method would allow 
me to recover more EV material from the limited sample volume I had. However, I faced a similar 
problem as in chapter 4 where I was not able to load the same amount of EVs per 96 well plate as in 
my previous ‘standard’ experiment.  
I therefore decided to change the aim of this sub-study. Rather than comparing TRF signals from the 
same load of ‘columned’ vs ‘non-columned’ EV samples for the cellular and adipocytokine markers, I 
decided to reduce the loaded EV number per well to 3x109/ well and simply compare the baseline to 
follow-up EV profile within this subgroup. However, it turned out that such a low loading number led 
to readings below the background EV signal for some markers (values lower than wells where EVs 
only with no primary antibody were added) which possibly indicates that I did not have enough EV 
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material containing that specific marker to be able to detect it. Such markers included CD235a 
(erythrocyte) and CD144 (endothelial), which might be expected to show lower expression based on 
previous studies, and PPARγ. In some instances, I also found undetectable readings for the other 
markers. Interestingly, however, I obtained TRF signals for EV IL-6 in all the subjects in my sub-study 
though I used a different antibody supplier as discussed above. What also can be observed from 
figures 5.7 and 5.14 is that irrespective of the isolation method used, TRF signals for the exosomal 
markers CD9 and CD63 are detectable. Furthermore, neither of the isolation methods showed any 
differences in the pre- and post-intervention signals which means that both methods in this study 
allowed reproducible EV/exosome isolation despite their pros and cons. From my experience, 
however, of the current methods available for EV isolation, implementation of SEC would require 
much more than 1ml of plasma meaning that more columns would need to be used. This would 
therefore not provide any significant time or cost advantage compared to the ultracentrifugation 
method. 
The main common observation from both isolation techniques is the reduction in EV FABP4 signal, 
which provides some evidence for a reduction in adipocyte stress/inflammation following a 
structured healthy lifestyle intervention.  
There was no difference in EV TNFα in the ‘columned’ SEC sub-cohort.  In my opinion, this result 
could be secondary to both the very small sample size (n=8) and the low EV load available for this 
experiment. It is notable that the standard errors for the TRF adipokine signals in my study were 
wide, which limits the chances of detecting significant differences after intervention.  Similar to 
previous chapters, I did not observe any correlation between EV-expressed and plasma free 
adipokines, which argues against a significant effect of free protein aggregates /contaminants as 
confounders.  
The most striking difference between the ultracentrifugation and the SEC was the strongly significant 
reduction in CD41-expressing EVs 6 months’ post-intervention when samples were isolated by 
ultracentrifugation compared to no effect on platelet-derived EVs when using the Exo Spin columns. 
At first glance the reduction in CD41 expression may be unexpected as subjects did not have any 
new anti-platelet medication introduced during the study period.  However, other studies of lifestyle 
intervention have shown an effect on platelet- and endothelial-derived EVs, hence this result may 
not be entirely surprising. Importantly, all plasma samples were double-spun in the same manner at 
the time of sample collection, before being subjected to either ultracentrifugation or SEC, hence 
there should be no differences in platelet contamination between them. A very similar protocol (x2 
2500g spins for 15mins) was used by Arraud et al who performed electron microscopy of their EV 
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samples. They did not find any significant platelet contamination and postulated that such an 
isolation method does not lead to artificial platelet activation that could lead to release of additional 
platelet EVs [Arraud N, 2014]. Platelet-derived EVs are reported to be between 100-250nm in 
diameter [Aatonen MT, 2014] so it is perhaps possible that some of the larger platelet EVs were 
‘lost’ whilst passing through the Exospin columns since these primarily aim to extract exosomes 
which are small in diameter. This, coupled with the low number of samples in this study, could have 
contributed to the discrepancy between methods.  
Study limitations 
As discussed in the methods section, it was not possible to recruit the number of participants that I 
initially intended. There are numerous reasons for this that were outside the control of this study. 
The new tier 3 weight management services were just being established when this study was being 
designed, and the services were undergoing some readjustments when the recruitment commenced 
which unfortunately coincided with a 2-month period when the review of newly referred patients 
was limited. Secondly, not all patients attending this once-weekly clinic were eligible for the study 
given their numerous comorbidities and/or complex psychological issues associated with their 
obesity. Finally, the drop-out rate in the study/clinic attendance was 30%, which likely reflected 
either a lack of motivation and/or lack of rapid effects on body weight and appearance that many of 
the study participants were hoping for.  
The outcomes achieved by the subjects I recruited and followed up therefore does not truly reflect 
the overall outcomes achieved by patients attending weight loss management service at UHL 
between 2015-2017. According to the Annual Report data the median weight loss for patients who 
completed 6 months at the tier 3 service was -4.4kg (1.1-30.6) and for those who completed 12 
months: -7.3kg (1.3-33.1), n=48 and n=33, respectively (Data provided by Dr  D Datta, Lead 
Physician). This is in keeping with published outcomes from a UK weight loss management centre 
with a similar set up (Aintree University Hospital, Liverpool) where 39% of patients were able to lose 
>=5% of initial body weight at 12 months follow up [James M, 2008]. If I were able to follow up my 
cohort of patients for 12 months, I would possibly observe better outcomes in terms of weight loss 
as well. However, this was not possible due to time restrictions. 
A second limitation of my study was that the ‘intervention’ was not well defined but was individually 
tailored to suit a participant’s needs. There were also no healthy food supplements/’superfoods’ 
provided in contrast to other studies. However, a strength of this study was the very frequent 
(almost weekly) involvement of the local dietician teams that encouraged the patients to make 
healthier dietary choices which possibly may have contributed to the observed EV changes.  
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Lastly, I did not undertake any experiments on EV function in my study. It would be of great interest 
to evaluate the effect of the changes in the EV profile in functional experiments such as recently 
developed methods in our lab looking at leukocyte adhesion or leukocyte migration. Due to time 
constraints and limited EV sample I was unable to undertake such experiments. Additional 
anthropometric characterisation, such as analysis of body fat percentage and/or distribution, would 
also have been preferable, but was not undertaken in this study which was conducted in a routine 
clinical setting.   
Study strengths 
The strengths of my study lie in the standardisation of the EV isolation and characterisation 
protocols I adopted for this work, which allows for good reproducibility and inter-study comparison. 
Compared to other lifestyle studies examining changes in EVs, my study benefits from the longer 
duration and greater depth of characterisation with respect to EV cellular origin and adipokine 
expression. Finally, the cohort I recruited, in contrast to other studies, was significantly overweight 
with associated comorbidities, whereas most other studies recruited either healthy individuals or 
overweight patients with few comorbidities. To my knowledge, no other lifestyle intervention study 
has examined EV function in such a morbidly obese population that would otherwise qualify for 
bariatric surgery. 
5.6 Conclusions 
This study demonstrates that lifestyle intervention aimed at healthy eating and gradual weight loss 
can lead to a change in circulating plasma EV profile with reduction in FABP4 and TNFα expressing 
EVs which speculatively may originate from adipose tissue.  These changes were observed before 
any visible improvements in body weight or traditional metabolic health markers were seen, which 
supports the view that EVs may represent early biomarkers of metabolic and adipose tissue health. 
The results of my study also confirm previous work showing differences between the EV profile of 
healthy subjects and morbidly obese individuals.  
Finally, the application of two different EV isolation methods was evaluated; whilst the use of SEC for 
EV isolation may improve sample purity, it reduces EV yield and thus may have reduced value when 
analysis of multiple markers is required.   
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Chapter 6 
 Evaluation of ex vivo/in vitro human 
adipocyte cultures for adipocyte-derived 
EV characterisation 
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Perspective  
Following the work undertaken on characterisation of plasma-derived EVs from various clinical 
cohorts, with a particular focus on obese subjects, I wanted to further characterise adipocyte-
derived EVs specifically obtained from human adipose tissue.  
This work was undertaken under an ongoing project conducted at the University Hospital of Wales 
which focused on characterisation of inflammatory properties of adipose tissue derived from various 
fat depots. The work was supported by an interdisciplinary collaboration with surgical Consultants at 
the University Hospital of Wales in Cardiff: Miss Rachel Hargest, Mr Michael Stechman and Mr David 
Scott-Coombes.  
This is a small pilot study performed alongside experiments that were simultaneously being 
undertaken by colleagues from my research group on characterisation and function of adipocyte-
derived EVs. 
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6.1 Introduction 
EVs originating from human adipose tissue appear to be a very interesting population of EVs given 
the numerous roles of adipose tissue [Trayhurn P, 2001]. However, comparatively few studies have 
analysed their characteristics and function. To date, most data are based on rodent studies or 
commercial lines of adipose-derived mesenchymal stem cells (Ad-MSC) or 3T3-L1 cells, which  
includes our own research group’s experience [Connolly K, 2015].  
Human adipose tissue culture itself is very challenging, with numerous pitfalls that have to be taken 
into consideration such as sample purity (since adipose tissue explants contain a mixture of other 
cells), and slow growth and differentiation rates which makes repeat experiments quite difficult.  In 
addition, access to the material/donors is limited as adipose tissue samples are usually harvested 
whilst planned medical procedures are being undertaken. Consequently, there is no option of 
obtaining more material from the same donor should additional experiments be required or in case 
of sample loss and/or contamination. Therefore, experiments involving adipocyte cultures require 
careful planning with respect to methodological strategy. Firstly, consideration should be given as to 
whether experiments should be undertaken on adipose tissue explants or preadipocytes, as the 
former contain many other cells such as fibroblasts, immune cells and endothelial cells [Fried SK, 
2001]. On the other hand, ‘organ’ culture is reportedly superior when evaluating the role of 
adipocytes within adipose tissue and long-term changes in gene expression [Carswell KA, 2015]. 
Moreover, differences between various adipose tissue depots have been described with regards to 
their morphology, molecular characteristics and biological function [Frayn KN, 2000, Fruhbeck G, 
2008].  Increased visceral adiposity is linked to the development of dyslipidaemia, insulin resistance 
and subsequently type 2 diabetes [Despress JP, 2006]. Compared to subcutaneous depots, visceral 
sites express more genes encoding proinflammatory proteins [Dussere E, 2000]. Given the emerging 
role of EVs as biological paracrine and endocrine messengers, characterisation of EVs derived from 
various human fat depots under different conditions would provide valuable insight into their role in 
the regulation of numerous biological processes. 
6.2 Aims 
Despite the challenges in working with primary adipocyte cultures, I wanted to explore the 
possibility of utilising human-derived visceral and subcutaneous adipose tissue samples in my EV 
research. This could help characterise ADEV content and function and allow comparison with the 
results of my experiments on plasma-derived EVs.  
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Secondly, I wanted to compare the concentration and content of EVs harvested from subcutaneous 
and visceral fat depots and finally, to establish a methodology that could be reproduced in further 
experiments. 
6.3 Methods 
6.3.1 Adipose tissue harvesting 
Visceral and subcutaneous adipose tissue samples were collected from patients undergoing  elective 
laparoscopic or open surgery at the University Hospital of Wales in Cardiff. Additionally, commercial  
primary human visceral preadipocytes obtained from deceased donors were used (PT-5005, Lonza, 
UK). 
6.3.2 Ethical approval 
The study at the University Hospital of Wales and Cardiff University was performed under Research 
Ethics Committee approval reference 06WSE03/3.  Study participants provided informed written 
consent and were coded using a unique study number. No tissue/cells were stored, as the explants 
were processed the same day.  The work on Lonza cells was conducted at Cardiff Metropolitan 
University. 
6.3.3. General methods 
6.3.3.1 Cell culture 
In order to obtain preadipocytes from adipose tissue explants, I used established protocols 
developed by other colleagues working with Professor Marian Ludgate, which are described in the 
Methods chapter section 2.8.1 where the content of control and differentiation media and 
experimental timeframes are also detailed. The same culture conditions were applied to the 
commercial cells obtained from Lonza, UK. Differentiation was evaluated by Oil Red O staining 
(Methods chapter, section 2.8.6). 
6.3.3.2 Adipocyte-derived EV isolation 
The methodological approach to adipocyte-derived EV isolation is described in the Methods chapter 
(section 2.8.3). One hundred millilitres of serum-free medium were collected at day 0 and day 21 of 
differentiation.  
6.3.3.3 Characterisation of ADEVs 
The methodology for the evaluation of ADEV concentration and content is described in the Methods 
chapter (sections 2.8.4 and 2.8.5).  FUNRich  software (Functional Enrichment analysis)  based on 
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integrated genomic and proteomic database systems was used to analyse the dot assays with 
respect to the biological and molecular relevance of the expressed proteins [Pathan M, 2015]. 
6.4 Results 
6.4.1 Subcutaneous and visceral preadipocyte culture: methodological observations 
As previously discussed, I observed that the culture of human-derived visceral and subcutaneous 
preadipocytes was very challenging and time-consuming. Based on the work of my colleagues on 
3T3 cells [Connolly K, 2015], I was aware I needed to passage my cells until I was able to seed them 
into 4 x T175 cm2 tissue culture flasks (Cellstar, Greiner Bio-One, Germany) that would allow me to 
collect a total of 100 mL of serum-free medium at day 0 and 21 for EV isolation. That amount of 
medium was adequate to provide sufficient EV yield from 3T3 cells for further characterisation; in 
practice this was difficult to replicate using human cells. I faced significant problems with the 
deceleration of cell growth after passage 2 which made the whole experiment very time-consuming:  
typically, it would take around 6-8 weeks until the required confluence at passage 3 was achieved for 
the differentiation to commence. Given the low differentiation rates, I was also culturing the cells in 
the differentiation medium for 21 days rather than the standard 14 used for 3T3 cells which 
extended the experimental timescales further. Such a long incubation was also associated with a 
high rate of fungal infections, which led to the need to repeat the process from a new donor on a 
number of occasions and required me to start adding an antifungal agent prophylactically to the 
medium. I also decided to switch from using T175 cm2 flasks (n=4) per sample to using x10 T75 cm2 
flasks hoping that this would allow the cells to reach confluence faster in order for me to obtain a 
total volume of 100 mL of medium for EV isolation.  
Figures 6.1. and 6.2 illustrate the morphology of the cultured visceral and subcutaneous adipocytes 
at different stages of their growth and differentiation. 
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Fig.6.1 Visceral preadipocyte cultures at day 0 (a,b) and day 21 (c,d) of differentiation. 
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a)   c) 
b)  d) 
Fig. 6.2:  Subcutaneous preadipocyte cultures at day 0 (a,b) and day 21 of differentiation 
(c,d). 
Differentiation rates were not as high as those observed by our group in 3T3 experiments; however, 
there was an increase in signal when Oil Red O absorbance was evaluated (for this part of the 
experimental work cells were grown in separate 6 well plates). (Fig.6.3) 
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Fig.6.3: Oil Red O absorbance of subcutaneous (a) and visceral (b) adipocyte cultures 
measured at day 0 and day 21. 
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6.4.2 The culture of commercial visceral preadipocytes – methodological observations 
In view of the above challenges, I sought to explore alternative methods of culturing human 
preadipocytes and decided to evaluate the visceral preadipocytes provided by Lonza UK which were 
obtained from deceased donors. I obtained cells from 3 different donors: a healthy one with no 
history of diabetes, a donor  with a history of T2DM and a donor  with a history of T2DM and heart 
disease. The results were initially very encouraging as following the first passage of the cells from a 
healthy donor, cells grew very rapidly, with further passages required at 3 days intervals as their 
confluence was reaching >70%. This enabled me to complete the experiment, from cell seeding 
through to differentiation, in less than 4 weeks. The cells from the diabetic donor grew somewhat 
slower but I was still able to complete the experimental process within 4 weeks. The cells from the 
donor with T2DM and cardiovascular disease grew very slowly, however, making the culture process 
time-consuming and providing a low EV yield. Unfortunately, the first experiment was difficult to 
replicate as those cells that were aliquoted post-passage 1 from the initial lot, and stored in liquid 
nitrogen, showed very slow growth once thawed and seeded again which made it challenging to 
replicate experiments. I contacted the supplier who stated that they should not be used post-
passage 1; thus, given my study design, these cells did not appear suitable for long-term use as this 
would require purchase of a new vial for each replicate to ensure that the cellular biology remained 
stable.  
Figure 6.4  shows the Lonza cells’ morphology at day 0 and day 21. 
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a)   b) 
c)  d) 
e)   f) 
g)                                                                                               h) 
Fig.6.4: a-b Visceral commercial (Lonza) preadipocytes culture from a healthy (control)
donor at day 0 (a-b) and day 21 (c-d); from the diabetic donor: day 0 (e) and day 21 (f) and 
from the donor with diabetes and heart disease: day 0 (g), day 21 (h). 
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Fig.6.5: Oil Red O absorbance signals for healthy (control) adipocytes at day 0 and day 21. 
6.4.3 ADEVs concentration and size 
The EV concentration obtained from various donors was low and  very variable and did not seem to 
follow any particular pattern i.e. no differences pre- vs post-differentiation. 
As there was only one repetition of the Lonza cells’ experiment, no statistical analysis was 
undertaken. The size distribution of EV is illustrated in Figure 6.6 for ADEVs from visceral and 
subcutaneous adipocyte tissue extracts and in Figure 6.7 for ADEVs from the commercial cell lines
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Fig.6.6: Size distribution general (a-b)  and in 100nm intervals (c-d) of EVs obtained from 
visceral and subcutaneous adipose tissue explants at day 0 and day 21 of differentiation 
(n=5). There was a significant increase in EVs measuring 200-299nm at day 21 which was 
observed in EVs derived from subcutaneous adipose tissue only  (p<0.05). V-AT- visceral 
adipose tissue, S-AT- subcutaneous adipose tissue.
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Fig.6.7: Overall size distribution (a,c,e) and in 100nm intervals (b,d,f) at day 0 and day 21 
of EVs obtained from culture of commercial visceral preadipocytes from various donors: 
healthy(control) a-b, diabetic c-d  and diabetic with heart disease e-f.
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6.4.4 The use of SEC columns 
Centrifugation is one of the most commonly used methods to isolate EVs in manuscripts published 
on ADEVs to date (Table 6.1). Given the ISEV focus on sample purity [Witwer K, 2013], I decided to 
employ the ExoSpin midi columns (Cell Guidance Systems UK, EXO-01) to purify my samples further 
in an attempt to ensure the adipokines I was detecting with the proteome profile assay truly 
represents what is contained on or within the EVs. However, similar to the plasma work described in 
chapter 5, use of these columns led to significant EV loss from samples where the initial 
concentration was already quite low. As mentioned previously (Methods chapter 2.8.3.2), 6 x 100µL 
fractions were collected each time and NTA revealed that the EV-rich samples were typically in 
fractions 2 and 3. The protein concentration was also evaluated in a sample of these fractions for 
validation purposes. (Fig.6.8) In contrast to the plasma EV column experiments, the nanoparticles 
were present in 1 to 2 fractions only, with the other fractions hardly showing any particles as 
detectable by Nanosight. This suggests that not much free/contaminating particles were present in 
the stock ADEVs in PBS solution prior to the sample being columned.
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Fig.6.8.  Analysis of protein concentration (mg/mL)  by Nanodrop and nanoparticle 
concentration/mL by  NTA of 6 fractions obtained from EXOspin columns revealed a peak 
of EVs in fraction 2 and 3 in (a) EVs isolated from visceral preadipocyte medium at day 0, 
and (b) EVs isolated from visceral adipocyte medium at day 21, (n=3).
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However, I noted a reduction in the concentration of the already very low yield EVs when using the 
SEC method compared to EV concentration obtained by differential ultracentrifugation, perhaps 
because some of the EVs might have remained adherent to the column beads and were therefore 
lost in passage.  Figure 6.9 illustrates the differences in visceral ADEV concentration from 3 different 
donors pre- and post-SEC column.  
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Fig. 6.9. Differences in mean EV concentration pre- and post-SEC column at day 0 and day 
21 of differentiation for 3 different visceral ADEVs samples. 1-3 represent paired samples 
from 3 different donors. The lack of difference observed for donor 3 at d21 is likely due to 
the very low initial and post-column concentration which could have affected the 
Nanosight accuracy/detection threshold.
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6.4.5 Evaluation of ADEV content 
As the EV yield was very low, I was not able to use the TRF immunoassay method we developed for 
EV protein characterisation, as described in the Methods chapter (2.5.5.2). This led me to search for 
alternative ways to evaluate ADEV adipokine content, and subsequently the use of a commercial dot 
assay kit (Human Adipokine Proteome Profiler Array Kit (R&D Systems, UK, ARY024)). These benefit 
from only requiring a small amount of sample and the ability to assess multiple proteins 
simultaneously as described (Methods 2.8.5).  However, a drawback of this method is that it is more 
of a screening tool; quantitation is limited, as with other membrane based methods such as Western 
blotting.  
Figure 6.10 presents the heat map for an array of adipokines expressed in visceral and subcutaneous 
ADEVs obtained at day 0 and day 21 based on mean pixel density signals for a given protein from all 
donors (visceral (n=4), subcutaneous (n=4)). The Spearman correlation analysis revealed strong 
correlation between expressed markers in ADEVs from the same depot at different stages of 
differentiations (visceral d0 vs visceral d21 r2=0.73, subcutaneous d0 vs subcutaneous day 21 
r2=0.35) as well as strong correlations with ADEVs from different fat depots but at the same stages of 
differentiation (visceral d0 vs subcutaneous d0 r2=0.56 and visceral d21 vs subcutaneous d21 
r2=0.68, all p<0.0001). (Fig.6.11) 
As mentioned previously, I used the FUNRich software (V3) to measure expression of adipocytokines 
in EV samples against their unique gene expression IDs and analyse the adipocytokine profile 
expressed by ADEVs with respect to the biological and molecular processes they are involved in. (Fig. 
6.12-14)
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Fig.6.10:  Heatmap of adipokines expression presented as mean pixel density for 
subcutaneous and visceral ADEVs at day 0 and d21 (n=4). 
 Red represents highest expressing and green lowest expressing proteins. Heat map 
analysis was conducted within each adipose tissue type (V-AT or S-AT).
mean visc d0 mean visc d21 mean sc day 0 mean sc day 21
(A5-A6)(Adiponectin/Acrp30) 916.686 2483.395 0 34.608
(A7-A8)(Angiopoietin-1) 4106.724 8315.9125 286.4425 1939.252
(A9-A10)(Angiopoietin-2) 6666.63 10410.17 1949.44 3577.71
(A11-A12)(Angiopoietin-like 2) 7925.544 12376.94 1362.6525 4835.428
(A13-A14)(Angiopoietin-like 3) 3098.32 4321.9325 113.3 541.91
(A15-A16)(BAFF/BLyS/TNFSF13B) 3995.608 5243.0475 260.1575 1160.262
(A17-A18)(BMP-4) 4651.046 7598.4025 1139.8975 3431.668
(A19-A20)(Cathepsin D) 11440.544 14492.8675 2703.98 11967.398
(B1-B2)(Cathepsin L) 6715.584 8190.6825 0 7216.804
(B3-B4)(Cathepsin S) 8271.8 13093.2725 3157.805 5725.784
(B5-B6)(Chemerin) 1865.496 4107.3425 0 19.422
(B7-B8)(Complement Factor D) 1943.874 5718.1425 0 875.518
(B9-B10)(C-Reactive Protein/CRP) 1869.324 3457.6225 0 70.502
(B11-B12)(DPPIV/CD26) 17289.172 23196.7 2870.7725 11871.666
(B13-B14)(Endocan) 10699.702 17285.5975 4267.3 8157.658
(B15-B16)(EN-RAGE) 6606.512 11355.645 1931.7675 4483.086
(B17-B18)(Fetuin B) 2396.488 3560.07 142.745 868.8
(B19-B20)(FGF basic) 1683.584 2960.77 155.125 824.582
(B21-B22)(FGF-19) 5862.916 7842.4025 2750.11 4548.384
(B23-B24)(Fibrinogen) 10269.498 11454.2525 4134.4925 5199.07
(C1-C2)(Growth Hormone) 1521.384 4009.0925 0 101.278
(C3-C4)(HGF) 2247.296 4392.605 0 319.718
(C5-C6)(ICAM-I/CD54) 5681.502 11255.13 0 3282.94
(C7-C8)(IGFBP-2) 1292.386 3360.3675 0 36.092
(C9-C10)(IGFBP-3) 5100.628 13438.22 426.42 2636.62
(C11-C12)(IGFBP-4) 8278.396 14976.34 1682.4325 6795.642
(C13-C14)(IGFBP-6) 6427.426 12818.7225 1590.85 5794.454
(C15-C16)(IGFBP-rp1/IGFBP-7) 1131.49 3358.2175 0 1334.554
(C17-C18)(IL-1beta/IL-1F2) 3113.656 3889.715 30.1475 855.248
(C19-C20)(IL-6) 2487.77 5310.54 520.185 1432.91
(C21-C22)(CXCL8/IL-8) 8273.116 6758.8025 2226.085 3832.822
(C23-C24)(IL-10) 5284.918 7543.2825 2815.7 3976.198
(D1-D2)(IL-11) 1218.66 4176.8425 0 400.61
(D3-D4)(LAP (TGF-beta1)) 1397.558 2677.5525 0 229.562
(D5-D6)(Leptin) 1809.478 4350.2525 0 1901.782
(D7-D8)(LIF) 1547.254 3481.5375 0 12.666
(D9-D10)(Lipocalin-2/NGAL) 8428.766 5977.005 212.76 1112.782
(D11-D12)(CCL2/MCP-1) 1754.962 3732.38 0 112.542
(D13-D14)(M-CSF) 3053.416 7115.855 325.965 1967.682
(D15-D16)(MIF) 8372.328 13807.1875 502.1 10258.572
(D17-D18)(Myeloperoxidase) 7401.32 2985.415 0 365.886
(D19-D20)(Nidogen-1/Entactin) 2927.818 5354.3625 545.095 3070.368
(D21-D22)(Oncostatin M (OSM)) 4288.012 5492.59 1720.395 3162.696
(D23-D24)(Pappalysin-1/PAPP-A) 8153.992 11573.7 4350.3175 6693.628
(E1-E2)(PBEF/Visfatin) 2405.294 4612.54 0 1605.448
(E3-E4)(Pentraxin-3/TSG-14) 2715.178 10554.2225 0 12214.292
(E5-E6)(Pref-1/DLK-1/FA1) 3130.356 6113.6875 0 1216.872
(E7-E8)(Proprotein Convertase 9/PCSK9) 1569.202 3571.8025 0 88.368
(E9-E10)(RAGE) 2865.786 4778.1425 0 517.22
(E11-E12)(CCL5/RANTES) 1670.46 3320.4525 0 0
(E13-E14)(Resistin) 5121.848 7789.06 685.3925 2474.43
(E15-E16)(Serpin A8/AGT) 1855.15 4558.38 5.26 763.194
(E17-E18)(Serpin A12) 2843.108 3307.17 0 356.708
(E19-E20)(Serpin E1/PAI-1) 4364.484 12061.9375 764.895 6259.136
(E21-E22)(TIMP-1) 7619.158 9606.905 1354.405 12306.852
(E23-E24)(TIMP-3) 3181.908 3785.9875 1206.96 1619.648
(F5-F6)(TNF-alpha) 2811.504 8286.99 95.16 1770.114
(F7-F8)(VEGF) 876.318 2833.015 0 160.04
207 
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 5 0 0 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
S u b c u t a n e o u s  E V s  a d ip o k in e  p r o f ile  d a y  0  v s  d a y  2 1
s c  d a y  0
s
c
 d
a
y
 2
1
r
2
=  0 .3 5
p < 0 .0 0 1
0 5 0 0 0 1 0 0 0 0 1 5 0 0 0 2 0 0 0 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
V is c e r a l A D E V s  a d ip o k in e  p r o f i le  d 0  v s  d 2 1
v is c  d 0
v
is
c
 d
2
1
r
2
= 0 .7 3
p < 0 .0 0 1
0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 5 0 0 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
S u b c u t a n e o u s  v e r s u s  v is c e r a l A D E V s  d a y  0  a d ip o k in e  p r o f ile
s c  d a y  0
v
is
c
 d
0
r
2
= 0 .5 6
p < 0 .0 0 0 1
0 5 0 0 0 1 0 0 0 0 1 5 0 0 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
2 5 0 0 0
S u b c u t a n e o u s  v e r s u s  v is c e r a l  A D E V s  d a y  2 1  a d ip o k in e  p r o f ile
s c  d a y  2 1
v
is
c
 d
2
1
r
2
= 0 .6 8
p < 0 .0 0 0 1
a )
b )
c )
d )
Fig.6.11: Spearman correlation analysis of 58 ADEV expressed adipokines at day 0 and day 
21: a) subcutaneous ADEVs day 0 vs day 2; b) visceral ADEVs day 0 vs d21; c) subcutaneous 
vs visceral EVs at day 0; d) subcutaneous versus visceral  EVs day 21.
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Fig.6.12: Functional enrichment analysis by FunRich of visceral ADEV-expressed proteins’ involvement in various biological processes (a-b) 
and molecular pathways (c-d); a,c-day 0 , b,d- d21 of differentiation (n=5).
209 
 
2 5 .1 7 %   P r o te in  m e ta b o lis m
2 7 .4 2 %   S ig n a l t r a n s d u c t io n
2 6 .7 7 %   C e ll  c o m m u n ic a t io n
1 1 .2 6 %   Im m u n e  r e s p o n s e
4 .5 2 %   C e ll  g r o w th / m a in te n a n c e
2 .5 1 %   C e ll d e v e lo p m e n t
1 .2 8 %   A p o p to s is
1 .0 7 %   M e ta b o lis m
S u b c u t a n e o u s  E V s  d 0
2 4 .5 1 %   P r o te in  m e ta b o lis m
2 6 .5 7 %   S ig n a l t r a n s d u c t io n
2 5 .9 0 %   C e ll  c o m m u n ic a t io n
1 1 .0 8 %   Im m u n e  r e s p o n s e
3 .1 9 %   C e ll  g r o w th / m a in te n a n c e
3 .4 6 %   C e ll d e v e lo p m e n t
1 .4 6 %   A p o p to s is
0 .8 1 %   M e ta b o lis m
3 .0 2 %   E n e r g y  p a th w a y s
S u b c u ta n e o u s  E V s  d 2 1
3 4 .7 6 %   C y to k in e  a c t iv ity
1 3 .4 0 %   G r o w t h  fa c to r  a c t iv it y
4 .6 1 %   R e c e p to r  b in d in g
2 6 .0 8 %   C e ll  a d h e s io n  m o le c u le C
1 2 .8 5 %   A s p a r tr ic  p e p t id a s e  a c t iv it y
2 .4 2 %   T r a n s p o r te r  a c t iv it y
5 .8 8 %   P e p t id a s e  a c t iv ity
S u b c u ta e n o u s  E V s  d 0
2 7 .4 8 %   C y to k in e  a c t iv ity
8 .2 9 %   G r o w th  fa c to r  a c t iv it y
6 .2 9 %   R e c e p to r  b in d in g
2 1 .4 1 %   C e ll  a d h e s io n  m o le c u le C
3 .6 9 %   C y s te in e  p e p t id a s e  a c t iv ity
4 .9 3 %   A s p a r tr ic  p e p t id a s e  a c t iv ity
1 .6 9 %   T r a n s p o r te r  a c t iv it y
6 .2 7 %   D e fe n s e / im m u n ity  p ro te in
0 .7 4 %   R e c e p to r  a c t iv it y
1 9 .2 1 %   P e p t id a s e  a c t iv ity
S u b c u ta n e o u s  E V s  d 2 1
a )                                            b )
c )                                             d )
Fig.6.13: Functional enrichment analysis by FunRich of subcutaneous ADEV-expressed proteins’ involvement in various biological processes 
(a-b) and molecular pathways (c-d); a,c-day 0 , b,d- d21 of differentiation (n=4). Interestingly, there are some differences in the distribution 
and number of the molecular pathways subcutaneous EVs expressed adipokines are involved in at day 0 versus day 21. This could be due 
the fact that many of the adipokines within S-AT EVs at day 0  were below the detection threshold/absent using the Proteome Profiler 
Assay. 
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Fig.6.14: Functional enrichment analysis by FunRich of Lonza control non -diabetic ADEV-expressed proteins’ involvement 
in various biological processes (a-b) and molecular pathways (c-d); a,c- day 0 ; b,d- d21 of differentiation (n=1). 
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6.5 Discussion 
6.5.1. Characteristics and function of ADEVs 
Most manuscripts evaluating ADEVs are based on 3T3 cells, Ad-Msc or rodent models and the 
availability of studies on adipose tissue derived from living human donors is still limited.  As shown 
above, the culture of primary adipocytes from human donors and harvesting of the sufficient 
amount of EVs required for further analysis is very challenging and time -consuming. However, given 
that the mechanisms regulating adipose tissue homeostasis and dysfunction are different between 
humans and rodents [Muniayappa R, 2009], further information about the characteristics and 
function of human ADEVs is needed. The studies available to date already provide some insight into 
the potentially important pluripotent function of this EV population which needs to be further 
explored.  
Han et al recently published a study in nude mouse models, reporting that exosomes derived from 
hypoxia-preconditioned mesenchymal stem cells promote neovascularisation and fat graft survival 
[Han YD, 2018]. Furthermore, Mleczko el al evaluated the effects of EVs derived from 3T3 cells, 
Simpson-Golabi-Behmel Syndrome (SGBS) cells as well as plasma-derived EVs from lean and obese 
individuals on insulin-mediated glucose uptake. They found that adipocytes exposed to EVs derived 
from hypoxic adipocytes show a 25% decrease in insulin-stimulated glucose uptake [Mleczko J, 
2018]. A dose-dependent decline in AKT S473 phosphorylation was also observed in those cells 
compared to those that were left untreated or exposed to ADEVs from control/normoxic adipocytes.  
The effects of plasma-derived EVs from healthy lean and obese donors on the SGBS human 
adipocyte cell line was also examined and revealed that insulin-stimulated glucose uptake was 
reduced in adipocytes treated with EVs from obese women [Mleczko J, 2018]. Interestingly, the 
study did not report any differences in plasma-derived EV concentration between healthy lean and 
obese subjects, which is in keeping with my findings from chapter 3 (3.4.3.1). 
The choice of SGBS cells as opposed to human adipose tissue explants allowed replicate experiments 
to be performed without the problems of donor-to-donor variability. SGBS is an X-linked condition 
associated with pre- and postnatal macrosomia, characteristic facial features and numerous 
congenital malformations [Gollabi, 2011]. The SGBS cell line originated from an adipose tissue 
specimen of one SGBS patient and has proven very useful in studying adipocyte biology such as 
differentiation, apoptosis, lipolysis, glucose uptake and regulation of adipokine expression [Fischer-
Posovszky P, 2008]. Interestingly, these unique cells which are neither transformed nor immortalised 
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can proliferate for up to 50 generations, retaining their adipogenic differentiation potential (>90% 
differentiation rate in 14 days) and, in fact, differentiating quite easily in PPARγ agonist 
supplemented and serum/albumin depleted medium. They resemble human subcutaneous 
adipocytes with regard to their function and gene expression pattern [Wabitsch M, 2001] and can be 
grown in 96 or 12 well plates, making them an attractive source to study ADEV biology. However, a 
limitation is they do not represent a genetically normal healthy adipose tissue.  
Only a small handful of ADEV studies have been undertaken using adipose tissue derived from 
human donors. At the time of writing, two important manuscripts have been published by 
Krankendonk et al recently.  The authors used ADEVs from adipose tissue explants and SGBS 
preadipocytes to stimulate primary monocyte differentiation into human adipose tissue 
macrophages (ATM). Adiponectin positive ADEVs and those originating from visceral rather than 
subcutaneous fat depot were found to have particularly strong effects on monocyte to macrophage 
transformation [Krankendonk ME, 2014]. In addition to differential centrifugation, sucrose gradient 
ultracentrifugation was used in this study to generate EV-containing fractions, as confirmed by 
specific EV markers (CD9 and CD63), and adipocyte proteins such as adiponectin and FABP4. Further 
separation of these EV populations by flow cytometry revealed that ADEVs were enriched in 
adiponectin.  Moreover, they had the ability to induce higher mRNA expression of IL6, TNFα and 
MCP-1 in the adipose tissue macrophages (ATM). They also showed that ATMs pre-treated with EVs 
from subcutaneous and visceral fat depots could inhibit insulin signalling in adipocytes (HSBG cells) 
[Krankendonk ME, 2014]. 
This study also used a multiplex immunoassay to demonstrate  that ADEVs contain a mixture of  
various adipokines. Interestingly, there was no correlation between the number of subcutaneous 
and visceral ADEVs and BMI (r=0.01 and r=0.16, respectively, p=ns) which is similar to my 
observations on the plasma-derived EVs expressing FABP4 which did not correlate with BMI/waist 
circumference as opposed to ‘free’ plasma concentration of that adipokine (Chapter 3, section 
3.5.3.5). 
Another recent important study by this group described the effects of EVs from human adipose 
tissue on insulin signalling in liver and muscle cells in order to evaluate if EVs contribute to the 
development of insulin resistance [Krankendonk ME, 2014]. Ex vivo explants of subcutaneous and 
visceral fat tissue were used to stimulate in vitro hepatocyte and myocyte cultures and  insulin-
induced Akt-phosphorylation, expression of gluconeogenic genes (Glucose6- phosphatase (G6P) and 
phosphoenolpyruvate carboxykinase  (PEPCK)) was also assessed. As before, ADEVs were measured 
by flow cytometry and their adipokine content was established by a multiplex assay.  It was 
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demonstrated that ADEVs inhibited insulin-induced Akt phosphorylation in hepatocytes but the 
effect on myocytes was inconclusive, since in general there was significant individual variation in the 
measurements reported [Krankendonk ME, 2014].  Hepatic Akt phosphorylation also correlated 
negatively with G6P-expression, and omental ADEVs had higher IL-6, MCP-1 and MIF (macrophage 
migration inhibitory factor) concentration. The authors hypothesised that it is the adipokine content 
of ADEVs that affects either positively or negatively their effect on the development of insulin 
resistance, with a potential role of MIF in this process [Krankendonk ME, 2014].   
I observed interesting differences in the methodological approach in these manuscripts compared to 
my work.  The authors incubated the entire adipose tissue explant in medium and collected the 
supernatant after 24 hours, centrifuged this at 500g and stored the sample for EV isolation. EVs 
isolated by differential centrifugation were later used ‘fresh’ for the functional experiments. The use 
of the whole tissue explant rather than, as in my project, collagenase digestion followed by 
preadipocyte culture in flasks, appears to enable much faster EV collection. On the other hand, one 
may argue that the EVs present in such a supernatant are not purely obtained from adipocytes but 
rather a mixture of other cells such as macrophages, red cells or endothelial cells.  
Further functional studies on human ADEVs were published by Koeck et al and showed that 
fluorescently labelled exosomes derived from visceral adipose tissue integrate into cultured hepatic 
cell lines and deposit in the perinuclear area. This induces dysregulation of the TGF-β pathway which 
could indicate that ADEVs play a role in the development of NAFLD (non-alcoholic fatty liver 
disease), a well-recognised complication of obesity and T2DM [Koeck E, 2014]. 
Park et al isolated visceral ADEVs (by ExoQuick-TC, System Biosciences) and incubated them with 
mature myotubes obtained from lean and obese individuals. ADEVs supressed Akt phosphorylation 
in the myocyte culture but had no effect on insulin-stimulated glycogen synthesis and glucose 
oxidation [Park S, 2016]. 
Finally, Ferrante et al isolated ADEVs from human subcutaneous and visceral adipose tissue samples 
from lean and obese adolescents and profiled exosomal miRNA. They used small pieces of adipose 
tissue explants which were cultured in 12 well plates and FBS- free medium which was then 
harvested, centrifuged to remove cells and debris and finally EVs were isolated by a commercial 
precipitation assay. They found 55 mature miRNAs differentially expressed between lean and obese 
subjects, with TGF-β and Wnt/β-catenin as the main pathways targeted by those miRNAs [Ferrante 
SC, 2015]. TGF-β and Wnt/β-catenin are involved in the development of chronic systemic 
inflammation and fibrotic disease [Henderson WR, 2010, Akhmetshina A, 2012]. Obese visceral 
ADEVs were shown to be taken up by lung epithelial cell lines (A459) and to affect, after 24 hours 
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incubation, the recipient cells’ gene expression of the activin receptor type-2B (ACVR2B), which is 
involved in TGFβ signalling and was downregulated in the presence of obese ADEVs [Ferrante SC, 
2015]. The authors used a flow cytometry bead-based technique, which used CD63 as an exosomal 
marker, and demonstrated that the visceral adipose tissue explants mainly shed EVs of adipose 
rather than macrophage origin, since both lean and obese ADEVs were positive for FABP4 with very 
low signals for the macrophage marker CD14, and no signal for the endothelial marker CD31.   
Further interesting insights into the role of ADEVs come from studies on various cell lines and are 
summarised in Table 6.
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*Isolation methods: 1- centrifugation, 2- centrifugation and filtration, 3- Centrifugation and
density gradient, 4- Commercial kit,  5- not specified
Tab.6.1: Summary of manuscripts on ADEVs in murine and rodent models to date in 
chronological order (adapted from Jayabalan N, Front Endocrinol (Lausanne) 2017; 8: 239).
Source Isolation 
technique 
Results Reference 
Ad-MSC 1 EVs had inhibitory effect on T cells 
differentiation and activation and reduced  
proliferation and IFN-γ release 
Blazquez et al 
Ad-MSC 5 Treatment with exosomes in graft-versus-host 
disease patients leads to symptoms reduction 
Ludwig et al  
Rat 
adipocytes(primary) 
2 509 proteins identified within ADEVs with 
differential expression of 200 proteins between 
obese diabetic and non-diabetic rats 
Lee et al 
Ad-MSC 1 Comparison between MSC and EVs showed 
enrichment of 4 miRNAs, 255 mRNAs, and 277 
proteins enriched in EVs 
Eirin et al  
Ad-MSC 1 Exosomes promote migration and upregulation 
of cancer-related signalling pathways in human 
breast adenocarcinoma cell line (MCF-7) 
Lin et al 
3T3-L1 cells 1 Higher EV concentration pre-adipogenesis with 
differences in EV protein expression pre- and 
post-adipogenesis 
Connolly et al 
Mice visceral  adipose 
tissue 
3 Visceral ADEVs from obese mice induce 
differentiation of monocytes to macrophages 
and development of insulin resistance in lean 
mice 
Deng et al  
Ad-MSC 1 EVs promote migration and upregulation of 
cancer-related signalling pathways in  human 
breast adenocarcinoma cell line (MCF7) 
Lin et al 
3T3-L1 4 EVs reduced the aggregation of mutant 
Huntington protein (mHtt), reduced 
mitochondrial dysfunction and prolonged cells 
survival 
Lee et al 
3T3-L1, primary rat 
adipocytes; plasma 
1 Perilipin A is enriched in ADEVs, especially from 
obese donors and its expression reduces with 
low calorie diet intervention 
Eguchi et al  
3T3-F442A 
(preadipocytes cell 
line); mice adipose 
tissue 
3 EVs promote tumor cells migration through 
fatty acid oxidation 
Lazar et al  
Ad-MSC 2 EVs reduced the neuronal cells apoptosis and 
increased remyelination and activation of 
neuroglial precursors 
Farinazzo et 
al  
Ad-stromal cells 4 EVs protected motor neuron-like cells (NSC-34) 
from oxidative damage and improved their 
survival 
Bonafede et 
al  
Ad-MSC 4 Exosomal miR-122 improved the sensitivity to 
chemotherapeutic agents in hepatocellular 
carcinoma cells 
Lou et al  
3T3-L1 2 The hypoxic ADEVs had different expression and 
increased secretion of proteins compared to 
normal ADEVs 
Sano et al  
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6.5.2 Methodological pitfalls, limitations  and future considerations 
 Although my study did not provide lots of data in terms of detailed EV characterisation, despite 
multiple methodological difficulties, it equipped me and my research group with a useful insight into 
practical considerations that can be applied in further studies on ADEVs.  Regrettably, because my 
main research focus was on the plasma-derived EVs, I did not have the opportunity to further 
explore alternative methodological ideas and the functional use of EVs derived from human adipose 
tissue nor the miRNA content of those EVs. I believe that efforts at optimising the harvesting of EVs 
from human adipose tissue samples derived from elective surgery is worth doing, as this provides 
the phenotypically closest model of human ADEVs. Although rodent and cell line experiments may 
seem easier and quicker to conduct, conclusions from these studies cannot be directly translated to 
human biology. Therefore, the use of adipose tissue explants from subcutaneous and visceral fat 
depots should continue in our group’s further experiments but in hindsight I would consider using 
whole fat explants as described by Krankendonk et al, rather than the labour-, time- and resource-
intensive method of preadipocyte culture in T25 cm2 and T75 cm2 flasks. The authors showed that 
EVs that are not adipocyte-derived from these adipose explants are in the minority [Krankendonk 
ME, 2014]. Having access to the post-operative material from elective surgery and being able to 
collect the EV-containing medium for experiments within 24 hours of obtaining the samples, would 
make it easier and faster to run various functional experiments and the EV yield could perhaps be 
higher. This might then potentially enable us to re-explore the use of SEC columns as the problem 
with sample/EV loss may not be so limiting then. The issue of sample purity could also be further 
addressed by evaluating the samples by magnetic bead experiments aiming to pull out EVs 
expressing antigens such as FABP4 and CD9/CD63, as used in recent studies[Ferrante SC, 2015]. A 
similar protocol is currently being developed by my colleagues: Dr K Connolly and Miss D Mathew 
[Connolly KD, 2018]. 
Even if contamination by other EV populations from adipose tissue explants was observed, this 
might nevertheless be interesting, especially in comparing ADEV differences between subcutaneous 
and visceral depots or even various types of visceral depot such as omental, perinephric or 
perihepatic fat.  The methodology could also perhaps be used to perform miRNA analyses. This is 
lacking in my work due to an inability to obtain enough biological material, but has become a very 
important area within the field of EV research. Moreover, the explants could also then be 
collagenase-digested and grown to obtain preadipocyte samples for corresponding protein and 
mRNA analysis from the preadipocyte cells themselves.  
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As discussed, the work performed on Lonza preadipocytes appeared encouraging at first but given 
the slow and unpredictable growth and differentiation rate of cells past P1 and the fact the cells 
originate from elderly deceased donors, these drawbacks would limit their value in future, larger 
scale experiments. However, the use of the SGBS cell line as described by other authors 
[Krankendonk ME, 2014, Mleczko J, 2018] appears to be an interesting and time-saving alternative in 
functional EV studies. 
On the positive side, my work has enabled us to establish a reproducible proteome profiler protocol 
which should prove useful for analysis of EV adipokine content in future studies and will enable 
inter-study comparison of results for our group. Somewhat surprisingly, I observed that there were 
striking similarities in the adipokine profiles expressed within EVs derived from subcutaneous and 
visceral fat depots and also between day 0 and day 21, as shown by the heat map and the Spearman 
correlation analysis (Fig. 6.10 and 6.11) and the functional enrichment analysis looking into the 
biological processed and the molecular pathways these adipokines are involved in (Fig.6.12-6.14). 
The similarities in profiles between day 0 and day 21 could, in my opinion, be explained by slow 
growth and differentiation  rates of the cells I harvested from living donors. (Fig.6.1-6.3). The only 
subset of EVs that appear to show differences in their adipokine profiles at day 0 vs day 21 were S-
AT derived EVs, although as can be seen from the heat map many of the adipokines were below the 
detection threshold of the Proteome Profiler Assay which in itself is more of a screening rather than 
quantitative tool. Therefore, as one may expect, these could be true differences, but no firm 
conclusions can be made based on the pixel density of the spots alone.  
It was interesting to observe however, that overall signals from V-AT derived EVs appeared to be 
higher and most of the adipokines were detectable within the V-AT EVs using this assay as opposed 
to the S-AT EVs. Despite that, as mentioned above, there was strong correlation between the 
adipokine profiles of EVs from those 2 adipose tissue types.  As both types of adipose tissue were 
cultured in the same media and conditions, it would perhaps be interesting to compare S-AT and V-
AT derived EVs harvested from cells exposed to hypoxia/TNFα to mimic the local milieu changes 
occurring in adipose tissue in obesity. Concomitant  data on adipokine profiles obtained from 
corresponding cell lysates would add further depth to this data set and I am hoping this will be 
pursued by my colleagues who continue the work on characterisation and function of ADEVs.  
Finally, the use of NTA for evaluation of ADEV size distribution I applied in this study also enables 
direct comparison with other research groups since NTA is a well standardised and broadly used 
methodology in EV research.  
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6.6 Conclusions 
The evaluation of ADEVs and their potential use in functional studies remain an important area to be 
addressed in future studies by our group. However, development in the methodology for both the 
adipocyte culture as well as EV harvesting is required to enable a quicker pace of such experiments, 
better reproducibility and decreased risk of EV material loss during the isolation processes. The 
methodology used in this chapter turned out not to be suitable for large scale experiments but 
alternative methods could be explored based on the more recent literature. However, the proteome 
profiler assay appears to be promising as a screening tool for ADEV protein content. In hindsight, I 
do not think that the use of SEC columns added much in terms of sample purity, as I harvested EV 
from FCS-free medium and was losing lots of EVs from an already low starting concentration. This 
may have affected my final results on the dot assay.  
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Chapter 7  
Conclusions and future directions 
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7.1 Relevance of research undertaken 
In the last 2 decades there has been a tremendous rise in interest in the biology of extracellular 
vesicles, which is reflected both by the number of scientific publications on the subject (>75000 to 
date) [PubMed, 2018] and the establishment of the International Society of Extracellular Vesicles in 
2011. It is no longer a matter of debate that EVs are carriers of important biological information 
between cells, and EVs have thus been proposed as potential biomarkers of many pathological 
processes. However, the exact mechanisms controlling their secretion and content are still not clear 
and more research is needed to characterise their role in physiological conditions. Their potential 
use in clinical practice could be applied in various ways from disease and/or treatment response 
biomarkers to drug delivery vectors, but progress is currently hindered by significant variation in 
isolation techniques, difficulties in separating/selectively isolating EV populations of interest, and the 
fact that current methods are too expensive and time-consuming to be used routinely in 
translational medicine.  
In view of the current obesity pandemic and the recognition of adipose tissue as an active endocrine 
organ, EV research has also begun to examine the role and characteristics of EVs in obesity and their 
potential contribution to obesity-driven comorbidities. 
My study therefore sought to explore how obesity affects the circulating EV profile and how they 
change in response to treatment. Secondly, current EV isolation and characterisation techniques 
were applied and reviewed with regard to their future applicability.  
7.2 Contribution of my findings to the field of EV research 
Although the work I performed is largely descriptive in nature, given the EV field is a novel area in 
biomedical sciences, I believe my work contributed significantly and provides new knowledge on 
plasma EV characteristics. 
Firstly, I have shown that the circulating plasma EV concentration, cellular origin and adipokine 
content in metabolically healthy volunteers is unaffected by their BMI and waist circumference. 
Similar observations were recently reported by other researchers [Mleczko J, 2018, Krankendonk 
ME, 2014, Zhang X, 2014]. However, I observed that the EV profile in healthy men appears to be 
more pro-inflammatory compared to healthy women, which is also accompanied by lower plasma 
‘free’ adiponectin concentration in male subjects and higher plasma ‘free’ IL6. Intriguingly, these 
gender differences in EV profile were not observed in subjects who developed comorbidities 
secondary to obesity such as type 2 diabetes mellitus. Many previous studies evaluated EV 
characteristics in cohorts with established metabolic syndrome or obesity-associated comorbidities 
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[Lakhter AJ, 2015, Krankendonk ME, 2014]. There are not many studies focusing on EV 
characterisation in the healthy state, although it is believed that EVs play an important role in 
cellular cross-talk and maintaining physiological homeostasis in health as well [Samuelson I, 2018]. If 
EVs are to be used in future as disease biomarkers, not only is a more standardised and quicker 
method for their isolation and characterisation needed but also a normal ‘references range’ of EV 
characteristics will need to be defined.  
In my study, the TRF signal from EV-expressed adipokines did not correlate with the free plasma 
concentration evaluated by commercial ELISA assays, which suggests that mechanisms involved in 
adipokine packaging into EVs differ from those regulating secretion of ‘free’ adipokines into the 
circulation. This is further supported by my observation that EV adipokines such as FABP4, 
adiponectin, TNFα and interferon-γ correlated with the expression of the exosomal marker CD9, 
suggesting this specific subpopulation of EVs is the main EV carrier of these molecules and might 
therefore be of greater interest with respect to future potential study in clinical practice.  
Although no EV profile differences were demonstrated between ‘healthy lean’ and’ healthy 
overweight and obese’ individuals, I observed that “free” plasma FABP4 concentration differs 
significantly between these subgroups before differences in traditional metabolic health markers, 
such as HOMA-IR, are observed. Plasma FABP4 also correlated very strongly with BMI in all the 
cohorts I evaluated.  This adds further to a growing body of evidence that plasma FABP4 is an 
adipokine which is likely to emerge as an important and sensitive marker of cardiometabolic health 
[Hotamisligil GS, 2015, Furuhashi M, 2015]. Given the ease of its measurement it could be easily 
incorporated into various cardiometabolic risk stratification models [von Eynatten M, 2012, Xu A, 
2007]. 
 Circulating adiponectin, which has emerged as an important regulator of various metabolic 
processes [Hotta K, 2000, Arita Y, 1999, Hivert MF, 2008], appears to be involved in an interplay with 
plasma EV dynamics since I observed a strong negative correlation between plasma adiponectin and 
plasma EV concentration, as well as with endothelial- and platelet-derived EVs, FABP4-, IL6 and 
interferon-γ expressing EVs. I cannot easily explain this result but speculate that, since adiponectin is 
perceived as the ‘guardian’ of metabolic homeostasis, there might be some mechanisms by which 
this adipokine regulates EV secretion and/or content that are yet to be elucidated (as discussed in 
chapter 3).  
There are not many studies evaluating the changes in circulating plasma EVs in response to surgical 
or conservative/lifestyle management of morbid obesity. The work I conducted shows that bariatric 
surgery is associated with a transient rise in plasma- and EV-associated FABP4, likely reflecting 
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increased lipolysis and alterations in adipose tissue homeostasis, and that dietary and lifestyle 
changes affect EV profile in severely obese subjects, with lower signals observed from platelet- 
derived EVs as well as FABP4- and TNFα-expressing EVs before significant weight loss is achieved. 
These results suggest that plasma EVs appear to be very plastic and dynamic in response to both 
invasive therapies and more conservative approaches to weight loss such as diet. This was apparent 
in recent studies examining the effects of diet on circulating EVs. [Zhang X, 2014, Eithan E, 2017, 
Horn P, 2015] Intriguingly, the changes in the EV concentration and profile were not as significant 
post-bariatric surgery as I initially predicted, despite significant weight loss achieved by all 
participants, whilst changes in EVs were observed prior to any weight loss in the conservative 
management group. On the one hand this could be attributed to the small sample size in the study, 
or the fact that the plasma sample for EV isolation in the bariatric surgery cohort was stored for 
significantly longer than in the other cohorts prior to ultracentrifugation, which could have affected 
the expression of various markers I analysed. On the other hand, the subjects from the surgical 
cohort, despite a mean 6 months total weight loss of 20% (121.6±26 kg from 151.3 ± 31 kg), still had 
an average BMI of 44 ± 10.2 kg/m2 (from 54 ± 12.6 kg/m2) which classifies them as severely obese 
[WHO, 1995]. Perhaps, once a certain degree of metabolic derangement is achieved, the ‘baseline’ 
EV profile remains quite static, and more dynamic EV differences would be observed if samples were 
obtained soon after surgery (24-72hours). Though the subjects in the conservative management 
cohort suffered from severe obesity as well (mean BMI 54.92± 6.6kg/m2), they did not have as many 
metabolic comorbidities and therefore did not qualify for bariatric surgery as per the DUBASCO 
score criteria (chapter 4.3.1). This is perhaps the reason why their EVs profile were more ‘plastic’ in 
response to simple lifestyle intervention. Further work on such clinical cohorts using the most up to 
date EV isolation methods, functional assays and EV RNA analysis is required to explore these 
observations further. 
7.3 Suggestions for further research 
I believe the research I conducted can be developed in several ways and some aspects of this work 
are already being continued by my colleagues from our research group at Cardiff Metropolitan 
University and Cardiff University. 
7.3.1 Developments in plasma EV isolation and characterisation in obese cohorts 
The recent developments in EV isolation methodology need to be addressed in further studies. I 
briefly attempted this in chapter 5 by using SEC commercial columns.  Since many researchers now 
employ size exclusion chromatography methods for plasma EV isolation, it would be interesting to 
characterise EVs from the cohorts I described using this isolation methodology and a similar array of 
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antibodies for EV origin and content characterisation. However, our group’s current TRF 
immunoassay methodology requires quite a significant plasma volume to obtain sufficient EV 
number. This would be associated with increased time and cost of running the experiments if more 
than one Exospin Column was required to obtain enough EV material from one donor to replicate 
some of the TRF experiments and/or perform other assays. It may therefore be necessary either to 
consider other novel isolation methods of EVs such as anion exchange chromatography [Heath N, 
2018] or filtration microfluidic devices [Liang LG, 2017] and/or alternative methods of analysing EV 
content such as microarrays/dot assays as the screening tool for proteins of interest. These could 
potentially be complemented by the development of local protocols for EV RNA expression analysis 
based on the recent literature [Crossland R, 2016, Maatescu B, 2017], which would require less 
sample volume and might be a good base for future functional EV studies. Such an altered approach 
to the analysis of various obese clinical cohorts could provide more insight into a possible 
explanation of the results I described and could also be used to validate my findings. 
7.3.2 Development of Adipocyte-derived EV isolation and characterisation 
The adipocyte-derived EV work was quite limited due to the length of time the preadipocyte cultures 
required and the very low final concentration of isolated EV material. Therefore, I do not think in its 
current form performing these experiments is sustainable. One option would be perhaps 
employment of commercially available human preadipocytes such as the Lonza cells I used, but 
these would incur significant cost in the context of EV experiments, especially as they are not 
recommended for use beyond passage 1. Therefore, as discussed in chapter 6, evaluation of EV 
isolation from the whole adipose tissue explant media [Krankendonk ME, 2014] could be trialled 
instead alongside immunoaffinity based  methods for EV isolation targeting the exosomal markers 
and adipokines to ensure that the material obtained represents ADEVs rather than EVs from 
contaminating cells [Ferrante SC, 2015]. As discussed above, EV RNA studies on material obtained 
from the adipocyte culture medium in parallel with PCR analysis of the adipose tissue culture itself 
would also be of great value, especially in the context of potential functional experiments that are 
being developed by our group and which I discuss below.   
7.3.3. Functional studies: why do these matter? 
As stated above, the research I present in my thesis is of a descriptive nature and understandably, 
more interest is directed nowadays towards the potential biological role of EVs and how that could 
be applied in clinical practice rather than the analysis of their characteristics alone. EVs are already 
being explored as potential vaccine or chemotherapy delivery agents [Fais S, 2016] and the potential 
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for such modified EVs to be used to affect target cells biology could completely change our approach 
to modern pharmacotherapy.  
I was therefore hoping to incorporate some functional experiments into my research on plasma EVs 
from lean and morbidly obese subjects. This was unfortunately not successful, but I think the 
hypotheses are still worth exploring with the developments in EV methodology. Firstly, I was hoping 
to evaluate the potential chemotactic properties of plasma-derived EVs on peripheral blood 
neutrophils isolated from healthy donors. The scientific question I wanted to answer was whether 
EVs isolated from obese subjects (both “healthy obese” and those with comorbidities) would have 
stronger chemoattractant properties than the EVs from healthy lean donors and how the 
neutrophils would react to EVs obtained directly from the adipose tissue explants (visceral and 
subcutaneous). In order to attempt these experiments, I used 3D µ-slide chemotaxis plates (80326, 
Ibidi GmBh, Germany) where the chemoattractant and control medium are injected to 2 chambers 
separated by a column where neutrophils resuspended in gel are injected and incubated and 
chemotaxis can be measured in real time by video-microscopy and cell tracking. In theory, video 
recording should allow to visualise the movements of the neutrophils towards the chemoattractant 
which can be measured and compared to controls. Unfortunately, I was faced with a lot of technical 
issues associated with this method, such as leakage of neutrophils into the main chambers or lack of 
neutrophil movement  towards control chemoattractant (CCL-19 (chemokine ligand 19) or FMLP(N-
formyl-L-methionyl-L-leucyl-phenylalanine)) which I used in various concentrations. Despite 
repeated trials and attempting various modifications which both myself and my colleagues 
evaluated, the control experiments were not successful and due to time restriction associated with 
recruitment of clinical cohorts, processing and analysis of my other samples, I was not able to 
continue to work on developing this functional experiment. In hindsight, perhaps a different 
chemotaxis assay could be explored to test my hypothesis, such as the Boyden chambers or micro- 
chemotaxis chambers [Taylor L, 2018], especially since recent investigations show potential 
chemotactic properties of EVs. Akbar et al showed that labelled endothelial EVs, when injected into 
to tail vein in mice, left the systemic circulation and accumulated in the spleen and mobilised splenic 
monocytes. Moreover, in vitro exposure of THP-1 and RAW264.7 cells to endothelial cell-derived EVs 
increased their chemotaxis to MCP-1 [Akbar N, 2017].  Similarly, Eguchi et al showed in vitro and in 
mice models that adipocyte-derived EVs induce migration of monocytes and primary macrophages, 
and transplanting EVs from plasma of ob/ob mice into the wild-type mice induces monocyte 
activation in the circulation and inflammatory macrophage infiltration [Eguchi A, 2015]. 
My colleague, Dr Rebecca Wadey, has recently developed a leukocyte adhesion assay with the aim 
of establishing if peripheral blood leukocytes (isolated from healthy donors in the same way as my 
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chemotaxis experiments) would show increased adhesion to primary endothelial cells (isolated from 
human umbilical cords) when pre-incubated with EVs isolated from 3T3 cells [unpublished data]. 
Once this methodology was established and validated, which was towards the end of my 
experimental work, I attempted this experiment on 2 occasions using surplus thawed EVs from 
healthy and obese individuals from my study cohorts. Although I did not observe any differences in 
adhesion of the leukocytes preincubated with EVs from lean versus morbidly obese donors, I believe 
repeated experimental work using this new assay should be attempted. I suspect the failure of my 
experiment might have been due to the fact that I used frozen EVs stored in -80 Cͦ for several months 
as they were surplus material from previous experiments; this could have affected their biological 
properties. Therefore, repeating these experiments by using freshly isolated EVs, ideally purified also 
by SEC columns and stored for a maximum of 24-72 hours at 4 C̊ could add a new perspective to the 
work on biological properties of EVs in obesity. Furthermore, the potential effects on gene 
expression in the endothelial cells exposed to EVs from various sources (plasma/ adipocyte-derived) 
and donors (healthy vs morbidly obese) could be evaluated to complement recently published 
functional ADEV studies [Mleczko J, 2018, Ferrante SC 2015, Koeck ES, 2014]. 
The potential pitfall of experimental design to use fresh EVs would however be the fact this work 
would be very time consuming using current isolation methodologies and therefore logistically it 
would be difficult to run these experiments on a large number of samples, unless several researchers 
worked simultaneously with responsibility for various steps of the isolation, characterisation and 
functional assay processes. Therefore, as discussed above, alternative isolation techniques may have 
to be considered. 
226 
7.4 Conclusions 
In summary, the recent developments in EV research appear to have opened a new chapter in our 
understanding of many pathological and biological processes. Further progress in understanding EV 
biology is likely to lead to significant developments in personalised medicine and modern 
nanopharmacological therapies in years to come. 
The work I conducted has contributed to our knowledge on EV characteristics in the context of
obesity and it formed a useful basis for my current and future research group colleagues who will 
hopefully pursue some of the hypotheses and ideas further, thus enabling us to gain a more holistic 
insight into the characteristics and role of EVs in obesity.      
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Fig.1 All Wales Obesity Pathway 
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Fig. 2:  Level 3 SWMS Initial assessment and intervention pathways 
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Roles of Multidisciplinary Team 
 
Dietitian 
 
The Specialist Dietitian delivers two clinics each week in Llandough Hospital out-patients and the 
initial six months part of the intervention is more intensive with frequent 1:1 appointments.  Longer 
term the frequency of appointments are reduced to reflect the person’s growing confidence with 
making changes. 
 
Motivational Interviewing is used as the foundation for the Dietetic intervention and at the initial 
meeting the focus is on engaging the person in the dietetic service as well as the Level 3 service as a 
whole.   The patient led model focuses on the behaviours and habits that the person feels they need 
to change in order to successfully lose weight long-term.  In a collaborative approach the patient and 
Dietitian work together on nutrition education, where necessary, including portion sizes, calorie 
requirements, reading food labels, meal plans etc, as well as working on the emotional relationship 
with food. 
 
For many people within this service they do not attend the first appointment ready to make changes 
and time is spent working with them on building their confidence to make changes, deciding if they 
want to attempt lifestyle change and supporting them with lapses.  Motivation fluctuates 
throughout the 18 months within the service and patients are supported with this in order to evoke 
their own motivation to change and work through the challenges. 
The Dietitian also provides long-term dietetic monitoring for patients who have undergone bariatric 
surgery.   
 
Doctor 
The medical consultant is allocated 1.5 sessions (5.6 hours per week) for the service. All referrals are 
reviewed by the consultant and MDT and triaged. All new patients are seen in a weekly MDT clinic at 
University Hospital Llandough and are reviewed every 3-4 months. Medical issues related to obesity 
are investigated and managed with medication changes made as appropriate, together with 
appropriate liaison with the patient’s GP, secondary care consultants and the bariatric surgical 
centre in Swansea. Education sessions, focusing on the process of appropriate referral and 
management, together with advice on use and withdrawal of the weight management drug Orlistat 
have been delivered to both GP clusters and individual practices. Offers of in-practice education 
have been provided across primary care in the UHB.  
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Nurse  
The clinical nurse specialist supports patients with complex needs throughout their weight loss 
journey. Once referrals are triaged into the service, the CNS meets with each patient, to complete a 
detailed evidenced based physical, emotional, and psychological assessment. This is an early 
intervention approach, providing awareness raising, psycho-education and signposting for patients. 
Working from a trauma informed perspective the consultation is based on a person-centred 
approach, to ensure that patient’s feel heard, supported, and involved during the appointment. This 
appointment is a critical component in the service pathway which facilitates not only the ability to 
gather key patient information but is a useful opportunity to gauge patient expectation and their 
commitment and ability to further engage well. This assessment is discussed in the weekly MDT to 
formulate an individualised plan for the patient and agree the best pathway of care and service 
provision. 
The CNS role is key to the overall service, acting as an efficient conduit between professional 
disciplines and as a relationship builder for the patient and their families in accessing and benefiting 
from the healthcare and service provided. The patient is therefore encouraged to claim ownership of 
their health and to develop a trusting therapeutic relationship not only with the CNS at each of their 
six-month appointments, but the wider MDT. 
 
Occupational Therapist   
The role of Occupational Therapy within the Specialist Weight Management Service is to focus on 
the occupational needs of the client group. Obesity and its co-morbidities, together with attitudinal 
barriers, stigma and discrimination has an effect on occupational choice and participation, 
potentially leading to occupational deprivation and marginalisation. 
The service is delivered primarily through domiciliary visits, allowing assessment of the person’s daily 
occupations (the practical and purposeful activities that allow people to live independently and have 
a sense of identity. This could be essential day-to-day tasks such as self-care, work or leisure) within 
their own home and local environment. 
Reasons for referral have been varied. These have included assessment of function in the home, 
provision of equipment to increase independence, identification of barriers to setting, maintaining 
and achieving goals, encouragement to develop positive routines, support to explore opportunities 
to increase social contact and  support to maintain their work role. Interventions focus on building 
rapport and trust, supporting behaviour change in the context of occupational participation, liaising 
with other organisations and services, provision of equipment. 
 
Physiotherapist 
The role of the physiotherapist working in the weight management service is primarily to support 
people to work towards meaningful life goals in which weight management, physical activity and 
movement have an important part to play. While the importance of being physically active is well 
recognised, in reality people often experience difficulties in doing so. Physiotherapists provide 
valuable input and expertise for service users who are struggling or unable to progress their activity 
levels with the support from their social networks or health and wellbeing services available in the 
community. A treatment plan for a service user may comprise of: 
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- personalised lifestyle advice, taking into account individual attitudes, beliefs, circumstances, 
cultural and social preferences, and readiness to change prescription, supervision, and progression of 
appropriate physical activity to increase muscle strength, flexibility, and endurance, and sustain 
energy output to enhance and maintain weight loss under safe and controlled condition 
-management of associated conditions such as arthritis, persistent pain, and other musculoskeletal 
or long-term conditions, such as COPD or heart disease 
- co-ordination of comprehensive and sustainable programmes of management in collaboration with 
service users, other health and social care professionals, and community services. 
Assessments and treatment may be delivered individually or with groups. The physiotherapist role 
includes the support of other members of the team in the multi-disciplinary management of obesity 
helping to optimise clinical outcomes and patient experience. The physiotherapist will participate in 
regular supervision and ensure that their practice is up to date and informed by current guidance 
and available research evidence. 
The physiotherapy component of the weight management service has had a therapist in post since 
January 2016. The service has been running from Whitchurch physiotherapy outpatient department 
with 15 hours of clinical and administration time per week. This has been reduced to 11.5 hours per 
week over the last 6 months secondary to maternity leave.  
Outcome measures specific to pain, function, fear of movement and quality of life are collected and 
repeated at 3,6,9 and 12 months. 
 
Psychologist 
Due to the limited access to clinical psychology services (0.4 wte) the service has adopted a direct 
clinical service and consultation model (working through others). This has enabled psychologically 
informed care from the point of entry into the service. In addition to direct clinical care the 
psychologist offers clinical supervision and support for other team members including the level 2 
weight management service, through monthly psychological consultations. These cover issues such 
as risk, trauma, mental health difficulties, mental health services, signposting, attachment, 
transference and a range of psychological models of care. The consultation group is currently being 
evaluated and appears to be well received amongst colleagues. 
 
Service Co-ordinator 
The role of Weight Management Service co-ordinator for the Level 3 service has proven to be 
complex much like its patient base. Working within a multi-disciplinary team, offering patients a 
consistent point of contact to assist with appointment making and accessibility challenges, has 
proven to be beneficial for the patients since service inception. This also contributes to good team 
communication by centralising information on how well people are engaging with the service in 
order to proactively identify any issues and necessary action required on the behalf of the clinical 
team. The role encompasses traditional clinic co-ordination elements however, it crosses inter-
departmental functionality normally seen separated within the larger Medical Records department. 
This specific role also includes daily secretarial, administrative and information support to the MDT 
team members on an ad hoc basis, the joint co-ordination of MDT meetings, minute taking and 
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assisting and liaising with patient data collation, sharing and reporting on a regular basis. The co-
ordinator works closely with the specialist nurse as a conduit for satellite team members to 
proactively centralise patient treatment information, the majority of which involves a significant 
amount of manual intensity in the absence of a suitable IT solution.  To collect and monitor service 
activity at each stage of the patent pathway, the co-ordinator also actively creates and assists with a 
number of databases, worksheets, process flow diagrams and data capture forms used by the clinical 
team members and management team.  
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Fig.3: Primary Care Pathway Referral for Adult 
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